data_2ljc_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2ljc _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.64 0.257 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.471 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 42' ' ' THR . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.405 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.533 ' N ' HD13 ' A' ' 46' ' ' LEU . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . 0.636 HD22 HE22 ' B' ' 48' ' ' GLN . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.471 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.412 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.629 HD22 ' NE2' ' C' ' 48' ' ' GLN . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.636 HE22 HD22 ' A' ' 47' ' ' ASN . 0.0 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.547 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.547 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.447 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.515 ' CD1' ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.515 ' N ' ' CD1' ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.629 ' NE2' HD22 ' B' ' 47' ' ' ASN . 0.0 OUTLIER -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.433 HG23 HD11 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.411 HD11 HG21 ' D' ' 39' ' ' ILE . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.419 ' O ' ' CD2' ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.419 ' CD2' ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.531 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.804 0.335 . . . . 0.0 110.655 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.462 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.659 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.659 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.441 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.415 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.507 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.522 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.522 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.469 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.469 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.496 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . 0.465 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.684 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.684 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . 0.552 ' CD2' ' NE2' ' C' ' 48' ' ' GLN . 59.6 t-80 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.552 ' NE2' ' CD2' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . 0.434 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.671 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.42 ' O ' ' OG1' ' D' ' 42' ' ' THR . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.536 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.536 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.696 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.6 mm-40 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.671 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 . . . . . 0 N--CA 1.455 -0.217 0 CA-C-O 120.603 0.239 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.49 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.528 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.3 tm0? -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.406 HG23 HD11 ' A' ' 49' ' ' ILE . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.541 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' SER . . . . . 0.423 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.493 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.493 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.553 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.553 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.484 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.681 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.681 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.413 HD11 HG23 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.401 HD13 ' H ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.401 ' H ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.52 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.52 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.583 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.541 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.655 0.264 . . . . 0.0 110.767 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 24' ' ' ASP . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.731 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.731 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.511 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.454 ' CD2' ' OE1' ' B' ' 48' ' ' GLN . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . 0.524 ' O ' ' N ' ' A' ' 51' ' ' ARG . 74.4 m-80 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.416 HG21 HD11 ' A' ' 49' ' ' ILE . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.602 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.515 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.515 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.578 HE21 ' N ' ' B' ' 48' ' ' GLN . 5.0 mm-40 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.458 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.458 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.448 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . 0.402 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' SER . . . . . 0.4 ' O ' ' N ' ' C' ' 34' ' ' GLY . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.559 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.422 ' O ' ' N ' ' C' ' 50' ' ' LYS . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.529 ' HG ' ' H ' ' D' ' 47' ' ' ASN . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.529 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.559 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.499 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.814 0.34 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.413 HG22 HD11 ' A' ' 33' ' ' ILE . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.476 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.435 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.477 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.5 tm0? -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.477 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.562 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.444 ' H ' HD23 ' B' ' 46' ' ' LEU . 68.4 m-80 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.465 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.42 HG23 HD12 ' B' ' 49' ' ' ILE . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.637 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.516 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . 0.598 ' CG2' ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.598 ' H ' ' CG2' ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . 0.562 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.444 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.498 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.498 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' D' ' 44' ' ' GLY . 23.3 m-80 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.516 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.477 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.461 0.124 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.502 ' H ' ' C ' ' A' ' 24' ' ' ASP . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.626 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.417 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.512 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.648 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.648 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.513 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.513 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.455 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.677 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.677 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.554 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.441 ' N ' ' CG2' ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.468 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.646 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.646 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.429 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' D' ' 52' ' ' GLY . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.512 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 N--CA 1.463 0.191 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.433 ' H ' ' C ' ' A' ' 24' ' ' ASP . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.75 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.75 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.494 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.456 ' CB ' ' O ' ' A' ' 48' ' ' GLN . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.525 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . 0.434 HG23 HD13 ' B' ' 43' ' ' ILE . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.571 HD21 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.571 ' H ' HD21 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.513 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.513 ' N ' ' CG2' ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.409 ' N ' ' CD1' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.649 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.649 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.45 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.447 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.697 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.697 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.421 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.525 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.882 0.373 . . . . 0.0 110.092 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.597 ' H ' ' CD2' ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.683 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.683 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.498 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-160 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . 0.491 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.626 ' HD1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.626 ' N ' ' HD1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.609 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.609 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.538 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.538 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.549 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.603 ' HD1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . 0.402 HG21 HD11 ' D' ' 39' ' ' ILE . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.666 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.4 mm-40 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . 0.409 HD13 HG22 ' D' ' 49' ' ' ILE . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 120.535 0.207 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.483 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.426 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.492 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.578 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.578 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' B' ' 47' ' ' ASN . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.541 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.541 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.485 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . 0.463 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.69 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.69 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.606 ' CG ' HE22 ' D' ' 48' ' ' GLN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.458 HD22 ' CB ' ' D' ' 47' ' ' ASN . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.456 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.648 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.426 HG23 HD11 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.659 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.659 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.437 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.488 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.488 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.458 ' CB ' HD22 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.661 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.8 mm-40 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.648 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.458 -0.05 0 CA-C-O 120.964 0.411 . . . . 0.0 110.021 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.529 ' H ' ' CD2' ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.474 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.413 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.527 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.55 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.47 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.513 ' HZ3' ' CB ' ' B' ' 50' ' ' LYS . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.485 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . 0.446 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.689 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.689 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.58 ' CD1' HD21 ' C' ' 47' ' ' ASN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.58 HD21 ' CD1' ' C' ' 46' ' ' LEU . 0.9 OUTLIER -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.595 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.639 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.639 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.406 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.402 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.548 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.472 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 . . . . . 0 C--O 1.232 0.149 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.472 ' H ' ' C ' ' A' ' 24' ' ' ASP . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.403 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.41 ' CB ' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . 0.549 ' CD1' ' HE2' ' B' ' 45' ' ' HIS . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.421 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.62 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . 0.549 ' HE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.562 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.562 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.419 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.45 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.45 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.484 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.553 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.525 ' HZ2' ' CZ ' ' D' ' 51' ' ' ARG . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 31' ' ' SER . . . . . 0.429 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.428 HD11 HG23 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.437 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.495 HE22 ' CD1' ' C' ' 46' ' ' LEU . 50.4 mm-40 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.525 ' CZ ' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.462 0.144 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.518 ' H ' ' C ' ' A' ' 24' ' ' ASP . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.437 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.411 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.56 ' CD2' HE21 ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.707 HD22 HE22 ' C' ' 48' ' ' GLN . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.443 ' O ' ' C ' ' B' ' 49' ' ' ILE . 0.1 OUTLIER -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.62 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.62 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.629 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.629 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.431 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.535 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.707 HE22 HD22 ' B' ' 47' ' ' ASN . 2.9 mm100 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.434 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 . . . . . 0 N--CA 1.457 -0.107 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.528 ' H ' ' C ' ' A' ' 24' ' ' ASP . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.638 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.583 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.405 HD13 HG21 ' B' ' 32' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.566 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.566 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.48 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.48 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.494 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.673 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.663 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . 0.673 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.424 HG23 HD11 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.402 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . 0.523 ' CD2' ' NE2' ' D' ' 48' ' ' GLN . 47.3 t-80 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.448 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.523 ' NE2' ' CD2' ' D' ' 45' ' ' HIS . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.492 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.663 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.483 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.415 HD13 HG23 ' A' ' 35' ' ' ILE . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 82.9 m-20 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.523 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . 0.517 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . 0.517 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.477 HE22 ' ND2' ' A' ' 47' ' ' ASN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.478 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.478 ' N ' ' CG2' ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' C' ' 24' ' ' ASP . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.677 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.677 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.557 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.429 ' O ' ' N ' ' C' ' 50' ' ' LYS . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.439 HG23 HD11 ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.523 ' HG ' ' H ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.523 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.547 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . 0.413 HD13 HG22 ' D' ' 49' ' ' ILE . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 120.698 0.285 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.411 ' N ' ' CG1' ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.58 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ILE . . . . . 0.418 HG23 HD12 ' A' ' 49' ' ' ILE . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.57 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' TRP . . . . . 0.429 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' THR . . . . . 0.41 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' GLN . . . . . 0.58 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 37' ' ' HIS . . . . . 0.643 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' C' C ' 38' ' ' PHE . . . . . 0.643 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 46' ' ' LEU . . . . . 0.591 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' C' C ' 47' ' ' ASN . . . . . 0.635 HD22 HE22 ' D' ' 48' ' ' GLN . 56.3 m-80 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.46 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 37' ' ' HIS . . . . . 0.632 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' D' D ' 38' ' ' PHE . . . . . 0.632 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 43' ' ' ILE . . . . . 0.404 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' D' D ' 46' ' ' LEU . . . . . 0.629 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' D' D ' 47' ' ' ASN . . . . . 0.629 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 48' ' ' GLN . . . . . 0.635 HE22 HD22 ' C' ' 47' ' ' ASN . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' D' D ' 51' ' ' ARG . . . . . 0.58 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 40.99 53.36 6.5 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.043 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.471 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.43 ' O ' ' CG2' ' A' ' 42' ' ' THR . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.405 ' O ' ' CD1' ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.533 ' N ' HD13 ' A' ' 46' ' ' LEU . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.636 HD22 HE22 ' B' ' 48' ' ' GLN . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.471 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.412 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.629 HD22 ' NE2' ' C' ' 48' ' ' GLN . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.636 HE22 HD22 ' A' ' 47' ' ' ASN . 0.0 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.547 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.547 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.447 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.515 ' CD1' ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.515 ' N ' ' CD1' ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.629 ' NE2' HD22 ' B' ' 47' ' ' ASN . 0.0 OUTLIER -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.433 HG23 HD11 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.411 HD11 HG21 ' D' ' 39' ' ' ILE . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.419 ' O ' ' CD2' ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.419 ' CD2' ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.531 ' CD ' ' H ' ' D' ' 48' ' ' GLN . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 42.12 50.29 4.89 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.655 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.462 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.659 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.659 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.441 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.415 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.473 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.507 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.522 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.522 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.469 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.469 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.496 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . 0.465 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.684 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.684 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . 0.552 ' CD2' ' NE2' ' C' ' 48' ' ' GLN . 59.6 t-80 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.552 ' NE2' ' CD2' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.434 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.671 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.42 ' O ' ' OG1' ' D' ' 42' ' ' THR . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.42 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.536 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.536 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.696 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.6 mm-40 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.671 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 45.71 54.71 14.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.064 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.49 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.528 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.3 tm0? -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.406 HG23 HD11 ' A' ' 49' ' ' ILE . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.541 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' SER . . . . . 0.423 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.493 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.493 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.553 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.553 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.484 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.681 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.681 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.413 HD11 HG23 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.401 HD13 ' H ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.401 ' H ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.52 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.52 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.583 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.541 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 7.6 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 40.4 52.86 5.5 Favored Pre-proline 0 C--N 1.31 -1.139 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.767 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 24' ' ' ASP . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.731 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.731 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.511 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.454 ' CD2' ' OE1' ' B' ' 48' ' ' GLN . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.524 ' O ' ' N ' ' A' ' 51' ' ' ARG . 74.4 m-80 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.416 HG21 HD11 ' A' ' 49' ' ' ILE . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.602 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.515 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.515 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.578 HE21 ' N ' ' B' ' 48' ' ' GLN . 5.0 mm-40 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.458 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.458 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.448 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . 0.402 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' SER . . . . . 0.4 ' O ' ' N ' ' C' ' 34' ' ' GLY . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.559 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.422 ' O ' ' N ' ' C' ' 50' ' ' LYS . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.529 ' HG ' ' H ' ' D' ' 47' ' ' ASN . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.529 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.559 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.499 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -157.09 57.94 1.44 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.356 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.413 HG22 HD11 ' A' ' 33' ' ' ILE . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.476 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.435 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.477 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.5 tm0? -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.477 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.562 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.444 ' H ' HD23 ' B' ' 46' ' ' LEU . 68.4 m-80 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.465 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.42 HG23 HD12 ' B' ' 49' ' ' ILE . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.637 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.637 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.516 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.598 ' CG2' ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.598 ' H ' ' CG2' ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.562 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.444 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 42' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.498 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.498 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' D' ' 44' ' ' GLY . 23.3 m-80 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.516 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.477 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.403 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 40.9 t . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 76.26 58.8 0.24 Allowed Pre-proline 0 C--N 1.312 -1.031 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.502 ' H ' ' C ' ' A' ' 24' ' ' ASP . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.626 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.626 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.417 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.512 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.648 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.648 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.513 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.513 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.455 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.677 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.677 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.554 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . 0.441 ' CG2' ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.441 ' N ' ' CG2' ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.468 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.646 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.646 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.429 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' D' ' 52' ' ' GLY . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.512 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.438 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 13.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 26' ' ' LEU . 2.2 m-20 79.66 61.22 0.17 Allowed Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.726 -179.356 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.433 ' H ' ' C ' ' A' ' 24' ' ' ASP . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.75 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.75 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.494 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.456 ' CB ' ' O ' ' A' ' 48' ' ' GLN . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.525 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . 0.434 HG23 HD13 ' B' ' 43' ' ' ILE . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.571 HD21 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.571 ' H ' HD21 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . . . . . . . . . 13.0 mm100 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.513 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.513 ' N ' ' CG2' ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.409 ' N ' ' CD1' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.649 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.649 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.45 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.447 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.697 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.697 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.421 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.444 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.525 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 45.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 77.25 65.18 0.22 Allowed Pre-proline 0 C--N 1.308 -1.223 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.092 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.597 ' H ' ' CD2' ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.683 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.683 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.498 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.9 t-160 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.491 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.626 ' HD1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.626 ' N ' ' HD1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.609 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.609 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.538 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.538 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.449 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.549 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.443 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.603 ' HD1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . 0.402 HG21 HD11 ' D' ' 39' ' ' ILE . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.666 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.4 mm-40 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.409 HD13 HG22 ' D' ' 49' ' ' ILE . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 31.8 t . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 58.17 48.5 2.67 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.191 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.483 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.426 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.492 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.578 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.578 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' B' ' 47' ' ' ASN . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.541 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.541 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.485 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . 0.463 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.69 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.69 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.606 ' CG ' HE22 ' D' ' 48' ' ' GLN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.458 HD22 ' CB ' ' D' ' 47' ' ' ASN . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.456 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.648 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.426 HG23 HD11 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.659 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.659 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.437 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.488 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.488 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . . . . . . . . . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.458 ' CB ' HD22 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.661 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.8 mm-40 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.648 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.407 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 29.1 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 23' ' ' SER . 2.1 m-20 79.23 65.7 0.18 Allowed Pre-proline 0 C--N 1.309 -1.167 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.021 -179.513 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.529 ' H ' ' CD2' ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.474 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.413 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.527 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.55 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.55 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.47 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.513 ' HZ3' ' CB ' ' B' ' 50' ' ' LYS . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.485 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . 0.446 ' CD1' ' C ' ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.689 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.689 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.58 ' CD1' HD21 ' C' ' 47' ' ' ASN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.58 HD21 ' CD1' ' C' ' 46' ' ' LEU . 0.9 OUTLIER -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.595 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.639 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.639 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.406 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.402 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.548 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.472 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 75.81 56.03 0.23 Allowed Pre-proline 0 C--N 1.308 -1.219 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.999 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.472 ' H ' ' C ' ' A' ' 24' ' ' ASP . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.403 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.41 ' CB ' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . 0.549 ' CD1' ' HE2' ' B' ' 45' ' ' HIS . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.421 ' CD1' ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.62 ' HD1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . 0.549 ' HE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.562 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.562 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.419 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.45 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.45 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.484 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.553 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.525 ' HZ2' ' CZ ' ' D' ' 51' ' ' ARG . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 31' ' ' SER . . . . . 0.429 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.428 HD11 HG23 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.437 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.495 HE22 ' CD1' ' C' ' 46' ' ' LEU . 50.4 mm-40 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.525 ' CZ ' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' OD2' ' A' ' 24' ' ' ASP . 4.4 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 78.19 56.14 0.18 Allowed Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.612 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.518 ' H ' ' C ' ' A' ' 24' ' ' ASP . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.437 ' H ' ' CD1' ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.411 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.56 ' CD2' HE21 ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.707 HD22 HE22 ' C' ' 48' ' ' GLN . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.443 ' O ' ' C ' ' B' ' 49' ' ' ILE . 0.1 OUTLIER -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.62 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.62 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.438 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.629 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.629 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.431 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.535 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.707 HE22 HD22 ' B' ' 47' ' ' ASN . 2.9 mm100 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.434 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.528 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 43.05 52.43 8.09 Favored Pre-proline 0 C--N 1.309 -1.165 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.104 179.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.528 ' H ' ' C ' ' A' ' 24' ' ' ASP . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.638 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.583 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.405 HD13 HG21 ' B' ' 32' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' THR . . . . . . . . . . . . . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.566 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.566 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.48 ' CG2' ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.48 ' H ' ' CG2' ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.494 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.673 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.663 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . 0.673 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.424 HG23 HD11 ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.402 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . 0.523 ' CD2' ' NE2' ' D' ' 48' ' ' GLN . 47.3 t-80 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.448 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.523 ' NE2' ' CD2' ' D' ' 45' ' ' HIS . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.492 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.663 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 52.63 53.15 11.88 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.055 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.483 ' CD1' ' N ' ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.415 HD13 HG23 ' A' ' 35' ' ' ILE . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.698 ' HD1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.698 ' N ' ' HD1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.439 ' O ' ' CG2' ' A' ' 42' ' ' THR . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 82.9 m-20 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.523 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . 0.517 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . 0.517 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.477 HE22 ' ND2' ' A' ' 47' ' ' ASN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.478 ' CG2' ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.478 ' N ' ' CG2' ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.409 ' H ' ' C ' ' C' ' 24' ' ' ASP . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.677 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.677 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.557 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.429 ' O ' ' N ' ' C' ' 50' ' ' LYS . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ3' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.439 HG23 HD11 ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.472 ' CD1' ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CD1' ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.523 ' HG ' ' H ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.523 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.547 ' N ' ' CD ' ' D' ' 48' ' ' GLN . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.413 HD13 HG22 ' D' ' 49' ' ' ILE . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ3' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.5 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 48.89 51.54 11.11 Favored Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.411 ' N ' ' CG1' ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.58 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . 0.418 HG23 HD12 ' A' ' 49' ' ' ILE . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.57 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' TRP . . . . . 0.429 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' THR . . . . . 0.41 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' GLN . . . . . 0.58 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . 0.479 ' CD1' ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 37' ' ' HIS . . . . . 0.643 ' HD1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 38' ' ' PHE . . . . . 0.643 ' N ' ' HD1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 43' ' ' ILE . . . . . . . . . . . . . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 46' ' ' LEU . . . . . 0.591 HD11 ' N ' ' C' ' 46' ' ' LEU . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' C' C ' 47' ' ' ASN . . . . . 0.635 HD22 HE22 ' D' ' 48' ' ' GLN . 56.3 m-80 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.46 ' CG2' ' N ' ' D' ' 33' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 37' ' ' HIS . . . . . 0.632 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' D' D ' 38' ' ' PHE . . . . . 0.632 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 43' ' ' ILE . . . . . 0.404 ' CG1' ' O ' ' D' ' 40' ' ' ALA . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' D' D ' 46' ' ' LEU . . . . . 0.629 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' D' D ' 47' ' ' ASN . . . . . 0.629 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 48' ' ' GLN . . . . . 0.635 HE22 HD22 ' C' ' 47' ' ' ASN . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' D' D ' 51' ' ' ARG . . . . . 0.58 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.64 0.257 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.432 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.887 ' O ' HD12 ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.905 HD13 ' H ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASN . . . . . 0.905 ' H ' HD13 ' A' ' 46' ' ' LEU . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.437 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.437 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.46 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.43 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.46 HG22 ' O ' ' B' ' 40' ' ' ALA . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.545 ' O ' HG22 ' B' ' 49' ' ' ILE . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.559 HD11 ' HB3' ' C' ' 48' ' ' GLN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.445 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.581 ' HB3' HD11 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.661 HG23 ' N ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.661 ' N ' HG23 ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.406 HG12 ' H ' ' C' ' 32' ' ' ILE . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.654 ' O ' HD12 ' C' ' 46' ' ' LEU . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 1.048 HD13 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 1.048 ' N ' HD13 ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.559 ' HB3' HD11 ' B' ' 46' ' ' LEU . 5.6 pm0 -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.412 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.847 ' O ' HD22 ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.847 HD22 ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.791 ' N ' HD23 ' D' ' 46' ' ' LEU . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.79 ' OE1' HD21 ' C' ' 46' ' ' LEU . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.804 0.335 . . . . 0.0 110.655 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.403 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.626 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.45 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.611 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASN . . . . . 0.444 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.518 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.437 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.471 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.649 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.649 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.636 HG23 ' N ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.636 ' N ' HG23 ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.545 HD12 ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 36' ' ' LEU . . . . . 0.857 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.673 ' HA2' HE22 ' D' ' 48' ' ' GLN . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 45' ' ' HIS . . . . . 0.502 ' CE1' ' HG3' ' C' ' 48' ' ' GLN . 44.7 t60 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.468 HD23 ' NE2' ' D' ' 48' ' ' GLN . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.502 ' HG3' ' CE1' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 49' ' ' ILE . . . . . 0.408 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.45 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.403 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.612 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.612 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.461 ' O ' HD22 ' D' ' 46' ' ' LEU . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.633 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.633 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.673 HE22 ' HA2' ' C' ' 44' ' ' GLY . 2.2 mm100 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.518 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 . . . . . 0 N--CA 1.455 -0.217 0 CA-C-O 120.603 0.239 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.684 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.439 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.56 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 23' ' ' SER . . . . . 0.4 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.409 HG22 HG11 ' C' ' 27' ' ' VAL . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.504 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.504 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.403 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.535 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.535 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 30.5 t60 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.582 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.582 ' N ' HD12 ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.667 HG23 ' N ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.667 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 27' ' ' VAL . . . . . 0.409 HG11 HG22 ' B' ' 27' ' ' VAL . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.518 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.518 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 45' ' ' HIS . . . . . 0.448 ' HA ' HE21 ' C' ' 48' ' ' GLN . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.563 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 1.7 mp0 -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.605 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.735 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.811 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.811 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.67 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.67 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.612 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.56 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.557 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.655 0.264 . . . . 0.0 110.767 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.798 HD13 ' CG2' ' B' ' 28' ' ' VAL . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.683 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.404 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.404 ' HA2' ' NE2' ' B' ' 48' ' ' GLN . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.604 ' CD2' ' NE2' ' B' ' 48' ' ' GLN . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASN . . . . . 0.524 ' O ' ' N ' ' A' ' 51' ' ' ARG . 36.3 m120 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.798 ' CG2' HD13 ' A' ' 26' ' ' LEU . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.446 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.551 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.606 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.606 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.604 ' NE2' ' CD2' ' A' ' 46' ' ' LEU . 5.4 mm100 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.695 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.695 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.561 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 28' ' ' VAL . . . . . 0.402 HG13 ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.436 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.846 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.576 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' D' ' 44' ' ' GLY . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.426 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.614 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.507 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.814 0.34 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.437 HD22 HG23 ' B' ' 28' ' ' VAL . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 29' ' ' ALA . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.427 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.433 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 64.4 t60 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.641 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.491 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.437 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.406 HG22 ' O ' ' B' ' 29' ' ' ALA . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.423 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.545 ' O ' HG22 ' B' ' 42' ' ' THR . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.545 HG22 ' O ' ' B' ' 39' ' ' ILE . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.428 ' N ' HG23 ' B' ' 42' ' ' THR . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.578 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.508 ' H ' HD23 ' B' ' 46' ' ' LEU . 27.6 m120 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.575 ' NE2' HD23 ' A' ' 46' ' ' LEU . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.417 ' C ' ' O ' ' B' ' 48' ' ' GLN . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.485 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.408 HG12 ' H ' ' C' ' 32' ' ' ILE . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.614 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.544 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 49' ' ' ILE . . . . . 0.871 HG23 ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.871 ' H ' HG23 ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 51' ' ' ARG . . . . . 0.578 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.788 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.995 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.995 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.506 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.544 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.491 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.461 0.124 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.426 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.64 HD13 ' CG2' ' B' ' 28' ' ' VAL . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.596 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.596 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.638 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.418 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.53 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.64 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.463 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.434 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.418 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.446 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.434 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.591 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.591 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.654 HG23 ' N ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.654 ' N ' HG23 ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.505 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.623 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.623 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.413 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.0 t60 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.645 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 49' ' ' ILE . . . . . 0.558 HG23 ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.558 ' N ' HG23 ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.594 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.629 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.629 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.49 ' O ' HD23 ' D' ' 46' ' ' LEU . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.49 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.457 ' CG ' HH21 ' A' ' 51' ' ' ARG . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.53 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.412 ' C ' ' H ' ' A' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 N--CA 1.463 0.191 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.738 HD13 ' CG2' ' B' ' 28' ' ' VAL . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 35' ' ' ILE . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.643 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.643 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.69 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.417 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 50' ' ' LYS . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.565 ' N ' HG22 ' A' ' 49' ' ' ILE . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.539 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.738 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' B' ' 29' ' ' ALA . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.442 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.534 ' O ' HG22 ' B' ' 42' ' ' THR . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.534 HG22 ' O ' ' B' ' 39' ' ' ILE . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.479 ' N ' HG23 ' B' ' 42' ' ' THR . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.774 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.774 ' H ' HD23 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.519 ' NE2' ' OD1' ' B' ' 47' ' ' ASN . 44.9 mm-40 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.604 HG23 ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.604 ' N ' HG23 ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.451 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 28' ' ' VAL . . . . . 0.409 HG13 ' N ' ' C' ' 29' ' ' ALA . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.409 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.401 HG12 ' H ' ' C' ' 32' ' ' ILE . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.479 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.686 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.929 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.929 ' H ' HD13 ' C' ' 46' ' ' LEU . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.473 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.538 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.715 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.715 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.768 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.891 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.891 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.882 0.373 . . . . 0.0 110.092 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.491 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.705 ' H ' HD23 ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 29' ' ' ALA . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.646 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.646 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.621 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.44 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.551 ' O ' HD12 ' A' ' 46' ' ' LEU . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 27.4 t60 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASN . . . . . 0.842 ' N ' HD13 ' A' ' 46' ' ' LEU . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.456 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.593 ' ND1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.593 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.432 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.555 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.555 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.77 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.77 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.489 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.532 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.532 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.755 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.831 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.831 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.562 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.567 ' ND1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.47 ' O ' HD22 ' D' ' 46' ' ' LEU . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.533 HD23 ' N ' ' D' ' 47' ' ' ASN . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.533 ' N ' HD23 ' D' ' 46' ' ' LEU . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.77 HE22 ' HG ' ' C' ' 46' ' ' LEU . 4.8 mm100 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 120.535 0.207 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 26' ' ' LEU . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.741 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.45 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.511 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.557 ' CG2' HD23 ' A' ' 26' ' ' LEU . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.444 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.482 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.45 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.482 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.58 HD12 ' N ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.58 ' N ' HD12 ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.458 ' OE1' HD23 ' A' ' 46' ' ' LEU . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.73 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.73 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.554 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 28' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 29' ' ' ALA . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.451 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' LEU . . . . . 0.883 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.613 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.768 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.515 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.488 ' NZ ' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.409 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.55 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.827 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.443 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.953 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.953 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.424 HD12 ' C ' ' D' ' 46' ' ' LEU . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.493 ' CB ' HD21 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.726 HE22 ' HG ' ' C' ' 46' ' ' LEU . 4.8 mm100 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.511 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.458 -0.05 0 CA-C-O 120.964 0.411 . . . . 0.0 110.021 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.532 ' O ' HG12 ' A' ' 28' ' ' VAL . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.645 ' N ' HD23 ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.462 HG22 HG11 ' B' ' 27' ' ' VAL . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 0.403 HG22 ' HE2' ' B' ' 37' ' ' HIS . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.456 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 27' ' ' VAL . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.493 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 29' ' ' ALA . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.461 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.506 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.638 HG23 ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.638 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.573 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 36' ' ' LEU . . . . . 0.794 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.526 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.578 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.451 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.3 mp0 -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 29' ' ' ALA . . . . . 0.425 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.607 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.452 ' O ' HG22 ' D' ' 43' ' ' ILE . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.526 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.456 ' O ' HD23 ' D' ' 46' ' ' LEU . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.456 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.578 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 . . . . . 0 C--O 1.232 0.149 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.855 HD13 ' CG2' ' B' ' 28' ' ' VAL . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.419 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ILE . . . . . 0.444 ' C ' HE22 ' B' ' 48' ' ' GLN . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' HIS . . . . . 0.456 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ILE . . . . . 0.456 HD11 ' CE1' ' A' ' 45' ' ' HIS . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLY . . . . . 0.44 ' C ' HD13 ' D' ' 46' ' ' LEU . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.855 ' CG2' HD13 ' A' ' 26' ' ' LEU . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.427 HD13 HG21 ' B' ' 32' ' ' ILE . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.411 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.579 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.609 ' O ' HG22 ' B' ' 42' ' ' THR . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CZ2' ' HB1' ' A' ' 40' ' ' ALA . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.609 HG22 ' O ' ' B' ' 39' ' ' ILE . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 45' ' ' HIS . . . . . 0.436 ' NE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.61 HD12 ' N ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.61 ' N ' HD12 ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.444 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.683 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.683 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.553 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 29' ' ' ALA . . . . . 0.51 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.51 HG22 ' O ' ' C' ' 29' ' ' ALA . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.461 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.848 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.868 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.868 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 49' ' ' ILE . . . . . 0.411 HG22 ' O ' ' C' ' 46' ' ' LEU . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 31' ' ' SER . . . . . 0.422 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.573 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 34' ' ' GLY . . . . . 0.429 ' O ' ' CD2' ' D' ' 37' ' ' HIS . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.465 ' O ' HD23 ' D' ' 46' ' ' LEU . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.596 HE22 ' CD2' ' C' ' 46' ' ' LEU . 13.0 mm100 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.473 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.462 0.144 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.444 ' O ' HG12 ' A' ' 28' ' ' VAL . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.619 HD22 HG23 ' B' ' 28' ' ' VAL . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.622 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.47 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 59.5 t60 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.5 ' CD2' ' NE2' ' B' ' 48' ' ' GLN . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.404 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.619 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.534 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.534 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.628 ' O ' HG22 ' B' ' 42' ' ' THR . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.429 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.628 HG22 ' O ' ' B' ' 39' ' ' ILE . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.451 ' N ' HG23 ' B' ' 42' ' ' THR . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.529 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.5 ' NE2' ' CD2' ' A' ' 46' ' ' LEU . 20.2 mm-40 -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.859 ' H ' HG23 ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.516 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.447 ' H ' HG22 ' C' ' 42' ' ' THR . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.741 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.764 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.764 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.443 ' CD ' ' N ' ' C' ' 48' ' ' GLN . 10.2 mm-40 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.597 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 . . . . . 0 N--CA 1.457 -0.107 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 HG23 ' B' ' 28' ' ' VAL . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 35' ' ' ILE . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.615 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.413 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.596 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 28' ' ' VAL . . . . . 0.603 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.403 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.585 ' O ' HG22 ' B' ' 42' ' ' THR . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.585 HG22 ' O ' ' B' ' 39' ' ' ILE . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.624 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.624 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.715 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.715 ' H ' HG23 ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.549 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.449 HG12 ' H ' ' C' ' 32' ' ' ILE . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.507 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.865 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.865 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.729 ' H ' HD13 ' C' ' 46' ' ' LEU . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.714 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.628 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 51' ' ' ARG . . . . . 0.714 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.58 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.4 HG21 HD13 ' D' ' 33' ' ' ILE . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.447 ' O ' HD23 ' D' ' 46' ' ' LEU . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 45' ' ' HIS . . . . . 0.635 ' O ' ' CD2' ' D' ' 45' ' ' HIS . 12.5 t60 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.491 ' HA ' HD12 ' D' ' 49' ' ' ILE . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.461 ' N ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.485 ' OE1' ' N ' ' D' ' 48' ' ' GLN . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 49' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' D' ' 46' ' ' LEU . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.628 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.641 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.542 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 27.6 m120 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.537 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' ILE . . . . . 0.412 ' H ' HG22 ' B' ' 35' ' ' ILE . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.402 HD13 HG21 ' B' ' 43' ' ' ILE . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 46' ' ' LEU . . . . . 0.535 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 47' ' ' ASN . . . . . 0.489 ' N ' HD12 ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.475 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.611 HG23 ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.611 ' N ' HG23 ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.507 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.405 HG12 ' H ' ' C' ' 32' ' ' ILE . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.424 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.84 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.857 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.857 ' H ' HD13 ' C' ' 46' ' ' LEU . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.569 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.84 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.94 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' D' D ' 44' ' ' GLY . . . . . 0.94 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.495 HD12 ' N ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.495 ' N ' HD12 ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.579 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 120.698 0.285 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 29' ' ' ALA . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.676 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.601 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.582 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 29' ' ' ALA . . . . . 0.572 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.572 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.472 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 43' ' ' ILE . . . . . 0.472 HG22 ' O ' ' B' ' 40' ' ' ALA . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 48' ' ' GLN . . . . . 0.601 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 26' ' ' LEU . . . . . 0.531 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' C' C ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 40' ' ' ALA . . . . . 0.516 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' C' C ' 43' ' ' ILE . . . . . 0.821 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 44' ' ' GLY . . . . . 0.411 ' O ' HD13 ' C' ' 46' ' ' LEU . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 46' ' ' LEU . . . . . 0.821 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' C' C ' 47' ' ' ASN . . . . . 0.715 ' H ' HD13 ' C' ' 46' ' ' LEU . 28.9 m120 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.56 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' D' D ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 43' ' ' ILE . . . . . 0.685 ' O ' HD22 ' D' ' 46' ' ' LEU . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' D' D ' 46' ' ' LEU . . . . . 0.872 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' D' D ' 47' ' ' ASN . . . . . 0.872 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 48' ' ' GLN . . . . . 0.655 ' OE1' HD21 ' C' ' 46' ' ' LEU . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' D' D ' 51' ' ' ARG . . . . . 0.582 ' CA ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 40.99 53.36 6.5 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.043 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.432 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.887 ' O ' HD12 ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.905 HD13 ' H ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.905 ' H ' HD13 ' A' ' 46' ' ' LEU . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.437 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.437 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.46 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.43 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.46 HG22 ' O ' ' B' ' 40' ' ' ALA . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.545 ' O ' HG22 ' B' ' 49' ' ' ILE . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.559 HD11 ' HB3' ' C' ' 48' ' ' GLN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.445 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.581 ' HB3' HD11 ' A' ' 46' ' ' LEU . 0.4 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.661 HG23 ' N ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.661 ' N ' HG23 ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.406 HG12 ' H ' ' C' ' 32' ' ' ILE . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.654 ' O ' HD12 ' C' ' 46' ' ' LEU . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 1.048 HD13 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 1.048 ' N ' HD13 ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.559 ' HB3' HD11 ' B' ' 46' ' ' LEU . 5.6 pm0 -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.412 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.847 ' O ' HD22 ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.847 HD22 ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.791 ' N ' HD23 ' D' ' 46' ' ' LEU . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.79 ' OE1' HD21 ' C' ' 46' ' ' LEU . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 42.12 50.29 4.89 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.655 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.403 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.626 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.45 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.611 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.444 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.518 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.437 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.471 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.649 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.649 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.636 HG23 ' N ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.636 ' N ' HG23 ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.545 HD12 ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 36' ' ' LEU . . . . . 0.857 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.673 ' HA2' HE22 ' D' ' 48' ' ' GLN . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 45' ' ' HIS . . . . . 0.502 ' CE1' ' HG3' ' C' ' 48' ' ' GLN . 44.7 t60 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.468 HD23 ' NE2' ' D' ' 48' ' ' GLN . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.502 ' HG3' ' CE1' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.408 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.45 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.403 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.612 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.612 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.461 ' O ' HD22 ' D' ' 46' ' ' LEU . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.633 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.633 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.673 HE22 ' HA2' ' C' ' 44' ' ' GLY . 2.2 mm100 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.518 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 45.71 54.71 14.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.064 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.684 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.439 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 27.9 t60 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.56 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 23' ' ' SER . . . . . 0.4 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.409 HG22 HG11 ' C' ' 27' ' ' VAL . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.504 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.504 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.403 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.535 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.535 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 30.5 t60 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.582 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.582 ' N ' HD12 ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.667 HG23 ' N ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.667 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' VAL . . . . . 0.409 HG11 HG22 ' B' ' 27' ' ' VAL . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.518 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.518 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 45' ' ' HIS . . . . . 0.448 ' HA ' HE21 ' C' ' 48' ' ' GLN . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.563 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 1.7 mp0 -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.605 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.735 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.811 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.811 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.67 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.67 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.612 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.56 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.557 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 7.6 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 40.4 52.86 5.5 Favored Pre-proline 0 C--N 1.31 -1.139 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.767 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.798 HD13 ' CG2' ' B' ' 28' ' ' VAL . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.683 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.404 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.404 ' HA2' ' NE2' ' B' ' 48' ' ' GLN . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.604 ' CD2' ' NE2' ' B' ' 48' ' ' GLN . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.524 ' O ' ' N ' ' A' ' 51' ' ' ARG . 36.3 m120 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.798 ' CG2' HD13 ' A' ' 26' ' ' LEU . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.446 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.551 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.606 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.606 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.604 ' NE2' ' CD2' ' A' ' 46' ' ' LEU . 5.4 mm100 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.695 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.695 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.561 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.402 HG13 ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.436 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.846 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.576 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' D' ' 44' ' ' GLY . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.426 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.614 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.507 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -157.09 57.94 1.44 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.356 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.437 HD22 HG23 ' B' ' 28' ' ' VAL . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 29' ' ' ALA . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.427 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.433 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 64.4 t60 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.641 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.491 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.437 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.406 HG22 ' O ' ' B' ' 29' ' ' ALA . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.423 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.545 ' O ' HG22 ' B' ' 42' ' ' THR . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.545 HG22 ' O ' ' B' ' 39' ' ' ILE . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.428 ' N ' HG23 ' B' ' 42' ' ' THR . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.578 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.508 ' H ' HD23 ' B' ' 46' ' ' LEU . 27.6 m120 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.575 ' NE2' HD23 ' A' ' 46' ' ' LEU . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.417 ' C ' ' O ' ' B' ' 48' ' ' GLN . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.485 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.408 HG12 ' H ' ' C' ' 32' ' ' ILE . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.614 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.544 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.871 HG23 ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.871 ' H ' HG23 ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.578 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.788 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.995 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.995 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.506 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 16.7 m120 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.544 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.491 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.403 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 40.9 t . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 76.26 58.8 0.24 Allowed Pre-proline 0 C--N 1.312 -1.031 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.426 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.64 HD13 ' CG2' ' B' ' 28' ' ' VAL . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.596 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.596 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.638 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.418 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.53 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.64 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.463 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.434 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.418 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.446 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.434 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.591 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.591 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.654 HG23 ' N ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.654 ' N ' HG23 ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.505 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.623 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.623 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.413 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.0 t60 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.645 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.558 HG23 ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.558 ' N ' HG23 ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.594 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.629 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.629 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.49 ' O ' HD23 ' D' ' 46' ' ' LEU . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.49 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 21.2 m120 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.457 ' CG ' HH21 ' A' ' 51' ' ' ARG . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.53 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 13.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 23' ' ' SER . 2.2 m-20 79.66 61.22 0.17 Allowed Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.726 -179.356 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.738 HD13 ' CG2' ' B' ' 28' ' ' VAL . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.45 ' HB1' HE12 ' A' ' 1' ' ' RIM . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 35' ' ' ILE . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.643 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.643 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.69 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.417 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 50' ' ' LYS . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.565 ' N ' HG22 ' A' ' 49' ' ' ILE . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.539 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.738 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' B' ' 29' ' ' ALA . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.442 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.534 ' O ' HG22 ' B' ' 42' ' ' THR . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.534 HG22 ' O ' ' B' ' 39' ' ' ILE . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.479 ' N ' HG23 ' B' ' 42' ' ' THR . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.774 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.774 ' H ' HD23 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.519 ' NE2' ' OD1' ' B' ' 47' ' ' ASN . 44.9 mm-40 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.604 HG23 ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.604 ' N ' HG23 ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.451 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.409 HG13 ' N ' ' C' ' 29' ' ' ALA . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.409 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.478 ' HB3' ' HF3' ' A' ' 1' ' ' RIM . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.401 HG12 ' H ' ' C' ' 32' ' ' ILE . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.479 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.686 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.929 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.929 ' H ' HD13 ' C' ' 46' ' ' LEU . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.473 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.538 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.715 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.715 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.768 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.891 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.891 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' RIM . . . . . 0.478 ' HF3' ' HB3' ' C' ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 45.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 77.25 65.18 0.22 Allowed Pre-proline 0 C--N 1.308 -1.223 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.092 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.491 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.705 ' H ' HD23 ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 29' ' ' ALA . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.646 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.646 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.621 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.44 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.551 ' O ' HD12 ' A' ' 46' ' ' LEU . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 27.4 t60 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.842 ' N ' HD13 ' A' ' 46' ' ' LEU . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.456 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.593 ' ND1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.593 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.432 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.555 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.555 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.77 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.77 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.489 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.532 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.532 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.755 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.831 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.831 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.562 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.567 ' ND1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.47 ' O ' HD22 ' D' ' 46' ' ' LEU . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.533 HD23 ' N ' ' D' ' 47' ' ' ASN . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.533 ' N ' HD23 ' D' ' 46' ' ' LEU . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.77 HE22 ' HG ' ' C' ' 46' ' ' LEU . 4.8 mm100 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 31.8 t . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 58.17 48.5 2.67 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.191 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 26' ' ' LEU . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.741 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.45 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.511 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.557 ' CG2' HD23 ' A' ' 26' ' ' LEU . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.444 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.482 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.45 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.482 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.58 HD12 ' N ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.58 ' N ' HD12 ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.458 ' OE1' HD23 ' A' ' 46' ' ' LEU . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.73 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.73 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.554 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 28' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 29' ' ' ALA . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.451 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' LEU . . . . . 0.883 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.613 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.768 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.515 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.488 ' NZ ' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.409 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.55 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.827 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.443 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.953 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.953 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.424 HD12 ' C ' ' D' ' 46' ' ' LEU . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.493 ' CB ' HD21 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.726 HE22 ' HG ' ' C' ' 46' ' ' LEU . 4.8 mm100 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.511 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.407 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 29.1 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 23' ' ' SER . 2.1 m-20 79.23 65.7 0.18 Allowed Pre-proline 0 C--N 1.309 -1.167 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.021 -179.513 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.532 ' O ' HG12 ' A' ' 28' ' ' VAL . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.645 ' N ' HD23 ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.462 HG22 HG11 ' B' ' 27' ' ' VAL . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.403 HG22 ' HE2' ' B' ' 37' ' ' HIS . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.456 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 27' ' ' VAL . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.493 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 29' ' ' ALA . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.461 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.506 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.638 HG23 ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.638 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.573 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 36' ' ' LEU . . . . . 0.794 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.526 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.578 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 6.3 m-20 -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.451 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.3 mp0 -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 29' ' ' ALA . . . . . 0.425 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.607 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.452 ' O ' HG22 ' D' ' 43' ' ' ILE . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.526 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.456 ' O ' HD23 ' D' ' 46' ' ' LEU . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.456 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.578 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 75.81 56.03 0.23 Allowed Pre-proline 0 C--N 1.308 -1.219 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.999 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.855 HD13 ' CG2' ' B' ' 28' ' ' VAL . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.419 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ILE . . . . . 0.444 ' C ' HE22 ' B' ' 48' ' ' GLN . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' HIS . . . . . 0.456 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 0.456 HD11 ' CE1' ' A' ' 45' ' ' HIS . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLY . . . . . 0.44 ' C ' HD13 ' D' ' 46' ' ' LEU . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.855 ' CG2' HD13 ' A' ' 26' ' ' LEU . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.427 HD13 HG21 ' B' ' 32' ' ' ILE . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.411 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.579 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.609 ' O ' HG22 ' B' ' 42' ' ' THR . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CZ2' ' HB1' ' A' ' 40' ' ' ALA . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.609 HG22 ' O ' ' B' ' 39' ' ' ILE . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 45' ' ' HIS . . . . . 0.436 ' NE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.61 HD12 ' N ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.61 ' N ' HD12 ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.444 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.683 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.683 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.553 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 29' ' ' ALA . . . . . 0.51 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.51 HG22 ' O ' ' C' ' 29' ' ' ALA . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.461 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.848 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.868 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.868 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 49' ' ' ILE . . . . . 0.411 HG22 ' O ' ' C' ' 46' ' ' LEU . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 31' ' ' SER . . . . . 0.422 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.573 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 34' ' ' GLY . . . . . 0.429 ' O ' ' CD2' ' D' ' 37' ' ' HIS . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.465 ' O ' HD23 ' D' ' 46' ' ' LEU . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.596 HE22 ' CD2' ' C' ' 46' ' ' LEU . 13.0 mm100 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' OD2' ' A' ' 24' ' ' ASP . 4.4 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.473 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 78.19 56.14 0.18 Allowed Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.612 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.444 ' O ' HG12 ' A' ' 28' ' ' VAL . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.619 HD22 HG23 ' B' ' 28' ' ' VAL . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.622 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.47 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 59.5 t60 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.5 ' CD2' ' NE2' ' B' ' 48' ' ' GLN . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.404 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.619 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.534 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.534 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.628 ' O ' HG22 ' B' ' 42' ' ' THR . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.429 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.628 HG22 ' O ' ' B' ' 39' ' ' ILE . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.451 ' N ' HG23 ' B' ' 42' ' ' THR . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.529 ' C ' HD12 ' B' ' 46' ' ' LEU . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.5 ' NE2' ' CD2' ' A' ' 46' ' ' LEU . 20.2 mm-40 -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.859 ' H ' HG23 ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.516 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.447 ' H ' HG22 ' C' ' 42' ' ' THR . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.741 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.764 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.764 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.443 ' CD ' ' N ' ' C' ' 48' ' ' GLN . 10.2 mm-40 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.597 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 43.05 52.43 8.09 Favored Pre-proline 0 C--N 1.309 -1.165 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.104 179.547 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 HG23 ' B' ' 28' ' ' VAL . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 35' ' ' ILE . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.615 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.413 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.596 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 28' ' ' VAL . . . . . 0.603 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.403 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.585 ' O ' HG22 ' B' ' 42' ' ' THR . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.585 HG22 ' O ' ' B' ' 39' ' ' ILE . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.624 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.624 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.715 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.715 ' H ' HG23 ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.549 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.449 HG12 ' H ' ' C' ' 32' ' ' ILE . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.507 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.865 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.865 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.729 ' H ' HD13 ' C' ' 46' ' ' LEU . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.714 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.628 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 51' ' ' ARG . . . . . 0.714 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.58 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.4 HG21 HD13 ' D' ' 33' ' ' ILE . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.447 ' O ' HD23 ' D' ' 46' ' ' LEU . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 45' ' ' HIS . . . . . 0.635 ' O ' ' CD2' ' D' ' 45' ' ' HIS . 12.5 t60 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.491 ' HA ' HD12 ' D' ' 49' ' ' ILE . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.461 ' N ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.485 ' OE1' ' N ' ' D' ' 48' ' ' GLN . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' D' ' 46' ' ' LEU . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.628 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 52.63 53.15 11.88 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.055 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.641 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.542 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 27.6 m120 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.537 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' ILE . . . . . 0.412 ' H ' HG22 ' B' ' 35' ' ' ILE . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.402 HD13 HG21 ' B' ' 43' ' ' ILE . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 46' ' ' LEU . . . . . 0.535 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 47' ' ' ASN . . . . . 0.489 ' N ' HD12 ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.475 ' OE1' ' N ' ' B' ' 48' ' ' GLN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.611 HG23 ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.611 ' N ' HG23 ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.507 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.405 HG12 ' H ' ' C' ' 32' ' ' ILE . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.424 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.84 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.857 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.857 ' H ' HD13 ' C' ' 46' ' ' LEU . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.569 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.84 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.94 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 44' ' ' GLY . . . . . 0.94 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.495 HD12 ' N ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.495 ' N ' HD12 ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.579 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.5 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 48.89 51.54 11.11 Favored Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 29' ' ' ALA . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.676 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.601 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.582 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 29' ' ' ALA . . . . . 0.572 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.572 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.472 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 43' ' ' ILE . . . . . 0.472 HG22 ' O ' ' B' ' 40' ' ' ALA . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 48' ' ' GLN . . . . . 0.601 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 26' ' ' LEU . . . . . 0.531 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 40' ' ' ALA . . . . . 0.516 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 43' ' ' ILE . . . . . 0.821 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 44' ' ' GLY . . . . . 0.411 ' O ' HD13 ' C' ' 46' ' ' LEU . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 46' ' ' LEU . . . . . 0.821 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' C' C ' 47' ' ' ASN . . . . . 0.715 ' H ' HD13 ' C' ' 46' ' ' LEU . 28.9 m120 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.56 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' D' D ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 43' ' ' ILE . . . . . 0.685 ' O ' HD22 ' D' ' 46' ' ' LEU . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' D' D ' 46' ' ' LEU . . . . . 0.872 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' D' D ' 47' ' ' ASN . . . . . 0.872 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 48' ' ' GLN . . . . . 0.655 ' OE1' HD21 ' C' ' 46' ' ' LEU . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' D' D ' 51' ' ' ARG . . . . . 0.582 ' CA ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.64 0.257 . . . . 0.0 111.043 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.432 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.887 ' O ' HD12 ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.905 HD13 ' H ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.905 ' H ' HD13 ' A' ' 46' ' ' LEU . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.471 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.437 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.437 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.46 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.43 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.46 HG22 ' O ' ' B' ' 40' ' ' ALA . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.545 ' O ' HG22 ' B' ' 49' ' ' ILE . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.559 HD11 ' HB3' ' C' ' 48' ' ' GLN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.668 HD21 ' NE2' ' C' ' 48' ' ' GLN . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.702 HE22 HD21 ' A' ' 47' ' ' ASN . 0.0 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.661 HG23 ' N ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.661 ' N ' HG23 ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.406 HG12 ' H ' ' C' ' 32' ' ' ILE . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.654 ' O ' HD12 ' C' ' 46' ' ' LEU . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 1.048 HD13 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 1.048 ' N ' HD13 ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.668 ' NE2' HD21 ' B' ' 47' ' ' ASN . 0.0 OUTLIER -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.412 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.847 ' O ' HD22 ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.847 HD22 ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.791 ' N ' HD23 ' D' ' 46' ' ' LEU . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.79 ' OE1' HD21 ' C' ' 46' ' ' LEU . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.804 0.335 . . . . 0.0 110.655 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.403 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.626 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.45 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.611 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.444 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.518 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.437 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.471 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.649 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.649 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.636 HG23 ' N ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.636 ' N ' HG23 ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.545 HD12 ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . 0.857 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . 0.552 ' CD2' ' NE2' ' C' ' 48' ' ' GLN . 59.6 t-80 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.552 ' NE2' ' CD2' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . 0.408 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.45 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.403 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.612 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.612 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.461 ' O ' HD22 ' D' ' 46' ' ' LEU . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.633 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.633 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.724 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.6 mm-40 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.518 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 . . . . . 0 N--CA 1.455 -0.217 0 CA-C-O 120.603 0.239 . . . . 0.0 111.064 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.684 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.439 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.528 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.3 tm0? -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.56 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . 0.4 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.409 HG22 HG11 ' C' ' 27' ' ' VAL . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.504 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.504 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.403 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.535 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.535 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.582 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.582 ' N ' HD12 ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.667 HG23 ' N ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.667 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . 0.409 HG11 HG22 ' B' ' 27' ' ' VAL . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.518 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.518 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.605 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.735 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.811 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.811 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.67 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.67 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.612 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.56 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.557 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 . . . . . 0 N--CA 1.457 -0.096 0 CA-C-O 120.655 0.264 . . . . 0.0 110.767 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.798 HD13 ' CG2' ' B' ' 28' ' ' VAL . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.683 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.404 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.465 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.552 HD21 ' NE2' ' B' ' 48' ' ' GLN . 74.4 m-80 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.798 ' CG2' HD13 ' A' ' 26' ' ' LEU . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.446 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.551 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.606 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.606 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.601 HE21 ' N ' ' B' ' 48' ' ' GLN . 5.0 mm-40 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.695 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.695 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.561 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . 0.402 HG13 ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.436 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.846 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.576 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' D' ' 44' ' ' GLY . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.426 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.614 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.507 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.814 0.34 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.437 HD22 HG23 ' B' ' 28' ' ' VAL . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 29' ' ' ALA . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.427 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.433 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.641 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.477 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.5 tm0? -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.491 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.437 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.406 HG22 ' O ' ' B' ' 29' ' ' ALA . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.423 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.545 ' O ' HG22 ' B' ' 42' ' ' THR . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.545 HG22 ' O ' ' B' ' 39' ' ' ILE . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.428 ' N ' HG23 ' B' ' 42' ' ' THR . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.578 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.508 ' H ' HD23 ' B' ' 46' ' ' LEU . 68.4 m-80 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.575 ' NE2' HD23 ' A' ' 46' ' ' LEU . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.417 ' C ' ' O ' ' B' ' 48' ' ' GLN . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.485 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.408 HG12 ' H ' ' C' ' 32' ' ' ILE . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.614 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.544 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . 0.871 HG23 ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.871 ' H ' HG23 ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . 0.578 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.788 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.995 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.995 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.506 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' D' ' 44' ' ' GLY . 23.3 m-80 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.544 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.491 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.461 0.124 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.426 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.64 HD13 ' CG2' ' B' ' 28' ' ' VAL . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.596 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.596 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.638 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.418 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.408 ' H ' HD22 ' A' ' 47' ' ' ASN . 3.0 m-80 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.53 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.64 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.463 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.434 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.418 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.446 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.434 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.591 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.591 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.654 HG23 ' N ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.654 ' N ' HG23 ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.505 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.623 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.623 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.413 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.645 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . 0.558 HG23 ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.558 ' N ' HG23 ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.594 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.629 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.629 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.49 ' O ' HD23 ' D' ' 46' ' ' LEU . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.49 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.457 ' CG ' HH21 ' A' ' 51' ' ' ARG . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.53 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.412 ' C ' ' H ' ' A' ' 26' ' ' LEU . 2.2 m-20 . . . . . 0 N--CA 1.463 0.191 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.738 HD13 ' CG2' ' B' ' 28' ' ' VAL . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 35' ' ' ILE . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.643 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.643 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.69 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.417 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.41 ' CG ' HE22 ' B' ' 48' ' ' GLN . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 50' ' ' LYS . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.565 ' N ' HG22 ' A' ' 49' ' ' ILE . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.539 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.738 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' B' ' 29' ' ' ALA . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.442 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.534 ' O ' HG22 ' B' ' 42' ' ' THR . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.534 HG22 ' O ' ' B' ' 39' ' ' ILE . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.479 ' N ' HG23 ' B' ' 42' ' ' THR . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.774 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.774 ' H ' HD23 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.41 HE22 ' CG ' ' A' ' 47' ' ' ASN . 13.0 mm100 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.604 HG23 ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.604 ' N ' HG23 ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.451 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . 0.409 HG13 ' N ' ' C' ' 29' ' ' ALA . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.409 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.401 HG12 ' H ' ' C' ' 32' ' ' ILE . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.479 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.686 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.929 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.929 ' H ' HD13 ' C' ' 46' ' ' LEU . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.473 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.538 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.715 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.715 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.768 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.891 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.891 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 N--CA 1.454 -0.249 0 CA-C-O 120.882 0.373 . . . . 0.0 110.092 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.491 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.705 ' H ' HD23 ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 29' ' ' ALA . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.646 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.646 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.621 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.44 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.551 ' O ' HD12 ' A' ' 46' ' ' LEU . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.403 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.9 t-160 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.842 ' N ' HD13 ' A' ' 46' ' ' LEU . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.403 HD11 ' CE1' ' A' ' 45' ' ' HIS . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.456 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.593 ' ND1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.593 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.432 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.555 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.555 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.77 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.77 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.489 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.532 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.532 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.755 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.831 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.831 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.562 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.567 ' ND1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.47 ' O ' HD22 ' D' ' 46' ' ' LEU . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.533 HD23 ' N ' ' D' ' 47' ' ' ASN . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.533 ' N ' HD23 ' D' ' 46' ' ' LEU . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.697 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.4 mm-40 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 120.535 0.207 . . . . 0.0 111.191 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 26' ' ' LEU . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.741 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.45 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.511 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.557 ' CG2' HD23 ' A' ' 26' ' ' LEU . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.444 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.482 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.45 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.482 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.58 HD12 ' N ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.58 ' N ' HD12 ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.458 ' OE1' HD23 ' A' ' 46' ' ' LEU . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.73 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.73 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.554 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 29' ' ' ALA . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.451 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . 0.883 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.613 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.768 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.515 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.488 ' NZ ' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.409 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.55 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.827 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.443 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.953 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.953 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.424 HD12 ' C ' ' D' ' 46' ' ' LEU . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.493 ' CB ' HD21 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.685 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.8 mm-40 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.511 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.458 -0.05 0 CA-C-O 120.964 0.411 . . . . 0.0 110.021 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.532 ' O ' HG12 ' A' ' 28' ' ' VAL . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.645 ' N ' HD23 ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.462 HG22 HG11 ' B' ' 27' ' ' VAL . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 0.403 HG22 ' HE2' ' B' ' 37' ' ' HIS . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.456 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 27' ' ' VAL . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.493 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 29' ' ' ALA . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.461 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.506 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.638 HG23 ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.638 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.573 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . 0.794 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.526 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.6 ' CD1' HD22 ' C' ' 47' ' ' ASN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.6 HD22 ' CD1' ' C' ' 46' ' ' LEU . 0.9 OUTLIER -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.595 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . 0.425 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.607 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.452 ' O ' HG22 ' D' ' 43' ' ' ILE . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.526 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.456 ' O ' HD23 ' D' ' 46' ' ' LEU . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.456 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.578 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 . . . . . 0 C--O 1.232 0.149 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.855 HD13 ' CG2' ' B' ' 28' ' ' VAL . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.419 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . 0.444 ' C ' HE22 ' B' ' 48' ' ' GLN . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . 0.456 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . 0.456 HD11 ' CE1' ' A' ' 45' ' ' HIS . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . 0.44 ' C ' HD13 ' D' ' 46' ' ' LEU . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.855 ' CG2' HD13 ' A' ' 26' ' ' LEU . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.427 HD13 HG21 ' B' ' 32' ' ' ILE . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.411 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.579 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.609 ' O ' HG22 ' B' ' 42' ' ' THR . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CZ2' ' HB1' ' A' ' 40' ' ' ALA . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.609 HG22 ' O ' ' B' ' 39' ' ' ILE . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . 0.436 ' NE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.61 HD12 ' N ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.61 ' N ' HD12 ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.444 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.683 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.683 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.553 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . 0.51 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.51 HG22 ' O ' ' C' ' 29' ' ' ALA . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.461 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.848 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.868 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.868 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . 0.411 HG22 ' O ' ' C' ' 46' ' ' LEU . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . 0.422 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.573 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . 0.429 ' O ' ' CD2' ' D' ' 37' ' ' HIS . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.465 ' O ' HD23 ' D' ' 46' ' ' LEU . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.643 HE22 HD11 ' C' ' 46' ' ' LEU . 50.4 mm-40 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.473 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 . . . . . 0 N--CA 1.462 0.144 0 N-CA-C 109.612 -0.514 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.444 ' O ' HG12 ' A' ' 28' ' ' VAL . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.619 HD22 HG23 ' B' ' 28' ' ' VAL . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.622 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.47 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.404 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.619 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.534 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.534 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.628 ' O ' HG22 ' B' ' 42' ' ' THR . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.429 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.628 HG22 ' O ' ' B' ' 39' ' ' ILE . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.451 ' N ' HG23 ' B' ' 42' ' ' THR . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.819 HD21 HE21 ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.763 HD21 HE22 ' C' ' 48' ' ' GLN . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.443 ' O ' ' C ' ' B' ' 49' ' ' ILE . 0.1 OUTLIER -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.859 ' H ' HG23 ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.516 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.447 ' H ' HG22 ' C' ' 42' ' ' THR . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.741 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.764 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.764 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.819 HE21 HD21 ' B' ' 46' ' ' LEU . 2.9 mm100 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.597 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 . . . . . 0 N--CA 1.457 -0.107 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 HG23 ' B' ' 28' ' ' VAL . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 35' ' ' ILE . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.615 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.413 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.596 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . 0.603 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.403 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.585 ' O ' HG22 ' B' ' 42' ' ' THR . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.585 HG22 ' O ' ' B' ' 39' ' ' ILE . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.624 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.624 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.715 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.715 ' H ' HG23 ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.549 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.449 HG12 ' H ' ' C' ' 32' ' ' ILE . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.507 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.865 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.865 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.729 ' H ' HD13 ' C' ' 46' ' ' LEU . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.714 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.628 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . 0.714 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.58 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.4 HG21 HD13 ' D' ' 33' ' ' ILE . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.447 ' O ' HD23 ' D' ' 46' ' ' LEU . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . 0.523 ' CD2' ' NE2' ' D' ' 48' ' ' GLN . 47.3 t-80 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.491 ' HA ' HD12 ' D' ' 49' ' ' ILE . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.461 ' N ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.523 ' NE2' ' CD2' ' D' ' 45' ' ' HIS . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' D' ' 46' ' ' LEU . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.628 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 . . . . . 0 N--CA 1.453 -0.291 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.641 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.542 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 82.9 m-20 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.537 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . 0.412 ' H ' HG22 ' B' ' 35' ' ' ILE . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.402 HD13 HG21 ' B' ' 43' ' ' ILE . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . 0.535 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . 0.489 ' N ' HD12 ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.501 HE22 ' ND2' ' A' ' 47' ' ' ASN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.611 HG23 ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.611 ' N ' HG23 ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.507 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.405 HG12 ' H ' ' C' ' 32' ' ' ILE . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.424 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.84 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.857 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.857 ' H ' HD13 ' C' ' 46' ' ' LEU . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.569 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.84 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.94 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . 0.94 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.495 HD12 ' N ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.495 ' N ' HD12 ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.579 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 . . . . . 0 N--CA 1.452 -0.327 0 CA-C-O 120.698 0.285 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 29' ' ' ALA . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.676 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.601 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.582 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' ALA . . . . . 0.572 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.572 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.472 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' ILE . . . . . 0.472 HG22 ' O ' ' B' ' 40' ' ' ALA . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' GLN . . . . . 0.601 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . 0.531 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' C' C ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 40' ' ' ALA . . . . . 0.516 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' C' C ' 43' ' ' ILE . . . . . 0.821 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 44' ' ' GLY . . . . . 0.411 ' O ' HD13 ' C' ' 46' ' ' LEU . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 46' ' ' LEU . . . . . 0.821 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' C' C ' 47' ' ' ASN . . . . . 0.715 ' H ' HD13 ' C' ' 46' ' ' LEU . 56.3 m-80 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.56 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' D' D ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 43' ' ' ILE . . . . . 0.685 ' O ' HD22 ' D' ' 46' ' ' LEU . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' D' D ' 46' ' ' LEU . . . . . 0.872 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' D' D ' 47' ' ' ASN . . . . . 0.872 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 48' ' ' GLN . . . . . 0.692 HE22 HD21 ' C' ' 47' ' ' ASN . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' D' D ' 51' ' ' ARG . . . . . 0.582 ' CA ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 41.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 68.6 m-20 40.99 53.36 6.5 Favored Pre-proline 0 C--N 1.31 -1.141 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.043 179.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 19.1 Cg_endo -59.29 -18.33 44.55 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 C-N-CA 122.094 1.863 . . . . 0.0 110.274 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.549 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.1 mp -60.74 -38.32 84.78 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.28 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.4 t -70.05 -43.25 79.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.691 -179.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -70.64 -30.67 43.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 N-CA-C 112.23 0.455 . . . . 0.0 112.23 -178.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.22 -53.74 50.92 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.103 -0.639 . . . . 0.0 112.612 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -60.89 -50.55 72.95 Favored 'General case' 0 C--N 1.311 -1.106 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.821 -179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.432 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.4 t -49.8 -51.95 35.72 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.005 179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 13.2 mt -47.72 -45.26 10.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.771 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 84.9 mt -65.98 -38.98 83.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 178.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.545 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.98 -49.9 28.45 Favored Glycine 0 C--N 1.303 -1.255 0 CA-C-N 115.277 -0.874 . . . . 0.0 111.687 -179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 55.5 mt -69.99 -30.63 44.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.937 -179.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.6 tp -62.3 -30.48 71.18 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.41 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.51 -33.65 69.42 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 -178.896 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.592 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 83.4 t80 -57.36 -51.78 68.0 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.07 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.648 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.8 mp -55.16 -33.01 29.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.246 -179.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.43 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.51 -29.41 62.47 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.263 0.554 . . . . 0.0 110.731 178.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -58.88 -50.3 74.55 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.781 -177.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.43 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -47.72 -48.12 29.7 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -177.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.887 ' O ' HD12 ' A' ' 46' ' ' LEU . 19.5 pt -63.87 -36.47 76.77 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 C-N-CA 119.245 -0.982 . . . . 0.0 110.498 -179.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -67.68 -29.44 73.87 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.813 -0.515 . . . . 0.0 111.813 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 8.9 t-160 -60.9 -28.76 69.14 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-O 120.722 0.296 . . . . 0.0 111.226 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.905 HD13 ' H ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -44.7 -28.95 0.68 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.403 0.52 . . . . 0.0 112.403 -177.919 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.905 ' H ' HD13 ' A' ' 46' ' ' LEU . 75.0 m-20 -56.83 -52.18 66.08 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.034 -1.066 . . . . 0.0 109.614 178.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.471 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -56.25 -62.96 1.36 Allowed 'General case' 0 C--N 1.308 -1.229 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.117 179.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 33.5 mm -42.2 -62.55 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.981 -179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -58.87 -70.84 0.13 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.615 -179.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.532 ' NH2' ' O ' ' D' ' 51' ' ' ARG . 79.8 ttt180 -66.86 96.86 0.44 Allowed 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.695 -179.636 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.14 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.993 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.549 ' O ' ' N ' ' B' ' 26' ' ' LEU . 21.7 m-20 -154.13 77.99 5.42 Favored Pre-proline 0 C--N 1.308 -1.239 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.317 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -47.76 78.28 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.812 0 C-N-CA 123.056 2.504 . . . . 0.0 112.527 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.549 ' N ' ' O ' ' B' ' 24' ' ' ASP . 5.6 mt -70.25 -43.17 71.09 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.503 179.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.3 t -56.05 -50.72 68.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.78 -178.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -71.99 -24.11 22.49 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 CA-C-O 120.866 0.365 . . . . 0.0 111.116 179.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.437 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.21 -34.14 74.62 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.965 -178.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.95 7.74 Favored 'General case' 0 C--N 1.309 -1.159 0 C-N-CA 118.365 -1.334 . . . . 0.0 111.255 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.1 t -49.6 -28.96 6.32 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -179.169 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.437 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.2 tt -71.58 -38.35 67.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 120.52 -0.472 . . . . 0.0 110.645 -179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 37.4 mt -69.99 -46.83 71.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 116.377 -0.374 . . . . 0.0 111.516 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.87 -45.78 19.11 Favored Glycine 0 C--N 1.304 -1.231 0 C-N-CA 121.022 -0.608 . . . . 0.0 113.821 -175.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.412 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 3.2 pt -49.89 -29.79 5.44 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 CA-C-N 118.546 1.173 . . . . 0.0 109.691 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -70.4 -38.36 74.63 Favored 'General case' 0 C--N 1.307 -1.281 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.608 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.543 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -69.8 -44.19 70.55 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.609 -0.723 . . . . 0.0 111.258 -179.02 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -54.03 -42.66 69.38 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 112.514 0.561 . . . . 0.0 112.514 -178.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 pt -69.82 -43.73 79.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 -178.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.46 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.81 -29.1 65.18 Favored 'General case' 0 C--N 1.3 -1.548 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.196 179.814 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.43 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 7.4 t-105 -49.5 -50.37 41.9 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-N 115.545 -0.752 . . . . 0.0 112.459 -178.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -54.99 -30.18 58.77 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 112.121 0.415 . . . . 0.0 112.121 -178.057 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.46 HG22 ' O ' ' B' ' 40' ' ' ALA . 7.3 tt -48.7 -41.99 12.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.96 -0.296 . . . . 0.0 111.58 -178.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' B' ' 47' ' ' ASN . . . -52.37 -49.69 50.35 Favored Glycine 0 C--N 1.304 -1.22 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.545 ' O ' HG22 ' B' ' 49' ' ' ILE . 27.2 t-80 -40.48 -25.39 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -175.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.559 HD11 ' HB3' ' C' ' 48' ' ' GLN . 3.1 pp -61.98 -45.31 94.19 Favored 'General case' 0 C--N 1.3 -1.583 0 C-N-CA 118.796 -1.162 . . . . 0.0 108.037 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.668 HD21 ' NE2' ' C' ' 48' ' ' GLN . 67.3 m-80 -53.14 -49.47 66.5 Favored 'General case' 0 C--N 1.303 -1.452 0 CA-C-N 114.421 -1.263 . . . . 0.0 113.238 -177.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.702 HE22 HD21 ' A' ' 47' ' ' ASN . 0.0 OUTLIER -78.48 -61.32 2.05 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.413 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.661 HG23 ' N ' ' B' ' 50' ' ' LYS . 7.4 tt -35.09 -63.16 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.878 0 C-N-CA 121.033 -0.267 . . . . 0.0 111.077 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.661 ' N ' HG23 ' B' ' 49' ' ' ILE . 15.8 mmtp -44.62 -41.16 6.38 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 120.846 -0.341 . . . . 0.0 110.664 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . 0.46 ' N ' ' O ' ' B' ' 48' ' ' GLN . 93.2 mtt-85 -76.49 -54.1 7.19 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.698 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.159 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -179.914 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.418 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 5.0 p-10 41.88 54.51 8.61 Favored Pre-proline 0 C--N 1.309 -1.152 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.916 179.562 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.418 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 35.0 Cg_endo -65.68 -21.1 59.26 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.015 1.81 . . . . 0.0 110.35 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.518 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -60.67 -43.44 97.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.375 -179.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.96 -46.21 88.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 N-CA-C 112.586 0.587 . . . . 0.0 112.586 -178.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 4.3 p -73.12 -39.6 57.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.69 -28.28 64.64 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 113.467 0.914 . . . . 0.0 113.467 -178.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.23 -39.48 65.46 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 120.072 -0.651 . . . . 0.0 112.502 -178.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.8 t -64.99 -27.8 69.08 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-O 120.889 0.376 . . . . 0.0 111.838 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.406 HG12 ' H ' ' C' ' 32' ' ' ILE . 28.5 mm -46.46 -46.79 7.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.597 -178.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 88.0 mt -62.35 -38.98 82.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 CA-C-O 121.625 0.726 . . . . 0.0 109.597 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.538 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.03 -50.88 14.76 Favored Glycine 0 C--N 1.296 -1.639 0 CA-C-N 115.095 -0.957 . . . . 0.0 112.136 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.9 pt -71.22 -29.46 36.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 CA-C-N 117.579 0.689 . . . . 0.0 111.484 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 44.0 tp -60.11 -34.13 73.06 Favored 'General case' 0 C--N 1.307 -1.279 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.547 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.538 ' CD2' ' O ' ' C' ' 34' ' ' GLY . 0.2 OUTLIER -70.55 -35.35 73.07 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 112.272 0.471 . . . . 0.0 112.272 -178.244 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.417 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 61.3 t80 -58.68 -46.28 87.58 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.786 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.71 -35.38 72.73 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 C-N-CA 120.21 -0.596 . . . . 0.0 110.905 -179.132 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.6 -31.14 64.95 Favored 'General case' 0 C--N 1.301 -1.502 0 CA-C-O 121.163 0.506 . . . . 0.0 110.629 178.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.94 -49.59 49.57 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.535 -0.757 . . . . 0.0 113.027 -177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.456 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -48.15 -28.83 3.17 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -177.337 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.654 ' O ' HD12 ' C' ' 46' ' ' LEU . 73.1 mt -61.97 -28.78 45.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.302 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -60.12 -28.0 65.85 Favored Glycine 0 CA--C 1.535 1.283 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.68 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 15.7 t-80 -50.23 -27.6 6.25 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-O 121.574 0.702 . . . . 0.0 110.422 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 1.048 HD13 ' N ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -64.65 -17.46 64.06 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.443 178.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 1.048 ' N ' HD13 ' C' ' 46' ' ' LEU . 81.2 m-20 -59.31 -51.22 70.87 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.678 -179.082 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.668 ' NE2' HD21 ' B' ' 47' ' ' ASN . 0.0 OUTLIER -99.77 -14.53 18.8 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 112.531 0.567 . . . . 0.0 112.531 -179.338 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 11.5 tt -44.99 -30.84 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.471 -0.491 . . . . 0.0 111.265 -178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.2 tptt -105.65 89.34 3.07 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.821 0.344 . . . . 0.0 110.494 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.2 tmm_? -171.39 129.19 0.7 Allowed 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.54 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.184 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.938 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 27.0 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 6.2 t70 -74.76 132.77 77.24 Favored Pre-proline 0 C--N 1.304 -1.391 0 CA-C-O 118.78 -0.629 . . . . 0.0 109.701 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_exo -45.39 69.03 0.01 OUTLIER 'Trans proline' 0 N--CA 1.505 2.193 0 C-N-CA 122.637 2.225 . . . . 0.0 113.538 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.5 mp -63.76 -42.98 97.7 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-O 120.887 0.375 . . . . 0.0 110.162 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 65.4 t -60.33 -51.46 72.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 N-CA-C 113.07 0.767 . . . . 0.0 113.07 -178.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 p -73.24 -27.78 24.7 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 CA-C-N 118.54 0.609 . . . . 0.0 112.444 -179.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.412 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -62.39 -37.74 86.94 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.749 -178.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.432 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -74.12 -53.2 10.41 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.549 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 27.2 t -56.03 -28.23 56.52 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 115.202 -0.908 . . . . 0.0 112.337 -179.081 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -52.88 -47.56 52.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.835 -179.179 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.432 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 4.9 mt -64.5 -33.23 61.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.435 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.933 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.56 -43.33 10.86 Favored Glycine 0 C--N 1.306 -1.105 0 CA-C-O 119.276 -0.736 . . . . 0.0 114.383 -175.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -61.34 -29.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 CA-C-N 119.146 1.473 . . . . 0.0 110.375 -179.564 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.4 tp -63.9 -50.49 68.51 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.77 179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.38 -33.05 74.69 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 115.59 -0.732 . . . . 0.0 110.951 -178.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 27.0 t80 -66.19 -50.22 64.65 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 120.949 -0.3 . . . . 0.0 111.306 -179.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.9 mt -65.82 -40.64 88.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.225 0 CA-C-O 120.758 0.313 . . . . 0.0 111.191 -179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -61.99 -28.26 69.44 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-O 121.324 0.583 . . . . 0.0 110.286 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -58.03 -49.87 75.39 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.419 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 80.6 p -51.47 -53.91 32.37 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.495 0.554 . . . . 0.0 112.495 -177.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.847 ' O ' HD22 ' D' ' 46' ' ' LEU . 16.4 pt -51.54 -27.45 7.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 C-N-CA 120.109 -0.637 . . . . 0.0 111.285 -178.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.61 -51.95 54.17 Favored Glycine 0 C--N 1.305 -1.161 0 C-N-CA 119.76 -1.209 . . . . 0.0 111.0 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.412 ' O ' ' ND1' ' D' ' 45' ' ' HIS . 43.7 t-80 -51.15 -29.24 13.07 Favored 'General case' 0 C--N 1.31 -1.13 0 O-C-N 122.633 -0.333 . . . . 0.0 111.624 -179.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.847 HD22 ' O ' ' D' ' 43' ' ' ILE . 0.1 OUTLIER -47.88 -22.0 0.5 Allowed 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.072 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.791 ' N ' HD23 ' D' ' 46' ' ' LEU . 54.3 m-80 -68.98 -56.18 8.58 Favored 'General case' 0 C--N 1.31 -1.131 0 C-N-CA 119.217 -0.993 . . . . 0.0 111.156 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.79 ' OE1' HD21 ' C' ' 46' ' ' LEU . 4.5 mm-40 -44.08 -25.21 0.2 Allowed 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 -178.131 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 65.6 mt -46.21 -83.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 120.19 -0.604 . . . . 0.0 110.017 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.9 tptt -41.02 -33.96 0.37 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 120.701 0.286 . . . . 0.0 111.011 179.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.532 ' O ' ' NH2' ' A' ' 51' ' ' ARG . 0.0 OUTLIER 63.78 -70.28 0.07 Allowed 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.417 179.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.231 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 48.1 t . . . . . 0 N--CA 1.489 1.498 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.468 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.1 m-20 42.12 50.29 4.89 Favored Pre-proline 0 C--N 1.308 -1.227 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.655 179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.468 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.1 Cg_endo -49.42 -14.79 0.67 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.331 2.021 . . . . 0.0 110.598 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 26' ' ' LEU . 9.4 mp -57.77 -36.48 72.2 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.929 -179.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 89.5 t -68.96 -42.12 82.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 116.585 -0.279 . . . . 0.0 111.61 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.93 -32.92 45.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.19 -54.1 49.89 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 112.825 0.676 . . . . 0.0 112.825 -177.767 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.42 -50.32 74.39 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.432 -179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.403 ' OG ' ' HB2' ' D' ' 30' ' ' ALA . 32.3 t -49.72 -51.39 39.07 Favored 'General case' 0 C--N 1.296 -1.721 0 CA-C-N 114.449 -1.25 . . . . 0.0 110.049 179.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.3 mt -49.3 -47.59 18.84 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.14 -178.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 61.7 mt -60.02 -43.01 91.65 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.08 -0.648 . . . . 0.0 109.318 179.329 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.75 -49.06 23.0 Favored Glycine 0 C--N 1.303 -1.301 0 CA-C-N 115.184 -0.916 . . . . 0.0 111.957 -178.434 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.5 mt -69.99 -36.38 68.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 117.133 0.466 . . . . 0.0 110.967 -179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.2 tp -56.23 -36.43 68.48 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.174 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.67 -29.45 63.43 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -179.288 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 81.6 t80 -53.85 -50.94 65.12 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 112.146 0.425 . . . . 0.0 112.146 -177.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.626 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.85 -31.52 30.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.725 -179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.02 -29.01 62.69 Favored 'General case' 0 C--N 1.3 -1.58 0 CA-C-O 121.081 0.467 . . . . 0.0 110.93 179.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.8 t-105 -60.93 -51.63 68.44 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -177.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.45 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.83 -44.14 49.26 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -177.715 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.9 pt -65.84 -45.34 91.72 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.569 -178.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.8 -33.38 87.07 Favored Glycine 0 C--N 1.306 -1.098 0 C-N-CA 120.927 -0.654 . . . . 0.0 111.475 -179.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 57.6 t-80 -49.86 -27.83 5.69 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-O 120.585 0.231 . . . . 0.0 111.599 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.611 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -46.03 -28.93 1.29 Allowed 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 111.867 0.321 . . . . 0.0 111.867 -177.871 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.444 ' O ' ' N ' ' A' ' 51' ' ' ARG . 69.6 m-20 -57.05 -53.27 60.03 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.828 -0.749 . . . . 0.0 109.993 -179.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.9 tm0? -51.99 -54.32 31.2 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.656 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.0 mm -53.15 -50.61 45.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.941 -179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -74.8 -66.66 0.72 Allowed 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.533 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.518 HH22 ' C ' ' D' ' 51' ' ' ARG . 73.1 ttt180 -69.26 126.98 31.47 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.651 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.126 0 N-CA-C 110.851 -0.899 . . . . 0.0 110.851 -179.959 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 33.3 p . . . . . 0 N--CA 1.491 1.59 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.567 ' O ' ' N ' ' B' ' 26' ' ' LEU . 42.2 m-20 -157.82 71.57 4.19 Favored Pre-proline 0 C--N 1.307 -1.251 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.427 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.7 Cg_exo -44.32 78.06 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 123.278 2.652 . . . . 0.0 112.912 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.567 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.1 mt -70.77 -42.17 70.76 Favored 'General case' 0 C--N 1.303 -1.433 0 CA-C-O 121.235 0.541 . . . . 0.0 110.438 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.7 t -56.65 -50.67 73.04 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.233 -178.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -72.4 -23.75 21.5 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.889 0.376 . . . . 0.0 111.128 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.73 -33.9 72.24 Favored 'General case' 0 C--N 1.309 -1.193 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.605 -179.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.99 -53.22 9.32 Favored 'General case' 0 C--N 1.311 -1.095 0 C-N-CA 119.302 -0.959 . . . . 0.0 111.568 179.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 18.3 t -47.4 -37.3 11.12 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 18.2 tt -71.66 -31.25 41.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 C-N-CA 119.706 -0.797 . . . . 0.0 110.99 179.267 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 53.5 mt -71.57 -51.35 33.44 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.73 -49.49 27.87 Favored Glycine 0 C--N 1.306 -1.097 0 C-N-CA 121.016 -0.611 . . . . 0.0 114.127 -176.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.437 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.2 tt -49.76 -31.63 6.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 118.068 0.934 . . . . 0.0 110.119 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.3 tp -64.75 -49.1 72.11 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-O 121.624 0.726 . . . . 0.0 109.415 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.521 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -57.47 -36.48 71.52 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.195 -179.622 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 51.9 t80 -62.35 -47.04 85.95 Favored 'General case' 0 C--N 1.306 -1.308 0 N-CA-C 112.798 0.666 . . . . 0.0 112.798 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.404 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.6 pt -67.6 -37.92 79.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.933 -178.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.471 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.17 -29.52 65.29 Favored 'General case' 0 C--N 1.302 -1.493 0 CA-C-O 121.141 0.496 . . . . 0.0 110.173 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -51.46 -51.46 54.78 Favored 'General case' 0 C--N 1.305 -1.364 0 CA-C-N 115.547 -0.751 . . . . 0.0 112.929 -178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.404 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.32 -36.29 20.74 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.637 -177.712 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.471 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.3 tt -48.72 -37.16 8.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 N-CA-C 111.883 0.327 . . . . 0.0 111.883 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.2 -47.8 87.23 Favored Glycine 0 C--N 1.308 -1.017 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 45.8 t-80 -41.55 -23.11 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 -176.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.649 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.7 pp -51.03 -50.31 58.83 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 107.589 -1.263 . . . . 0.0 107.589 177.647 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.649 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.5 m-80 -48.89 -48.18 42.59 Favored 'General case' 0 C--N 1.304 -1.375 0 CA-C-N 114.756 -1.111 . . . . 0.0 111.737 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.438 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.0 mm100 -37.19 -99.26 0.0 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.636 HG23 ' N ' ' B' ' 50' ' ' LYS . 16.0 tt -37.92 -57.69 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.177 0 CA-C-N 116.207 -0.451 . . . . 0.0 112.084 -178.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.636 ' N ' HG23 ' B' ' 49' ' ' ILE . 23.4 mmtp -41.76 -49.14 4.35 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.966 -0.294 . . . . 0.0 111.153 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 86.8 mtt-85 -94.24 2.37 55.9 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-O 120.793 0.33 . . . . 0.0 110.527 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.41 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.6 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.409 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.4 p30 39.82 54.71 6.03 Favored Pre-proline 0 C--N 1.31 -1.12 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.216 179.281 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.409 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.0 Cg_endo -64.86 -20.15 64.43 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.018 1.812 . . . . 0.0 110.411 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.545 HD12 ' N ' ' C' ' 26' ' ' LEU . 7.5 mp -63.67 -45.1 91.65 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.322 -179.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -61.37 -47.33 93.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 N-CA-C 112.605 0.594 . . . . 0.0 112.605 -178.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.432 ' CG1' ' N ' ' C' ' 29' ' ' ALA . 2.8 p -72.26 -44.84 63.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 N-CA-C 112.497 0.554 . . . . 0.0 112.497 -178.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.432 ' N ' ' CG1' ' C' ' 28' ' ' VAL . . . -70.62 -26.94 63.71 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.237 0.828 . . . . 0.0 113.237 -178.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.55 -43.4 63.53 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.779 -0.769 . . . . 0.0 111.332 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -71.75 -29.33 64.39 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 112.242 0.46 . . . . 0.0 112.242 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.2 mm -47.57 -37.76 5.61 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 121.169 -0.213 . . . . 0.0 110.855 -177.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.7 mt -66.26 -45.38 90.02 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 C-N-CA 120.263 -0.575 . . . . 0.0 110.291 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.543 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.08 -45.79 26.76 Favored Glycine 0 C--N 1.301 -1.377 0 CA-C-N 115.219 -0.9 . . . . 0.0 113.225 -177.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 12.9 pt -65.84 -28.92 45.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 CA-C-N 117.491 0.645 . . . . 0.0 111.667 -179.034 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . 0.857 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -66.83 -28.65 68.53 Favored 'General case' 0 C--N 1.304 -1.375 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -178.981 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.72 -29.65 64.77 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 120.5 -0.48 . . . . 0.0 112.188 -179.347 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.7 t80 -56.98 -50.08 73.77 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.831 -0.347 . . . . 0.0 111.698 -178.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.426 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.94 -30.86 51.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.44 -179.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.87 -35.23 67.13 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.023 0.44 . . . . 0.0 110.421 179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.4 t-105 -51.56 -51.32 56.4 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.591 -178.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.426 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.77 -27.72 7.8 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 112.408 0.521 . . . . 0.0 112.408 -178.321 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.5 tt -62.21 -49.03 85.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.437 -0.505 . . . . 0.0 111.24 -178.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.44 -28.34 59.3 Favored Glycine 0 C--N 1.307 -1.075 0 N-CA-C 111.729 -0.548 . . . . 0.0 111.729 -179.653 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . 0.552 ' CD2' ' NE2' ' C' ' 48' ' ' GLN . 59.6 t-80 -48.38 -28.95 3.53 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 111.639 0.237 . . . . 0.0 111.639 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 1.7 pp -45.72 -32.94 2.71 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -176.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.27 -54.54 44.18 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.159 -1.017 . . . . 0.0 111.533 -178.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.552 ' NE2' ' CD2' ' C' ' 45' ' ' HIS . 7.2 pm0 -60.16 -50.31 74.17 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 120.06 -0.656 . . . . 0.0 111.958 -178.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.408 ' H ' ' HG2' ' C' ' 48' ' ' GLN . 4.0 tt -57.48 -38.28 62.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 C-N-CA 120.557 -0.457 . . . . 0.0 110.861 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 44.0 tptt -65.05 -45.88 83.55 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-O 120.725 0.298 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.8 tmm_? -63.51 134.52 55.73 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.337 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.976 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 11.6 t . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 13.4 t70 -82.73 125.49 75.52 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.874 -0.584 . . . . 0.0 109.744 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -43.52 72.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.504 2.126 0 C-N-CA 122.635 2.223 . . . . 0.0 113.412 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.6 tp -68.34 -42.3 79.49 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.021 0.439 . . . . 0.0 110.275 179.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 63.5 t -57.51 -50.59 76.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 112.285 -179.058 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -72.86 -25.79 22.62 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.09 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.45 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -61.48 -39.56 91.37 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.556 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.403 ' HB2' ' OG ' ' A' ' 31' ' ' SER . . . -73.11 -53.37 11.2 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.358 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 23.3 t -50.12 -27.41 5.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.386 -0.824 . . . . 0.0 112.231 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.67 -38.92 74.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.891 -179.357 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.8 mt -69.64 -40.05 78.95 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.729 -0.388 . . . . 0.0 111.319 -179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.87 -42.84 11.74 Favored Glycine 0 C--N 1.306 -1.131 0 CA-C-O 119.312 -0.715 . . . . 0.0 114.517 -175.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.1 pt -57.97 -28.95 34.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 CA-C-N 119.191 1.495 . . . . 0.0 109.886 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -63.19 -50.68 69.37 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.102 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.612 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -66.29 -30.62 71.08 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.797 -0.638 . . . . 0.0 111.019 -179.008 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.612 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 88.7 t80 -67.65 -50.3 58.6 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 116.418 -0.355 . . . . 0.0 111.311 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.2 mt -67.78 -38.06 79.59 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 CA-C-O 120.685 0.279 . . . . 0.0 111.406 -179.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.38 -28.76 68.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-O 121.166 0.508 . . . . 0.0 110.383 -179.659 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.421 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.9 t-105 -60.48 -42.39 96.15 Favored 'General case' 0 C--N 1.293 -1.864 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.279 -179.219 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 42.7 p -48.82 -50.57 33.76 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 113.083 0.772 . . . . 0.0 113.083 -177.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.461 ' O ' HD22 ' D' ' 46' ' ' LEU . 6.7 pt -54.99 -32.04 26.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.675 -178.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.84 -51.27 29.6 Favored Glycine 0 CA--C 1.531 1.058 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 48.0 t-80 -43.19 -24.24 0.08 Allowed 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 -176.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.633 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.4 OUTLIER -55.45 -48.92 73.73 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 108.043 -1.095 . . . . 0.0 108.043 178.323 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.633 ' H ' HD23 ' D' ' 46' ' ' LEU . 70.7 m-80 -46.36 -35.17 5.18 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 114.431 -1.259 . . . . 0.0 112.058 -176.59 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.724 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.6 mm-40 -71.1 -58.45 3.55 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.737 -0.385 . . . . 0.0 110.375 179.652 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.4 ' C ' ' O ' ' D' ' 48' ' ' GLN . 99.0 mt -36.17 -72.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.075 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.455 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.521 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.9 tptt -46.13 -39.7 9.89 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 120.802 0.334 . . . . 0.0 110.316 -179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.518 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.01 -72.92 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.595 179.521 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.521 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 79.4 m-20 45.71 54.71 14.22 Favored Pre-proline 0 C--N 1.306 -1.309 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.064 179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 64.0 Cg_endo -72.72 0.53 7.51 Favored 'Trans proline' 0 C--N 1.304 -1.785 0 C-N-CA 122.374 2.05 . . . . 0.0 110.872 179.216 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.1 mp -73.47 -48.22 35.24 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.047 178.128 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 46.7 t -66.2 -38.19 81.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.31 0 CA-C-N 115.664 -0.698 . . . . 0.0 111.635 -179.402 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -72.63 -30.98 35.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 N-CA-C 112.323 0.49 . . . . 0.0 112.323 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.23 -54.03 35.52 Favored 'General case' 0 C--N 1.314 -0.959 0 C-N-CA 120.004 -0.678 . . . . 0.0 112.706 -177.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.71 -48.65 80.85 Favored 'General case' 0 C--N 1.311 -1.075 0 C-N-CA 119.365 -0.934 . . . . 0.0 109.068 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.1 t -49.17 -51.0 35.26 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.58 -1.191 . . . . 0.0 110.219 179.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 16.4 mt -49.69 -48.85 20.71 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 CA-C-N 115.879 -0.6 . . . . 0.0 111.374 -179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.2 mt -62.61 -46.11 97.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.963 -0.695 . . . . 0.0 109.698 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.529 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.31 -45.95 28.3 Favored Glycine 0 C--N 1.302 -1.307 0 CA-C-N 115.562 -0.744 . . . . 0.0 112.189 -178.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 41.4 mt -70.23 -29.77 40.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 116.969 0.384 . . . . 0.0 111.109 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -63.27 -31.53 72.7 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.203 -0.453 . . . . 0.0 112.044 -179.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.62 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.88 -30.83 64.27 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.44 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.62 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.5 t80 -50.76 -50.93 54.7 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 112.137 0.421 . . . . 0.0 112.137 -177.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.684 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -60.7 -30.02 46.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 C-N-CA 120.472 -0.491 . . . . 0.0 110.937 -179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.41 -39.78 67.66 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.309 0.576 . . . . 0.0 110.41 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -49.73 -51.15 40.93 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 113.407 0.892 . . . . 0.0 113.407 -177.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.439 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.97 -36.54 28.5 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 113.06 0.763 . . . . 0.0 113.06 -177.869 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.454 ' CG1' ' N ' ' A' ' 44' ' ' GLY . 0.3 OUTLIER -69.64 -50.26 51.71 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.176 0 C-N-CA 120.214 -0.594 . . . . 0.0 111.983 -178.264 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' A' ' 43' ' ' ILE . . . -62.18 -33.43 85.89 Favored Glycine 0 C--N 1.308 -1.0 0 N-CA-C 111.221 -0.752 . . . . 0.0 111.221 -179.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -48.72 -26.45 2.33 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 120.744 0.307 . . . . 0.0 110.945 -179.68 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.93 -29.47 1.42 Allowed 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 -177.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 62.0 m-20 -60.09 -53.34 58.88 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.45 -179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.528 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.3 tm0? -51.18 -51.77 50.59 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.292 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.1 mm -56.32 -48.39 79.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.057 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -73.07 -69.85 0.39 Allowed 'General case' 0 C--N 1.306 -1.311 0 CA-C-O 120.87 0.367 . . . . 0.0 110.395 -179.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.56 HH21 ' CG ' ' D' ' 50' ' ' LYS . 69.0 ttt180 -76.04 124.59 27.64 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.429 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.141 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . 0.4 ' O ' ' OG ' ' B' ' 23' ' ' SER . 50.9 p . . . . . 0 N--CA 1.491 1.606 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.554 ' O ' ' N ' ' B' ' 26' ' ' LEU . 64.5 m-20 -158.59 76.7 3.38 Favored Pre-proline 0 C--N 1.308 -1.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.175 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -53.3 71.29 0.02 OUTLIER 'Trans proline' 0 N--CA 1.499 1.836 0 C-N-CA 123.07 2.513 . . . . 0.0 112.62 -179.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.554 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.6 mt -70.39 -40.06 74.16 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.408 179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.409 HG22 HG11 ' C' ' 27' ' ' VAL . 14.0 t -56.68 -50.17 75.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.687 -178.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 14.9 p -71.57 -23.52 22.7 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-O 121.134 0.492 . . . . 0.0 111.023 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.504 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -62.73 -33.98 76.25 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 115.731 -0.668 . . . . 0.0 112.025 -179.243 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.85 -52.43 17.49 Favored 'General case' 0 C--N 1.311 -1.081 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.734 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -46.61 -26.42 0.9 Allowed 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 116.224 -0.443 . . . . 0.0 112.123 -179.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.504 HG22 ' O ' ' B' ' 29' ' ' ALA . 3.7 tt -67.96 -37.05 77.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 120.138 -0.625 . . . . 0.0 109.864 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 2.4 mt -74.0 -24.27 19.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 CA-C-O 121.502 0.668 . . . . 0.0 110.944 177.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -57.16 -52.22 52.71 Favored Glycine 0 C--N 1.302 -1.356 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.533 -178.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.403 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.5 tt -71.56 -38.28 66.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -179.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 11.4 tp -56.63 -52.24 65.62 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-O 121.1 0.476 . . . . 0.0 110.734 -178.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.53 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.43 -29.19 70.33 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.655 -0.702 . . . . 0.0 110.582 -179.19 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.458 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 35.3 t80 -69.79 -42.59 73.57 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 112.781 0.66 . . . . 0.0 112.781 -178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -70.09 -37.61 72.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 120.494 -0.482 . . . . 0.0 112.012 -178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.535 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.44 -28.95 65.44 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.141 0.496 . . . . 0.0 109.973 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.29 -51.04 36.41 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 115.255 -0.884 . . . . 0.0 112.807 -178.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -49.25 -36.29 19.96 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 120.346 -0.542 . . . . 0.0 111.059 -178.152 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.535 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.8 tt -48.17 -33.37 4.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 N-CA-C 112.156 0.428 . . . . 0.0 112.156 -177.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.33 -43.1 99.8 Favored Glycine 0 CA--C 1.531 1.035 0 N-CA-C 110.654 -0.978 . . . . 0.0 110.654 179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 -42.05 -24.63 0.05 OUTLIER 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -176.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.582 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.8 pp -55.83 -46.1 78.21 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 176.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.582 ' N ' HD12 ' B' ' 46' ' ' LEU . 69.0 m-80 -51.37 -45.63 62.48 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.649 -1.16 . . . . 0.0 112.504 -179.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.509 ' CG ' ' N ' ' B' ' 49' ' ' ILE . 4.4 pt20 -87.36 -52.65 5.26 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 -177.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.667 HG23 ' N ' ' B' ' 50' ' ' LYS . 20.7 tt -33.23 -63.5 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -177.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.667 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -43.73 -47.21 7.83 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 120.867 -0.333 . . . . 0.0 111.003 -179.753 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -66.23 -38.82 88.82 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-O 120.818 0.342 . . . . 0.0 110.531 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.18 0 N-CA-C 110.864 -0.894 . . . . 0.0 110.864 -179.986 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.427 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.9 p-10 39.32 53.31 4.64 Favored Pre-proline 0 C--N 1.311 -1.101 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.885 179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.427 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.3 Cg_endo -58.31 -13.47 16.56 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 C-N-CA 122.195 1.93 . . . . 0.0 110.559 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.581 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -61.25 -43.79 98.3 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.987 -179.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . 0.409 HG11 HG22 ' B' ' 27' ' ' VAL . 21.6 t -68.11 -44.56 84.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 112.143 0.423 . . . . 0.0 112.143 -179.025 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.1 p -71.39 -29.3 34.94 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 C-N-CA 120.998 -0.281 . . . . 0.0 111.415 -178.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.518 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -66.33 -51.51 56.54 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 112.994 0.738 . . . . 0.0 112.994 -177.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.38 -29.85 66.6 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.762 -178.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 40.9 t -49.11 -51.74 30.13 Favored 'General case' 0 C--N 1.299 -1.593 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.574 -179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.518 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.1 tp -50.29 -34.67 11.39 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.8 -178.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 42.4 mt -61.97 -45.14 99.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.208 0 CA-C-O 121.249 0.547 . . . . 0.0 110.47 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.533 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.0 -48.59 14.24 Favored Glycine 0 C--N 1.298 -1.531 0 CA-C-N 115.758 -0.656 . . . . 0.0 112.116 -177.102 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 23.6 pt -71.04 -29.38 36.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 CA-C-N 117.492 0.646 . . . . 0.0 111.596 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 35.0 tp -60.91 -36.79 80.2 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 112.258 0.466 . . . . 0.0 112.258 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 1.2 p80 -72.23 -29.44 63.95 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 112.233 0.457 . . . . 0.0 112.233 -179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 60.6 t80 -61.12 -49.6 76.61 Favored 'General case' 0 C--N 1.305 -1.339 0 N-CA-C 112.512 0.56 . . . . 0.0 112.512 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . . . . . . . . . 4.8 tp -62.73 -31.25 51.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 C-N-CA 120.512 -0.475 . . . . 0.0 110.542 -179.188 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.12 -34.21 68.41 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.622 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.7 t-105 -55.06 -51.63 65.75 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 -177.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -51.8 -28.48 15.67 Favored 'General case' 0 C--N 1.299 -1.609 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.45 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 5.4 tt -58.86 -47.59 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 C-N-CA 120.573 -0.451 . . . . 0.0 111.259 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.45 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -55.6 -28.0 50.33 Favored Glycine 0 C--N 1.306 -1.128 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 45.2 t-80 -47.89 -28.87 2.88 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . . . . . . . . . 2.7 pp -45.18 -38.21 5.11 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.371 -0.532 . . . . 0.0 111.037 -177.752 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 84.5 m-20 -65.9 -51.74 56.07 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.185 -0.606 . . . . 0.0 110.927 179.581 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.616 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -44.73 -55.18 5.52 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-O 120.806 0.336 . . . . 0.0 111.445 -179.786 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 14.6 tt -66.22 -27.36 40.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 116.264 -0.426 . . . . 0.0 111.608 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 40.2 tptt -62.02 -46.45 89.14 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.717 -0.393 . . . . 0.0 110.811 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.4 tmm_? -66.28 124.6 23.12 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 120.794 0.33 . . . . 0.0 110.588 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.167 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.907 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 19.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.411 -0.589 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.653 ' O ' ' N ' ' D' ' 26' ' ' LEU . 22.1 t70 -87.64 121.34 71.04 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-O 118.816 -0.612 . . . . 0.0 109.752 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -41.84 73.42 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.981 0 C-N-CA 122.736 2.291 . . . . 0.0 113.687 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.653 ' N ' ' O ' ' D' ' 24' ' ' ASP . 3.0 tp -67.94 -39.47 83.46 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.071 -0.513 . . . . 0.0 109.867 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 66.2 t -60.5 -50.35 80.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 115.463 -0.79 . . . . 0.0 112.688 -178.687 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.1 p -73.0 -25.75 22.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.134 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -65.02 -46.8 79.84 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.325 -178.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.02 -51.42 25.48 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.954 -179.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . 0.485 ' O ' ' N ' ' D' ' 34' ' ' GLY . 31.6 t -48.13 -40.43 23.65 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -178.303 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.605 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.47 -29.37 4.04 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.203 0 CA-C-N 118.509 0.595 . . . . 0.0 111.491 -178.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 12.3 mt -73.35 -24.9 20.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 CA-C-O 121.82 0.819 . . . . 0.0 109.996 177.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . 0.485 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.82 -50.18 32.76 Favored Glycine 0 C--N 1.303 -1.304 0 CA-C-N 114.297 -1.32 . . . . 0.0 112.598 -178.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.0 pt -68.2 -29.63 45.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 N-CA-C 112.13 0.418 . . . . 0.0 112.13 -178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.7 tp -58.2 -50.7 72.63 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.0 0.429 . . . . 0.0 110.336 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.618 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.7 OUTLIER -64.77 -30.16 71.16 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.966 -179.506 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.618 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 63.5 t80 -69.89 -50.16 45.07 Favored 'General case' 0 C--N 1.308 -1.205 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.379 -179.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 75.5 mt -68.05 -36.76 76.65 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.778 0.323 . . . . 0.0 111.239 -179.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.735 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -69.37 -28.94 66.63 Favored 'General case' 0 C--N 1.302 -1.488 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.365 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.431 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 6.5 t-105 -56.89 -39.76 74.99 Favored 'General case' 0 C--N 1.295 -1.8 0 CA-C-O 120.947 0.403 . . . . 0.0 111.747 -179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 47.5 p -48.59 -46.23 39.1 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 -176.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.811 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -51.66 -29.08 9.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 C-N-CA 119.232 -0.987 . . . . 0.0 111.405 -178.174 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.811 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -56.37 -50.54 61.83 Favored Glycine 0 C--N 1.309 -0.931 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -41.87 -24.53 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -176.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.67 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -55.67 -48.51 74.92 Favored 'General case' 0 C--N 1.3 -1.564 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 177.685 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.67 ' H ' HD23 ' D' ' 46' ' ' LEU . 71.6 m-80 -45.7 -39.22 7.74 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-N 114.64 -1.164 . . . . 0.0 111.871 -177.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.612 ' N ' HE21 ' D' ' 48' ' ' GLN . 3.4 mm-40 -64.59 -63.14 1.2 Allowed 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.179 179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 96.8 mt -34.61 -72.68 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-N 115.873 -0.603 . . . . 0.0 111.662 -179.187 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.56 ' CG ' HH21 ' A' ' 51' ' ' ARG . 41.1 tptt -49.04 -46.77 44.79 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.086 -179.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.557 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 60.23 -73.45 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.592 179.6 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.152 0 N-CA-C 110.929 -0.868 . . . . 0.0 110.929 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 7.6 t . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 57.4 m-20 40.4 52.86 5.5 Favored Pre-proline 0 C--N 1.31 -1.139 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.767 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.432 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 12.6 Cg_endo -55.11 -11.63 4.17 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 C-N-CA 122.166 1.911 . . . . 0.0 110.802 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.798 HD13 ' CG2' ' B' ' 28' ' ' VAL . 58.9 mt -57.05 -37.39 71.74 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.373 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 99.5 t -64.77 -38.66 83.28 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 120.581 0.229 . . . . 0.0 111.575 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.62 -32.03 39.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 N-CA-C 112.454 0.539 . . . . 0.0 112.454 -179.108 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.53 -53.97 46.78 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -177.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.98 -49.17 78.91 Favored 'General case' 0 C--N 1.305 -1.333 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.177 -179.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 33.9 t -49.38 -50.7 39.08 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 114.325 -1.307 . . . . 0.0 109.899 179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 14.3 mt -49.3 -46.94 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.343 -179.019 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 80.1 mt -58.0 -47.64 86.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 119.709 -0.797 . . . . 0.0 109.177 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.556 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.57 -47.19 29.84 Favored Glycine 0 C--N 1.303 -1.272 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.619 -178.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 18.1 mt -70.27 -40.53 78.06 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 CA-C-N 117.218 0.509 . . . . 0.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 7.9 tp -63.14 -35.88 81.77 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.788 -0.642 . . . . 0.0 111.282 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.639 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -71.55 -28.53 63.92 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 112.455 0.539 . . . . 0.0 112.455 -178.506 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.639 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 80.0 t80 -59.56 -46.89 87.58 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.707 0.632 . . . . 0.0 112.707 -178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.683 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.3 mp -56.82 -30.78 33.89 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-O 120.984 0.421 . . . . 0.0 110.432 -179.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.404 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.0 -28.71 62.53 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -63.67 -51.04 66.85 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -177.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -48.98 -42.88 39.28 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 112.884 0.698 . . . . 0.0 112.884 -177.567 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.9 pt -64.26 -43.0 97.17 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.229 0 C-N-CA 119.523 -0.871 . . . . 0.0 111.204 -178.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -32.26 82.13 Favored Glycine 0 C--N 1.307 -1.06 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -179.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.1 t-160 -49.11 -27.14 3.18 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.705 -0.247 . . . . 0.0 111.614 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.465 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -45.08 -29.45 0.89 Allowed 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 111.626 0.232 . . . . 0.0 111.626 -177.443 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.552 HD21 ' NE2' ' B' ' 48' ' ' GLN . 74.4 m-80 -60.37 -52.04 66.96 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.089 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.7 tm0? -50.86 -53.42 32.55 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 116.257 -0.428 . . . . 0.0 110.717 -179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.2 mm -57.36 -44.43 84.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.945 -0.302 . . . . 0.0 110.681 -179.472 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -82.44 -72.98 0.42 Allowed 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.617 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.524 ' N ' ' O ' ' A' ' 47' ' ' ASN . 67.3 ttt180 -73.56 133.56 43.57 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.807 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.116 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -179.891 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 72.3 p . . . . . 0 N--CA 1.489 1.518 0 N-CA-C 109.389 -0.597 . . . . 0.0 109.389 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.585 ' O ' ' N ' ' B' ' 26' ' ' LEU . 16.1 m-20 -101.02 139.91 20.88 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.03 -179.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_exo -42.55 78.81 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.913 0 C-N-CA 122.318 2.012 . . . . 0.0 113.451 179.465 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.585 ' N ' ' O ' ' B' ' 24' ' ' ASP . 9.1 mt -70.32 -44.11 68.93 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.084 0.468 . . . . 0.0 109.895 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 21.9 t -56.07 -48.55 78.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-N 115.522 -0.763 . . . . 0.0 111.523 -178.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.798 ' CG2' HD13 ' A' ' 26' ' ' LEU . 8.9 t -71.2 -24.14 23.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 120.966 0.412 . . . . 0.0 111.132 179.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.66 -36.91 84.38 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 115.963 -0.562 . . . . 0.0 112.293 -179.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.27 -55.22 8.5 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 118.514 -1.275 . . . . 0.0 111.018 -179.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 41.0 t -53.95 -29.46 42.75 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.949 0.404 . . . . 0.0 111.238 -179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 36.7 mt -71.25 -48.17 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-N 115.836 -0.62 . . . . 0.0 111.077 179.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 93.1 mt -71.27 -44.31 73.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 C-N-CA 120.57 -0.452 . . . . 0.0 111.849 -179.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.11 -49.82 23.45 Favored Glycine 0 C--N 1.305 -1.164 0 C-N-CA 121.304 -0.474 . . . . 0.0 114.022 -177.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.446 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.0 OUTLIER -49.53 -29.58 4.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-N 118.151 0.975 . . . . 0.0 110.241 -179.193 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -64.76 -50.81 65.35 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 121.434 0.635 . . . . 0.0 110.03 179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.551 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -58.57 -29.44 66.4 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 115.285 -0.871 . . . . 0.0 111.261 -178.727 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.54 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.0 t80 -63.76 -47.46 80.88 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' B' ' 42' ' ' THR . 31.3 pt -70.12 -33.65 55.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.196 0 C-N-CA 120.394 -0.522 . . . . 0.0 111.766 -178.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.0 -27.32 63.61 Favored 'General case' 0 C--N 1.302 -1.497 0 CA-C-O 121.438 0.637 . . . . 0.0 109.646 178.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.404 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.3 t-105 -48.14 -49.85 30.8 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-N 115.477 -0.783 . . . . 0.0 112.82 -177.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -47.76 -30.85 4.25 Favored 'General case' 0 C--N 1.298 -1.643 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.094 -178.123 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 44' ' ' GLY . 0.7 OUTLIER -46.86 -45.79 7.81 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.837 0.31 . . . . 0.0 111.837 -177.934 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.472 ' N ' ' CG2' ' B' ' 43' ' ' ILE . . . -60.14 -48.57 85.45 Favored Glycine 0 C--N 1.306 -1.129 0 N-CA-C 111.097 -0.801 . . . . 0.0 111.097 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -42.3 -24.84 0.06 Allowed 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 113.567 0.951 . . . . 0.0 113.567 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.606 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -57.58 -50.56 72.7 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 118.466 -1.293 . . . . 0.0 107.854 177.632 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.606 ' H ' HD23 ' B' ' 46' ' ' LEU . 73.2 m-20 -50.45 -46.22 56.54 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-N 114.797 -1.092 . . . . 0.0 111.602 -178.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.601 HE21 ' N ' ' B' ' 48' ' ' GLN . 5.0 mm-40 -60.86 -75.82 0.06 Allowed 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 112.456 0.539 . . . . 0.0 112.456 -178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.695 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.5 tt -38.57 -62.19 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 C-N-CA 121.13 -0.228 . . . . 0.0 111.526 -178.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.695 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -39.1 -50.72 1.87 Allowed 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 120.798 0.332 . . . . 0.0 111.266 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.8 mtt-85 -68.85 -38.28 79.68 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.491 179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.966 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.562 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.41 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 3.7 p30 39.71 54.42 5.73 Favored Pre-proline 0 C--N 1.31 -1.113 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.983 179.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.41 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.76 -17.55 55.59 Favored 'Trans proline' 0 C--N 1.305 -1.733 0 C-N-CA 121.97 1.78 . . . . 0.0 110.473 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.561 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.6 mp -63.63 -47.0 83.13 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.466 -179.227 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 90.2 t -62.95 -46.44 96.3 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 112.585 0.587 . . . . 0.0 112.585 -178.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.402 HG13 ' N ' ' C' ' 29' ' ' ALA . 3.5 p -72.25 -43.28 65.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.402 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -71.06 -27.97 64.02 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 -178.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.52 -36.04 63.17 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 112.719 0.637 . . . . 0.0 112.719 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -70.1 -28.52 65.47 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 17.9 mm -45.15 -32.89 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.663 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.682 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 81.8 mt -70.04 -41.62 79.28 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.441 0 CA-C-O 121.223 0.535 . . . . 0.0 110.125 178.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.549 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.43 -50.11 24.74 Favored Glycine 0 C--N 1.303 -1.263 0 CA-C-N 115.532 -0.758 . . . . 0.0 112.663 -178.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.6 pt -69.58 -29.31 40.99 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 117.612 0.706 . . . . 0.0 111.263 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 32.6 tp -62.35 -29.39 70.43 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.679 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.604 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.98 -35.76 69.59 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 112.192 0.442 . . . . 0.0 112.192 -179.217 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.604 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.5 t80 -60.0 -50.71 72.68 Favored 'General case' 0 C--N 1.307 -1.245 0 N-CA-C 112.181 0.437 . . . . 0.0 112.181 -178.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.436 ' O ' ' CG2' ' C' ' 42' ' ' THR . 8.7 tp -64.08 -30.45 50.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 120.281 -0.568 . . . . 0.0 110.439 -179.359 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.436 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.6 -38.1 67.92 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 121.175 0.512 . . . . 0.0 110.072 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -49.73 -51.42 38.96 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.157 -0.928 . . . . 0.0 113.044 -177.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.436 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.24 -27.21 3.51 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.256 -178.733 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.846 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.6 tt -65.88 -35.4 75.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 N-CA-C 111.604 0.224 . . . . 0.0 111.604 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.94 -29.32 69.27 Favored Glycine 0 N--CA 1.469 0.869 0 N-CA-C 111.83 -0.508 . . . . 0.0 111.83 -179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 59.7 t-80 -56.41 -28.42 59.33 Favored 'General case' 0 C--N 1.295 -1.782 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -179.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.44 -33.05 3.66 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 113.201 0.815 . . . . 0.0 113.201 -177.343 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -60.45 -53.1 61.57 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.115 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.415 ' C ' ' O ' ' C' ' 47' ' ' ASN . 25.5 mm100 -31.74 -45.24 0.09 Allowed 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.956 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 26.6 mm -52.12 -42.29 35.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.228 -179.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.422 ' N ' ' O ' ' C' ' 47' ' ' ASN . 38.8 tptt -59.31 -43.46 92.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.921 -0.312 . . . . 0.0 110.8 -179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.5 tmm_? -50.59 128.71 20.98 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 120.851 0.358 . . . . 0.0 110.513 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.106 0 N-CA-C 110.914 -0.874 . . . . 0.0 110.914 179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.7 t . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.658 ' O ' ' N ' ' D' ' 26' ' ' LEU . 17.3 t0 -84.74 115.87 62.73 Favored Pre-proline 0 C--N 1.307 -1.246 0 CA-C-O 119.011 -0.519 . . . . 0.0 109.9 -179.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 91.8 Cg_exo -42.96 74.29 0.0 OUTLIER 'Trans proline' 0 N--CA 1.501 1.95 0 C-N-CA 122.598 2.199 . . . . 0.0 113.188 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.658 ' N ' ' O ' ' D' ' 24' ' ' ASP . 13.8 tp -67.35 -42.24 83.85 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.551 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 54.7 t -58.79 -50.66 78.56 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.401 -178.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.7 p -73.25 -25.39 21.42 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 N-CA-C 112.217 0.451 . . . . 0.0 112.217 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -66.77 -39.88 88.02 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.993 -0.549 . . . . 0.0 112.021 -178.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.69 -52.08 23.45 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.441 -179.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . 0.455 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.8 t -48.41 -35.47 12.8 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 113.343 0.868 . . . . 0.0 113.343 -177.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.576 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.39 -31.6 5.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 CA-C-N 118.168 0.44 . . . . 0.0 111.537 -178.385 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 7.4 mt -72.78 -23.96 21.01 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 CA-C-O 121.763 0.792 . . . . 0.0 110.298 177.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . 0.455 ' N ' ' O ' ' D' ' 31' ' ' SER . . . -49.76 -50.32 32.01 Favored Glycine 0 C--N 1.302 -1.336 0 CA-C-N 114.516 -1.22 . . . . 0.0 112.832 -178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 39.3 pt -66.7 -30.0 48.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 CA-C-N 117.141 0.471 . . . . 0.0 111.91 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 5.7 tp -58.5 -49.44 77.37 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-O 121.056 0.455 . . . . 0.0 110.62 -179.694 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.8 OUTLIER -68.9 -30.42 68.89 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.668 -0.697 . . . . 0.0 111.275 -179.353 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.611 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 41.0 t80 -69.8 -49.45 52.64 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 111.709 0.263 . . . . 0.0 111.709 -179.425 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 83.8 mt -64.62 -39.46 85.69 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -178.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.29 -27.76 64.66 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-O 121.241 0.544 . . . . 0.0 110.495 -179.764 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.6 t-105 -56.95 -45.97 82.43 Favored 'General case' 0 C--N 1.294 -1.825 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.939 -178.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 58.7 p -48.54 -44.52 36.42 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 114.044 1.127 . . . . 0.0 114.044 -176.774 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . . . . . . . . . 6.6 pt -61.32 -28.3 43.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 C-N-CA 119.776 -0.769 . . . . 0.0 111.391 -178.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.445 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.13 -49.13 19.19 Favored Glycine 0 C--N 1.308 -0.999 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -40.88 -20.26 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 113.209 0.818 . . . . 0.0 113.209 -177.127 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' D' ' 44' ' ' GLY . 3.4 pp -48.58 -44.06 36.46 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.426 ' H ' ' HG ' ' D' ' 46' ' ' LEU . 85.0 m-20 -45.82 -40.41 9.73 Favored 'General case' 0 C--N 1.299 -1.626 0 CA-C-N 113.861 -1.518 . . . . 0.0 111.761 -177.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.614 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.3 OUTLIER -74.62 -52.59 11.33 Favored 'General case' 0 C--N 1.309 -1.166 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.659 179.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 88.5 mt -39.98 -81.19 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.991 0 CA-C-O 120.663 0.268 . . . . 0.0 111.173 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.473 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.5 tptt -50.01 -38.12 35.93 Favored 'General case' 0 C--N 1.306 -1.312 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.507 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.64 -69.35 0.09 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.358 179.672 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.473 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.19 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 44.1 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 64.8 m-20 -157.09 57.94 1.44 Allowed Pre-proline 0 C--N 1.307 -1.263 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.356 179.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 81.0 Cg_endo -75.8 0.07 9.64 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 C-N-CA 122.842 2.361 . . . . 0.0 111.834 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.437 HD22 HG23 ' B' ' 28' ' ' VAL . 77.2 mt -70.73 -30.07 66.51 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.875 -179.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 22.3 t -70.6 -50.4 45.12 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.297 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.427 HG13 ' N ' ' A' ' 29' ' ' ALA . 14.9 p -70.72 -36.07 63.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.703 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.427 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -54.47 -28.32 43.77 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.721 0.638 . . . . 0.0 112.721 -179.037 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.1 -48.01 54.83 Favored 'General case' 0 C--N 1.309 -1.171 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.348 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 40.8 t -49.27 -41.23 37.26 Favored 'General case' 0 C--N 1.304 -1.382 0 CA-C-N 115.272 -0.876 . . . . 0.0 110.074 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 39.7 mt -48.52 -51.97 9.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.113 -177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 83.8 mt -70.1 -37.75 72.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 C-N-CA 120.278 -0.569 . . . . 0.0 110.134 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.68 -51.09 18.19 Favored Glycine 0 C--N 1.301 -1.411 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.969 -178.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 31.8 pt -71.03 -29.44 36.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 117.19 0.495 . . . . 0.0 111.164 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -61.31 -37.12 82.08 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.051 -0.522 . . . . 0.0 111.757 -178.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.5 -29.58 63.74 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 112.687 0.625 . . . . 0.0 112.687 -179.54 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 32.8 t80 -52.46 -51.45 59.26 Favored 'General case' 0 C--N 1.307 -1.242 0 N-CA-C 111.922 0.341 . . . . 0.0 111.922 -177.494 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.65 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.2 mp -55.61 -32.41 30.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 120.442 -0.503 . . . . 0.0 110.397 -179.62 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.48 -31.8 63.96 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-O 121.109 0.48 . . . . 0.0 110.848 178.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -60.2 -51.49 69.34 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 113.23 0.826 . . . . 0.0 113.23 -177.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.433 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.37 -45.34 45.73 Favored 'General case' 0 C--N 1.297 -1.681 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -177.823 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.465 ' O ' ' NE2' ' B' ' 48' ' ' GLN . 18.0 pt -64.38 -42.54 95.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 C-N-CA 119.67 -0.812 . . . . 0.0 111.309 -178.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.92 -38.02 95.89 Favored Glycine 0 C--N 1.305 -1.148 0 N-CA-C 111.687 -0.565 . . . . 0.0 111.687 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 34.0 t-80 -50.86 -27.93 8.47 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 111.715 0.265 . . . . 0.0 111.715 -179.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.641 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.79 -28.72 1.12 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.455 -177.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 39.0 m-20 -60.05 -51.62 68.87 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.885 -0.726 . . . . 0.0 109.929 179.281 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.477 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.5 tm0? -51.5 -53.91 32.65 Favored 'General case' 0 C--N 1.308 -1.215 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.795 -179.726 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.5 mm -50.82 -50.92 21.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-O 120.805 0.336 . . . . 0.0 110.415 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -66.75 -65.88 0.63 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.574 -179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.491 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -75.85 118.33 18.54 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.467 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.303 -1.26 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.947 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 68.8 m . . . . . 0 N--CA 1.489 1.488 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.594 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.9 m-20 -95.76 117.48 66.42 Favored Pre-proline 0 C--N 1.309 -1.166 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.971 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -39.94 80.63 0.0 OUTLIER 'Trans proline' 0 N--CA 1.496 1.657 0 C-N-CA 122.35 2.034 . . . . 0.0 113.221 179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.594 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.5 mt -60.35 -42.14 95.09 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 121.263 0.554 . . . . 0.0 109.674 178.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 25.3 t -56.94 -48.45 81.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.311 -0.859 . . . . 0.0 112.631 -178.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.437 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -72.4 -26.14 24.02 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -178.486 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.406 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.31 -51.62 23.38 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -178.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.46 -27.34 61.35 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-O 120.828 0.347 . . . . 0.0 111.667 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 33.6 t -64.55 -50.2 68.24 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -178.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.406 HG22 ' O ' ' B' ' 29' ' ' ALA . 13.4 tt -55.32 -22.48 11.61 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.173 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 48.5 mt -70.01 -22.93 24.86 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 CA-C-O 121.351 0.596 . . . . 0.0 110.411 178.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.43 -50.86 23.11 Favored Glycine 0 C--N 1.301 -1.376 0 CA-C-N 115.146 -0.934 . . . . 0.0 111.608 -179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.423 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.9 OUTLIER -71.14 -30.07 39.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.265 0 O-C-N 122.68 -0.306 . . . . 0.0 111.082 -179.812 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -59.2 -50.82 72.55 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-O 121.249 0.547 . . . . 0.0 110.148 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.516 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.2 OUTLIER -66.03 -29.26 69.59 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.852 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.475 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 67.8 t80 -69.36 -47.91 62.9 Favored 'General case' 0 C--N 1.308 -1.228 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -179.025 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.545 ' O ' HG22 ' B' ' 42' ' ' THR . 39.5 pt -70.3 -34.21 57.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.549 -0.46 . . . . 0.0 112.11 -178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -69.14 -27.46 65.58 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 121.267 0.556 . . . . 0.0 110.199 179.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.44 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.7 t-105 -47.7 -40.7 20.9 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.219 -0.9 . . . . 0.0 112.476 -178.426 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.545 HG22 ' O ' ' B' ' 39' ' ' ILE . 6.0 t -46.67 -37.12 7.83 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 121.009 -0.276 . . . . 0.0 111.279 -177.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.428 ' N ' HG23 ' B' ' 42' ' ' THR . 86.7 mt -48.74 -47.21 15.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.458 -178.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -60.12 -51.5 58.46 Favored Glycine 0 C--N 1.306 -1.127 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -40.97 -23.92 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 112.842 0.682 . . . . 0.0 112.842 -175.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.578 ' CD1' HH21 ' C' ' 51' ' ' ARG . 0.1 OUTLIER -58.13 -46.23 85.99 Favored 'General case' 0 C--N 1.299 -1.618 0 N-CA-C 107.785 -1.191 . . . . 0.0 107.785 177.475 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.508 ' H ' HD23 ' B' ' 46' ' ' LEU . 68.4 m-80 -47.04 -44.17 20.39 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.486 -177.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.575 ' NE2' HD23 ' A' ' 46' ' ' LEU . 5.4 mm100 -46.2 -87.42 0.0 OUTLIER 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 120.574 -0.45 . . . . 0.0 111.095 -179.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.417 ' C ' ' O ' ' B' ' 48' ' ' GLN . 96.9 mt -32.18 -62.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -178.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . . . . . . . . . 26.0 mmtp -47.84 -45.94 30.54 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.526 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.5 mtt-85 -90.05 33.31 0.87 Allowed 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.425 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.111 0 N-CA-C 110.902 -0.879 . . . . 0.0 110.902 179.986 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 6.4 t . . . . . 0 N--CA 1.49 1.526 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.4 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.9 p30 40.52 55.23 7.19 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.035 179.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.4 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 39.5 Cg_endo -67.36 -21.94 46.53 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 C-N-CA 121.926 1.75 . . . . 0.0 110.088 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.485 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.14 -40.7 98.33 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.726 -179.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.7 t -67.1 -49.25 74.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.8 p -73.3 -39.63 55.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -179.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -71.06 -29.54 65.46 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 113.682 0.994 . . . . 0.0 113.682 -178.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.52 -47.3 42.06 Favored 'General case' 0 C--N 1.314 -0.946 0 C-N-CA 119.136 -1.026 . . . . 0.0 111.529 -179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.4 t -51.24 -29.84 15.64 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 120.844 0.354 . . . . 0.0 111.744 -179.753 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.408 HG12 ' H ' ' C' ' 32' ' ' ILE . 25.5 mm -48.13 -46.73 13.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.735 -178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 60.4 mt -66.32 -44.36 91.03 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-O 121.284 0.564 . . . . 0.0 110.105 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.01 -49.94 22.63 Favored Glycine 0 C--N 1.302 -1.335 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.733 -177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 35.1 pt -70.16 -29.72 40.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 117.681 0.741 . . . . 0.0 111.484 -179.216 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -62.06 -30.44 70.98 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 116.427 -0.351 . . . . 0.0 111.741 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.45 -29.95 64.14 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.466 0.543 . . . . 0.0 112.466 -179.182 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.614 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 41.2 t80 -60.02 -49.92 75.77 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.57 -29.76 48.11 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 C-N-CA 120.659 -0.416 . . . . 0.0 110.874 -179.028 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.62 -34.14 67.13 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.4 179.176 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.53 -52.04 32.45 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-N 115.641 -0.708 . . . . 0.0 112.46 -178.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.427 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -52.36 -27.26 14.85 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 112.411 0.523 . . . . 0.0 112.411 -178.78 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.469 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 3.7 tt -62.44 -50.25 80.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.648 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.469 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -58.81 -28.89 63.79 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 -179.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.1 t-80 -48.19 -27.04 2.18 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-N 115.707 -0.246 . . . . 0.0 110.698 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.544 ' CD2' HE22 ' D' ' 48' ' ' GLN . 1.7 pp -44.54 -34.63 2.19 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 120.837 -0.345 . . . . 0.0 111.822 -176.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . . . . . . . . . 37.9 m-20 -58.82 -53.18 61.24 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 118.965 -1.094 . . . . 0.0 109.632 179.504 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 5.5 mm100 -79.38 108.79 13.17 Favored 'General case' 0 C--N 1.31 -1.143 0 CA-C-N 116.112 -0.494 . . . . 0.0 111.372 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.871 HG23 ' H ' ' C' ' 50' ' ' LYS . 4.2 tt -179.67 -90.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.019 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.871 ' H ' HG23 ' C' ' 49' ' ' ILE . 38.8 tptt -43.41 -40.33 3.68 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-O 120.557 0.217 . . . . 0.0 111.467 -179.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.578 HH21 ' CD1' ' B' ' 46' ' ' LEU . 3.4 tmm_? -46.03 133.9 8.57 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 120.8 -0.36 . . . . 0.0 110.593 -179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.213 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.643 ' O ' ' N ' ' D' ' 26' ' ' LEU . 23.4 t70 -74.71 123.83 89.28 Favored Pre-proline 0 C--N 1.305 -1.369 0 CA-C-O 118.986 -0.53 . . . . 0.0 109.733 -179.442 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_exo -42.62 73.52 0.0 OUTLIER 'Trans proline' 0 N--CA 1.5 1.856 0 C-N-CA 122.476 2.117 . . . . 0.0 113.631 179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.643 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.4 mp -68.97 -41.54 77.8 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 61.9 t -58.69 -49.15 83.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 CA-C-N 116.34 -0.391 . . . . 0.0 112.047 -178.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.4 p -70.05 -24.47 26.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 122.321 -0.237 . . . . 0.0 111.09 -179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.06 -49.16 78.93 Favored 'General case' 0 C--N 1.307 -1.255 0 CA-C-N 116.335 -0.393 . . . . 0.0 112.04 -179.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.77 -53.98 11.66 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 119.791 -0.764 . . . . 0.0 110.047 179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.2 m -49.88 -27.24 4.91 Favored 'General case' 0 N--CA 1.431 -1.38 0 C-N-CA 123.791 0.837 . . . . 0.0 112.87 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.544 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.72 -47.24 39.11 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.147 -179.424 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 89.5 mt -58.02 -36.94 58.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 N-CA-C 111.785 0.291 . . . . 0.0 111.785 -179.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.34 -50.82 12.75 Favored Glycine 0 C--N 1.305 -1.158 0 C-N-CA 120.89 -0.671 . . . . 0.0 113.492 -176.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 7.6 pt -56.86 -40.26 70.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 118.712 1.256 . . . . 0.0 109.954 -179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 46.8 tp -68.77 -37.61 79.46 Favored 'General case' 0 C--N 1.308 -1.205 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 178.417 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 38.7 t-80 -63.12 -48.97 76.25 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.394 -179.509 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.43 ' C ' ' CD1' ' D' ' 38' ' ' PHE . 34.6 t80 -66.34 -47.0 74.89 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.288 0.477 . . . . 0.0 112.288 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . 0.43 ' O ' ' OG1' ' D' ' 42' ' ' THR . 87.4 mt -60.02 -45.62 95.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 111.976 0.361 . . . . 0.0 111.976 -178.425 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.788 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.4 -28.29 64.96 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.441 -179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.464 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -65.22 -40.79 94.58 Favored 'General case' 0 C--N 1.296 -1.755 0 CA-C-O 120.798 0.332 . . . . 0.0 111.52 -179.13 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' D' ' 39' ' ' ILE . 20.3 p -48.33 -47.62 36.81 Favored 'General case' 0 C--N 1.302 -1.491 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.995 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -52.08 -28.2 10.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 120.057 -0.657 . . . . 0.0 111.185 -178.61 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.995 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -49.04 -50.95 26.47 Favored Glycine 0 C--N 1.308 -1.021 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.67 -25.18 0.16 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 122.874 -0.192 . . . . 0.0 111.504 -177.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.506 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.2 pp -46.46 -26.47 0.86 Allowed 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.478 -0.489 . . . . 0.0 112.025 -178.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.428 ' ND2' ' O ' ' D' ' 44' ' ' GLY . 23.3 m-80 -72.24 -28.53 63.21 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 119.37 0.986 . . . . 0.0 113.277 179.073 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.544 HE22 ' CD2' ' C' ' 46' ' ' LEU . 54.1 mm-40 -67.55 -42.57 82.45 Favored 'General case' 0 C--N 1.315 -0.909 0 CA-C-O 120.855 0.36 . . . . 0.0 110.55 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 86.1 mt -48.44 -86.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.473 -179.675 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.479 ' O ' ' N ' ' D' ' 52' ' ' GLY . 36.7 tptt -54.66 -45.0 73.79 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 116.44 -0.345 . . . . 0.0 110.74 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.491 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.26 -70.11 0.09 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 116.422 -0.353 . . . . 0.0 110.481 179.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.479 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.181 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.403 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 40.9 t . . . . . 0 N--CA 1.489 1.508 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 76.26 58.8 0.24 Allowed Pre-proline 0 C--N 1.312 -1.031 0 N-CA-C 109.924 -0.399 . . . . 0.0 109.924 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.426 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 37.8 Cg_endo -65.83 9.32 0.22 Allowed 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 122.373 2.048 . . . . 0.0 112.25 -179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.64 HD13 ' CG2' ' B' ' 28' ' ' VAL . 33.0 mt -61.93 -40.33 95.13 Favored 'General case' 0 C--N 1.302 -1.491 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.306 -179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.4 t -70.0 -47.78 66.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.824 0.345 . . . . 0.0 111.879 -179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 4.4 p -72.47 -32.22 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.333 179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.426 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -60.63 -28.18 68.34 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 -47.56 61.49 Favored 'General case' 0 C--N 1.314 -0.971 0 C-N-CA 118.562 -1.255 . . . . 0.0 109.596 179.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 31.6 t -49.85 -38.92 37.31 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.128 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 48.3 mt -47.88 -50.96 9.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.653 -177.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 71.1 mt -70.33 -38.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 CA-C-O 121.388 0.613 . . . . 0.0 109.436 178.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.28 -50.28 23.49 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.344 -0.844 . . . . 0.0 112.078 -178.379 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 mt -70.1 -31.26 46.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 122.326 -0.514 . . . . 0.0 110.911 -179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.3 tp -60.3 -32.09 70.88 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.137 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.596 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -73.22 -30.14 63.29 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 113.181 0.808 . . . . 0.0 113.181 -179.709 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.596 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 50.2 t80 -55.02 -51.1 67.34 Favored 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 112.808 0.67 . . . . 0.0 112.808 -177.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.638 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.2 mp -57.63 -29.41 34.39 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.632 -0.427 . . . . 0.0 110.531 -179.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.418 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.88 -28.84 61.76 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-O 121.113 0.482 . . . . 0.0 111.157 179.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -63.59 -51.57 64.72 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.061 0.763 . . . . 0.0 113.061 -176.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 42' ' ' THR . 0.1 OUTLIER -53.5 -39.04 64.27 Favored 'General case' 0 C--N 1.299 -1.62 0 N-CA-C 112.662 0.616 . . . . 0.0 112.662 -177.594 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.7 pt -65.4 -41.5 91.3 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.455 -179.088 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.59 -33.93 86.03 Favored Glycine 0 C--N 1.306 -1.115 0 N-CA-C 111.467 -0.653 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 35.1 t-80 -49.06 -26.1 2.44 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-O 120.534 0.207 . . . . 0.0 110.996 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.2 pp -44.66 -29.54 0.77 Allowed 'General case' 0 C--N 1.31 -1.14 0 C-N-CA 121.016 -0.274 . . . . 0.0 110.924 -177.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.408 ' H ' HD22 ' A' ' 47' ' ' ASN . 3.0 m-80 -62.93 -52.38 63.27 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.699 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.0 tm0? -48.62 -48.58 39.33 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.725 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 25.4 mm -55.2 -43.63 71.42 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 CA-C-O 120.796 0.332 . . . . 0.0 110.26 -179.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.0 tmtp? -73.64 -71.58 0.31 Allowed 'General case' 0 C--N 1.304 -1.411 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.28 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.53 HH22 ' C ' ' D' ' 51' ' ' ARG . 60.1 ttt180 -80.23 131.21 35.65 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.629 -179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.179 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.968 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.49 1.535 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.537 ' O ' ' N ' ' B' ' 26' ' ' LEU . 1.6 m-20 -120.72 150.43 52.59 Favored Pre-proline 0 C--N 1.314 -0.976 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.191 -179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -39.5 86.91 0.01 OUTLIER 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 122.146 1.897 . . . . 0.0 112.089 179.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.537 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.8 OUTLIER -69.72 -49.59 51.81 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.085 179.789 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.4 t -56.75 -45.58 82.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.213 -179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.64 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.4 t -71.36 -24.82 24.21 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 N-CA-C 112.065 0.394 . . . . 0.0 112.065 -179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.463 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -70.87 -50.3 36.73 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 116.072 -0.513 . . . . 0.0 112.162 -179.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.44 -27.51 62.36 Favored 'General case' 0 C--N 1.306 -1.311 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -178.367 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.4 t -69.36 -36.64 77.06 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -49.1 -25.2 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 112.715 0.635 . . . . 0.0 112.715 -178.503 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 96.5 mt -71.39 -23.84 23.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-O 121.255 0.55 . . . . 0.0 110.629 178.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.16 -52.63 34.95 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-N 115.098 -0.955 . . . . 0.0 112.347 -178.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -72.16 -41.62 66.92 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 122.543 -0.387 . . . . 0.0 110.524 179.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -50.16 -48.43 53.9 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-O 121.582 0.706 . . . . 0.0 109.788 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.488 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.93 -37.9 69.58 Favored 'General case' 0 C--N 1.296 -1.736 0 CA-C-N 114.939 -1.028 . . . . 0.0 110.787 -179.529 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 37.2 t80 -63.96 -45.07 90.79 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.333 0.864 . . . . 0.0 113.333 -178.262 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . . . . . . . . . 14.7 pt -65.86 -40.47 87.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 C-N-CA 120.016 -0.674 . . . . 0.0 111.958 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.434 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.21 -31.64 67.84 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 120.257 -0.577 . . . . 0.0 110.097 179.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.418 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 5.8 t-105 -51.43 -51.68 52.73 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.741 -178.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.446 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -50.1 -35.27 24.85 Favored 'General case' 0 C--N 1.306 -1.291 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 -177.547 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.434 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.9 tt -49.25 -44.22 17.12 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.6 -178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' B' ' 46' ' ' LEU . . . -50.51 -48.39 42.37 Favored Glycine 0 C--N 1.307 -1.043 0 N-CA-C 110.064 -1.214 . . . . 0.0 110.064 179.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.411 ' O ' ' C ' ' B' ' 46' ' ' LEU . 51.4 t-80 -41.69 -21.58 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.591 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.1 pp -48.44 -51.76 25.35 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.058 -1.057 . . . . 0.0 108.272 178.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.591 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 71.7 m-80 -50.02 -45.85 52.31 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.872 -178.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.421 ' O ' ' O ' ' B' ' 47' ' ' ASN . 16.1 mm100 -38.88 -99.21 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.654 HG23 ' N ' ' B' ' 50' ' ' LYS . 17.4 tt -35.8 -58.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 CA-C-N 116.365 -0.379 . . . . 0.0 111.864 -178.371 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.654 ' N ' HG23 ' B' ' 49' ' ' ILE . 2.1 mmmp? -41.05 -51.7 3.29 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 120.732 0.301 . . . . 0.0 110.782 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.8 mtt-85 -71.37 -39.67 71.09 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.627 179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.194 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.917 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . 0.414 ' O ' ' OD1' ' C' ' 24' ' ' ASP . 33.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.442 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.5 p-10 41.71 53.19 7.28 Favored Pre-proline 0 C--N 1.31 -1.128 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.596 179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.442 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 25.0 Cg_endo -61.03 -18.18 56.27 Favored 'Trans proline' 0 C--N 1.308 -1.592 0 C-N-CA 122.305 2.003 . . . . 0.0 110.87 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.505 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.3 mp -62.7 -41.34 99.08 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.639 -0.71 . . . . 0.0 111.529 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 55.3 t -66.64 -45.2 88.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -178.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 5.0 p -73.55 -41.5 55.92 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 -179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.78 -50.49 72.13 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.802 1.038 . . . . 0.0 113.802 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.43 -42.97 88.5 Favored 'General case' 0 C--N 1.309 -1.156 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.834 -177.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.61 -37.79 42.18 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-O 120.963 0.411 . . . . 0.0 111.088 179.519 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 39.5 mm -48.56 -41.5 11.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.308 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.19 -178.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.2 mt -66.43 -42.37 90.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.368 0.604 . . . . 0.0 110.183 179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.561 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.73 -45.91 18.41 Favored Glycine 0 C--N 1.3 -1.463 0 CA-C-N 115.652 -0.704 . . . . 0.0 112.598 -177.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 27.7 pt -70.55 -29.07 36.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 118.025 0.913 . . . . 0.0 111.599 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 26.9 tp -60.04 -33.58 72.22 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 116.582 -0.281 . . . . 0.0 111.546 -179.36 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.623 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.02 -30.07 64.83 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 -178.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.623 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 38.7 t80 -64.09 -50.06 69.8 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -178.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.425 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.7 tp -65.17 -31.86 55.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.546 -0.462 . . . . 0.0 110.747 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.413 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.58 -35.92 68.04 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-O 121.212 0.53 . . . . 0.0 110.035 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -50.17 -51.57 42.61 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.591 -178.065 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.425 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -53.67 -27.58 28.42 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -177.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.465 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 6.5 tt -57.42 -47.3 85.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 N-CA-C 111.819 0.303 . . . . 0.0 111.819 -178.742 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.465 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -57.11 -27.67 57.63 Favored Glycine 0 C--N 1.304 -1.211 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -47.92 -28.47 2.7 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 120.916 0.388 . . . . 0.0 110.46 -178.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.499 ' CD2' ' OE1' ' D' ' 48' ' ' GLN . 2.3 pp -47.14 -37.24 9.58 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.427 -178.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.456 ' ND2' ' O ' ' C' ' 44' ' ' GLY . 4.2 m-80 -68.72 -54.97 12.94 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -178.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.645 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 0.0 OUTLIER -57.48 -52.36 65.7 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 119.936 -0.705 . . . . 0.0 111.176 -178.371 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.558 HG23 ' N ' ' C' ' 50' ' ' LYS . 15.0 tt -60.08 -45.01 96.22 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.392 0 C-N-CA 120.666 -0.414 . . . . 0.0 111.706 -179.044 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.558 ' N ' HG23 ' C' ' 49' ' ' ILE . 38.3 tptt -63.41 -45.83 89.17 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 120.701 -0.399 . . . . 0.0 110.826 -179.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -51.52 135.48 27.89 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-O 120.947 0.403 . . . . 0.0 110.57 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.07 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 -179.999 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 26.8 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.63 ' O ' ' N ' ' D' ' 26' ' ' LEU . 35.2 t70 -83.87 125.9 71.87 Favored Pre-proline 0 C--N 1.308 -1.196 0 CA-C-O 119.063 -0.494 . . . . 0.0 109.875 -179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo -41.53 75.89 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.975 0 C-N-CA 122.663 2.242 . . . . 0.0 113.219 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.63 ' N ' ' O ' ' D' ' 24' ' ' ASP . 2.6 mp -68.11 -45.68 73.01 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 120.814 0.34 . . . . 0.0 110.7 179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 48.8 t -59.17 -47.93 88.56 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -177.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 1.2 p -71.53 -25.24 24.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 122.279 -0.263 . . . . 0.0 111.523 -179.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.26 -43.04 99.72 Favored 'General case' 0 C--N 1.307 -1.258 0 CA-C-N 116.281 -0.418 . . . . 0.0 112.119 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.85 -54.16 12.56 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.086 -179.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 44.1 t -57.84 -26.53 62.17 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-N 115.467 -0.788 . . . . 0.0 112.615 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.594 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.28 -48.95 13.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.481 -178.256 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.468 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 79.5 mt -70.01 -30.89 45.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.568 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.24 -44.1 19.85 Favored Glycine 0 C--N 1.306 -1.106 0 CA-C-O 119.541 -0.588 . . . . 0.0 114.179 -176.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.1 pt -60.58 -29.55 44.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-N 118.785 1.292 . . . . 0.0 110.292 -179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -61.97 -50.48 71.92 Favored 'General case' 0 C--N 1.307 -1.261 0 CA-C-O 121.121 0.486 . . . . 0.0 110.639 179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.629 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -61.88 -33.02 73.45 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 115.613 -0.721 . . . . 0.0 111.371 -178.953 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.629 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 31.9 t80 -64.84 -47.06 79.33 Favored 'General case' 0 C--N 1.307 -1.248 0 CA-C-N 116.546 -0.297 . . . . 0.0 111.671 -179.394 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 65.4 mt -68.28 -41.57 83.85 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 CA-C-O 120.806 0.336 . . . . 0.0 111.657 -179.143 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -65.89 -26.97 67.87 Favored 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.212 0.529 . . . . 0.0 110.475 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.435 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.3 t-105 -64.52 -44.46 90.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.765 -179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.8 p -49.04 -46.83 44.85 Favored 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 -177.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.49 ' O ' HD23 ' D' ' 46' ' ' LEU . 5.7 pt -54.31 -28.55 18.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.527 -179.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.14 -50.43 28.16 Favored Glycine 0 C--N 1.306 -1.087 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 54.5 t-80 -42.26 -22.94 0.03 OUTLIER 'General case' 0 C--N 1.309 -1.18 0 O-C-N 122.768 -0.254 . . . . 0.0 111.016 -177.103 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.49 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.5 pp -46.25 -25.97 0.71 Allowed 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.942 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 48.7 m-80 -71.26 -30.21 66.02 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.499 ' OE1' ' CD2' ' C' ' 46' ' ' LEU . 66.4 mm-40 -66.4 -57.57 7.13 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 120.674 0.273 . . . . 0.0 110.884 -179.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 82.1 mt -39.71 -81.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.909 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.457 ' CG ' HH21 ' A' ' 51' ' ' ARG . 37.9 tptt -52.1 -47.56 65.19 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 120.845 -0.342 . . . . 0.0 110.479 179.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.53 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 65.9 -70.71 0.09 Allowed 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.592 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.42 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 13.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.42 ' CB ' ' O ' ' A' ' 23' ' ' SER . 2.2 m-20 79.66 61.22 0.17 Allowed Pre-proline 0 C--N 1.311 -1.097 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.726 -179.356 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.41 9.46 0.53 Allowed 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 122.333 2.022 . . . . 0.0 112.011 -179.272 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.738 HD13 ' CG2' ' B' ' 28' ' ' VAL . 24.7 mt -66.55 -36.81 83.58 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.287 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 17.2 t -69.99 -45.15 77.52 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.507 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.2 p -71.83 -31.39 41.02 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 120.589 -0.444 . . . . 0.0 110.551 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.08 -27.4 68.33 Favored 'General case' 0 C--N 1.307 -1.25 0 CA-C-N 115.973 -0.558 . . . . 0.0 112.325 -179.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.45 ' HB1' HE12 ' A' ' 1' ' ' RIM . . . -68.37 -50.87 49.98 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.486 179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.5 t -49.08 -37.08 20.22 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.026 179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.2 mt -47.99 -50.85 9.84 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.924 -177.862 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 93.4 mt -63.32 -43.47 98.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 C-N-CA 120.227 -0.589 . . . . 0.0 109.758 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.56 ' O ' ' ND1' ' A' ' 37' ' ' HIS . . . -48.15 -50.6 21.99 Favored Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.527 -0.76 . . . . 0.0 112.324 -178.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.407 HG21 HD13 ' A' ' 35' ' ' ILE . 4.0 mt -71.12 -29.57 37.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.619 0.709 . . . . 0.0 110.713 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.11 -39.29 82.83 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.348 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.643 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.0 OUTLIER -72.66 -28.67 62.86 Favored 'General case' 0 C--N 1.304 -1.391 0 N-CA-C 112.974 0.731 . . . . 0.0 112.974 -178.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.643 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 34.9 t80 -55.53 -49.07 73.61 Favored 'General case' 0 C--N 1.307 -1.281 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -178.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.69 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.6 mp -55.93 -31.69 31.11 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 C-N-CA 120.416 -0.513 . . . . 0.0 110.344 -179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.91 -29.57 63.24 Favored 'General case' 0 C--N 1.301 -1.516 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.011 179.173 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.1 t-105 -63.15 -51.06 67.95 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -177.643 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.417 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.26 -43.93 43.34 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -177.449 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.2 pt -63.0 -43.29 99.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 C-N-CA 119.639 -0.825 . . . . 0.0 111.433 -178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.13 -31.72 81.79 Favored Glycine 0 C--N 1.308 -0.973 0 N-CA-C 111.829 -0.508 . . . . 0.0 111.829 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -49.06 -25.62 2.17 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-O 120.842 0.353 . . . . 0.0 110.647 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.1 pp -43.46 -28.94 0.4 Allowed 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.071 -176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.41 ' CG ' HE22 ' B' ' 48' ' ' GLN . 77.1 m-20 -54.3 -51.72 63.76 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.382 -0.927 . . . . 0.0 109.405 179.423 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' O ' ' CB ' ' A' ' 49' ' ' ILE . 42.4 tt0 -79.64 110.88 15.38 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.814 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.565 HG22 ' N ' ' A' ' 50' ' ' LYS . 0.5 OUTLIER 153.57 -68.13 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 O-C-N 124.268 0.98 . . . . 0.0 108.652 179.547 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.565 ' N ' HG22 ' A' ' 49' ' ' ILE . 1.4 tmtp? -76.75 -66.88 0.76 Allowed 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 120.837 0.351 . . . . 0.0 111.115 -179.149 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.539 HH22 ' C ' ' D' ' 51' ' ' ARG . 80.5 ttt180 -61.67 144.43 54.57 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.931 -179.378 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.307 -1.049 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.822 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 21.3 m . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.559 ' O ' ' N ' ' B' ' 26' ' ' LEU . 14.4 m-20 -118.77 149.8 47.18 Favored Pre-proline 0 C--N 1.312 -1.053 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.045 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -37.81 85.36 0.01 OUTLIER 'Trans proline' 0 N--CA 1.494 1.501 0 C-N-CA 122.271 1.981 . . . . 0.0 112.329 179.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.559 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -70.61 -49.82 43.59 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.164 0.507 . . . . 0.0 109.947 179.772 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 89.7 t -58.58 -47.46 88.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.182 0 CA-C-N 115.452 -0.795 . . . . 0.0 112.391 -179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.738 ' CG2' HD13 ' A' ' 26' ' ' LEU . 14.8 t -71.98 -25.38 23.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 N-CA-C 112.162 0.43 . . . . 0.0 112.162 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.547 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -71.13 -52.0 21.81 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 116.295 -0.411 . . . . 0.0 111.757 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.84 -27.58 61.16 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-O 120.847 0.356 . . . . 0.0 111.66 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 32.0 t -69.06 -39.5 79.09 Favored 'General case' 0 C--N 1.308 -1.238 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.8 -179.192 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.547 HG22 ' O ' ' B' ' 29' ' ' ALA . 8.7 tt -49.03 -23.76 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 N-CA-C 112.762 0.653 . . . . 0.0 112.762 -179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 68.9 mt -64.6 -42.82 96.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 C-N-CA 120.543 -0.463 . . . . 0.0 112.026 -178.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.31 -50.51 13.15 Favored Glycine 0 C--N 1.304 -1.248 0 C-N-CA 120.848 -0.691 . . . . 0.0 113.698 -176.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.442 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.0 OUTLIER -62.06 -36.21 72.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.366 1.083 . . . . 0.0 110.088 -179.877 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 7.1 tp -61.66 -51.02 70.17 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.611 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -62.82 -33.13 74.58 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.307 -179.772 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' B' ' 38' ' ' PHE . 32.2 t80 -65.07 -47.38 77.5 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 -178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.534 ' O ' HG22 ' B' ' 42' ' ' THR . 34.3 pt -70.29 -34.7 59.6 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 C-N-CA 120.54 -0.464 . . . . 0.0 112.115 -178.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.76 -27.34 66.69 Favored 'General case' 0 C--N 1.302 -1.487 0 CA-C-O 121.256 0.55 . . . . 0.0 110.27 179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.433 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 6.2 t-105 -48.53 -45.19 37.07 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.705 -178.545 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.534 HG22 ' O ' ' B' ' 39' ' ' ILE . 10.2 t -47.41 -38.6 13.65 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 120.915 -0.314 . . . . 0.0 111.758 -177.185 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.479 ' N ' HG23 ' B' ' 42' ' ' THR . 98.8 mt -48.26 -50.21 11.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.494 -0.483 . . . . 0.0 111.497 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -54.68 -51.42 52.64 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -44.0 -24.76 0.16 Allowed 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 112.701 0.63 . . . . 0.0 112.701 -177.079 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.774 HD23 ' H ' ' B' ' 47' ' ' ASN . 0.3 OUTLIER -52.33 -51.25 59.76 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 178.158 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.774 ' H ' HD23 ' B' ' 46' ' ' LEU . 17.0 t-20 -64.07 -50.17 69.41 Favored 'General case' 0 C--N 1.296 -1.746 0 CA-C-N 114.627 -1.169 . . . . 0.0 112.8 -178.177 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.41 HE22 ' CG ' ' A' ' 47' ' ' ASN . 13.0 mm100 -65.16 48.24 0.02 OUTLIER 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 114.655 1.354 . . . . 0.0 114.655 -177.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.604 HG23 ' N ' ' B' ' 50' ' ' LYS . 18.7 tt -157.78 -50.71 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 120.345 -0.542 . . . . 0.0 111.047 178.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.604 ' N ' HG23 ' B' ' 49' ' ' ILE . 1.9 mmmp? -43.74 -43.91 6.32 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-O 120.696 0.284 . . . . 0.0 110.868 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 85.7 mtt-85 -65.07 -41.19 95.32 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.454 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.143 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.939 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -173.61 58.73 0.22 Allowed Pre-proline 0 C--N 1.305 -1.347 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.583 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -73.75 9.65 1.55 Allowed 'Trans proline' 0 C--N 1.307 -1.621 0 C-N-CA 122.745 2.297 . . . . 0.0 111.964 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.451 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.0 mp -63.51 -39.63 94.95 Favored 'General case' 0 C--N 1.302 -1.481 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.325 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 47.4 t -64.68 -46.35 92.58 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 N-CA-C 112.919 0.711 . . . . 0.0 112.919 -178.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.409 HG13 ' N ' ' C' ' 29' ' ' ALA . 4.6 p -73.63 -42.32 55.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 N-CA-C 112.737 0.643 . . . . 0.0 112.737 -179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.409 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.95 -28.79 64.74 Favored 'General case' 0 C--N 1.307 -1.27 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -178.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.478 ' HB3' ' HF3' ' A' ' 1' ' ' RIM . . . -73.04 -42.83 62.71 Favored 'General case' 0 C--N 1.311 -1.086 0 C-N-CA 120.044 -0.663 . . . . 0.0 111.78 -179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 27.1 t -57.54 -28.42 63.51 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-O 121.005 0.431 . . . . 0.0 111.552 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.401 HG12 ' H ' ' C' ' 32' ' ' ILE . 31.8 mm -47.73 -43.92 10.19 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 CA-C-N 115.708 -0.678 . . . . 0.0 110.676 -178.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 66.6 mt -67.62 -42.92 87.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-O 121.267 0.556 . . . . 0.0 109.919 178.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.26 -44.94 21.14 Favored Glycine 0 C--N 1.303 -1.294 0 CA-C-N 115.631 -0.713 . . . . 0.0 112.642 -177.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 22.7 pt -70.3 -29.35 38.89 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 CA-C-N 117.811 0.805 . . . . 0.0 111.368 -179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.6 tp -61.4 -31.35 71.26 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.655 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.9 -30.97 65.93 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 112.342 0.497 . . . . 0.0 112.342 -179.027 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.627 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.6 t80 -63.07 -50.0 72.33 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 120.689 -0.404 . . . . 0.0 111.951 -178.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -63.78 -29.52 47.5 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.689 -0.404 . . . . 0.0 110.822 -179.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.479 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.27 -34.4 68.19 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.311 179.289 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.1 32.92 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 115.529 -0.76 . . . . 0.0 112.621 -177.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.464 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.21 -26.49 2.95 Favored 'General case' 0 C--N 1.297 -1.709 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.421 -179.399 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.686 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.7 tt -68.02 -35.93 73.61 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 C-N-CA 121.273 -0.171 . . . . 0.0 111.423 -179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.62 -28.9 70.26 Favored Glycine 0 N--CA 1.472 1.077 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.4 t-80 -55.78 -28.11 54.45 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 115.296 -0.452 . . . . 0.0 111.518 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.929 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -44.94 -36.46 3.38 Favored 'General case' 0 C--N 1.308 -1.226 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 -176.643 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.929 ' H ' HD13 ' C' ' 46' ' ' LEU . 22.0 m120 -63.38 -51.27 66.58 Favored 'General case' 0 C--N 1.299 -1.62 0 C-N-CA 119.579 -0.848 . . . . 0.0 110.098 178.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.473 HE22 ' CD1' ' B' ' 46' ' ' LEU . 49.2 tp60 -41.57 -57.32 2.29 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 115.836 -0.62 . . . . 0.0 112.534 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.8 tt -57.12 -32.56 40.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.122 -178.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 38.3 tptt -88.04 98.03 11.3 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 120.759 0.314 . . . . 0.0 110.447 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.7 tmm_? -166.65 137.33 3.29 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.638 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.085 0 N-CA-C 110.986 -0.846 . . . . 0.0 110.986 179.962 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 9.8 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.607 ' O ' ' N ' ' D' ' 26' ' ' LEU . 5.7 t70 -86.46 135.18 36.68 Favored Pre-proline 0 C--N 1.308 -1.209 0 CA-C-O 119.111 -0.471 . . . . 0.0 109.898 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_exo -44.66 75.67 0.01 OUTLIER 'Trans proline' 0 N--CA 1.502 1.982 0 C-N-CA 122.184 1.923 . . . . 0.0 113.262 179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.607 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.7 mp -71.02 -45.21 64.33 Favored 'General case' 0 C--N 1.308 -1.224 0 CA-C-O 120.788 0.328 . . . . 0.0 110.327 179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 40.5 t -56.18 -48.03 79.9 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 CA-C-N 116.184 -0.462 . . . . 0.0 112.061 -178.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -71.34 -23.87 23.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 CA-C-O 120.616 0.246 . . . . 0.0 111.232 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.84 -45.13 95.13 Favored 'General case' 0 C--N 1.308 -1.206 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -178.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.6 -54.21 12.92 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.381 -0.927 . . . . 0.0 109.877 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.8 t -54.43 -26.12 28.94 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.287 -0.87 . . . . 0.0 112.434 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.538 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -48.37 -48.55 13.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.577 -178.422 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.465 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 67.2 mt -62.36 -33.86 61.36 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.563 -179.249 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . 0.471 ' O ' ' ND1' ' D' ' 37' ' ' HIS . . . -46.93 -44.41 18.29 Favored Glycine 0 C--N 1.305 -1.144 0 C-N-CA 121.233 -0.508 . . . . 0.0 113.553 -177.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 6.4 pt -62.79 -35.27 70.13 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 118.656 1.228 . . . . 0.0 110.331 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.7 tp -69.92 -50.43 42.23 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.358 0.599 . . . . 0.0 109.659 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.715 ' HD1' ' N ' ' D' ' 38' ' ' PHE . 0.0 OUTLIER -63.26 -29.88 71.13 Favored 'General case' 0 C--N 1.301 -1.524 0 CA-C-N 115.039 -0.982 . . . . 0.0 111.152 -178.988 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.715 ' N ' ' HD1' ' D' ' 37' ' ' HIS . 36.3 t80 -70.81 -47.24 60.49 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 121.076 -0.25 . . . . 0.0 111.386 -179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.12 -39.96 87.29 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 120.776 0.322 . . . . 0.0 111.466 -178.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.768 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.14 -27.92 64.95 Favored 'General case' 0 C--N 1.301 -1.504 0 CA-C-N 116.352 -0.385 . . . . 0.0 110.536 -179.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.413 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.7 t-105 -56.62 -45.64 81.39 Favored 'General case' 0 C--N 1.292 -1.907 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -178.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 74.9 p -48.53 -41.77 31.18 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 -176.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.891 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -57.33 -27.29 28.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.591 -178.542 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.891 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.01 -50.56 21.23 Favored Glycine 0 C--N 1.309 -0.959 0 C-N-CA 120.772 -0.727 . . . . 0.0 111.418 -179.196 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.9 t-80 -42.28 -23.56 0.04 OUTLIER 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.754 0.277 . . . . 0.0 111.427 -177.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.444 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.3 pp -46.4 -25.34 0.64 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.148 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 76.0 m-20 -70.74 -29.74 66.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 119.101 0.864 . . . . 0.0 113.156 179.344 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.531 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -71.07 -45.45 63.73 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-O 120.829 0.347 . . . . 0.0 110.449 -179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 67.5 mt -45.59 -87.14 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.533 -179.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.456 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -51.64 -42.61 62.18 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 120.904 -0.319 . . . . 0.0 110.45 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.539 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 66.05 -69.32 0.11 Allowed 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.398 179.881 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.178 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . 0.478 ' HF3' ' HB3' ' C' ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 45.4 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 77.25 65.18 0.22 Allowed Pre-proline 0 C--N 1.308 -1.223 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.092 -179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.491 ' O ' ' HB2' ' A' ' 29' ' ' ALA . 57.5 Cg_endo -87.09 26.37 0.62 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 C-N-CA 122.784 2.323 . . . . 0.0 110.773 179.347 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.705 ' H ' HD23 ' A' ' 26' ' ' LEU . 1.1 pt? -63.94 -38.34 90.71 Favored 'General case' 0 C--N 1.303 -1.451 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.934 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 11.7 t -69.98 -47.57 68.1 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 CA-C-O 120.753 0.311 . . . . 0.0 110.598 179.416 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 13.5 p -72.33 -31.17 37.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.944 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.491 ' HB2' ' O ' ' A' ' 25' ' ' PRO . . . -55.46 -27.64 49.48 Favored 'General case' 0 C--N 1.308 -1.221 0 N-CA-C 112.287 0.477 . . . . 0.0 112.287 -179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -68.15 -51.2 48.68 Favored 'General case' 0 C--N 1.306 -1.325 0 C-N-CA 118.842 -1.143 . . . . 0.0 109.079 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -49.56 -39.04 33.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.779 179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.407 HD12 ' HA ' ' A' ' 29' ' ' ALA . 44.1 mt -48.65 -52.27 9.43 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.585 -177.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 55.3 mt -68.88 -35.46 69.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 120.235 -0.586 . . . . 0.0 109.619 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.417 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.5 -51.36 16.58 Favored Glycine 0 C--N 1.303 -1.299 0 CA-C-N 115.388 -0.823 . . . . 0.0 112.0 -178.264 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 35.2 pt -71.85 -30.63 38.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 CA-C-N 117.172 0.486 . . . . 0.0 111.248 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.0 tp -61.34 -39.19 89.65 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.268 -179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.646 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.56 -29.5 63.6 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -179.246 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.646 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 65.9 t80 -52.67 -51.18 61.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 120.779 -0.368 . . . . 0.0 111.656 -177.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.621 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -61.44 -29.82 46.79 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 C-N-CA 120.446 -0.502 . . . . 0.0 111.057 -179.211 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.41 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.68 -28.51 62.74 Favored 'General case' 0 C--N 1.302 -1.468 0 CA-C-O 121.221 0.534 . . . . 0.0 111.096 179.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -60.52 -51.27 70.16 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 -177.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.44 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.6 -38.99 48.79 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 113.402 0.89 . . . . 0.0 113.402 -177.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.551 ' O ' HD12 ' A' ' 46' ' ' LEU . 13.8 pt -70.1 -41.77 79.14 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.685 -178.906 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -63.66 -29.56 75.05 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.403 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.9 t-160 -56.01 -26.86 50.48 Favored 'General case' 0 C--N 1.297 -1.702 0 CA-C-N 115.205 -0.498 . . . . 0.0 110.294 179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.842 HD13 ' N ' ' A' ' 47' ' ' ASN . 0.0 OUTLIER -45.82 -29.56 1.38 Allowed 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.666 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.842 ' N ' HD13 ' A' ' 46' ' ' LEU . 69.4 m-80 -58.76 -52.3 66.31 Favored 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 118.913 -1.115 . . . . 0.0 109.42 179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.456 ' NE2' ' C ' ' A' ' 48' ' ' GLN . 1.1 tm0? -51.24 -57.74 8.03 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.883 -179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.403 HD11 ' CE1' ' A' ' 45' ' ' HIS . 25.0 mm -47.4 -52.8 4.87 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 CA-C-O 120.875 0.369 . . . . 0.0 110.613 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.5 tmtp? -75.48 -69.72 0.47 Allowed 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.656 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.491 ' N ' ' O ' ' A' ' 47' ' ' ASN . 65.0 ttt180 -71.03 129.27 38.56 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.611 -179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.158 0 N-CA-C 111.009 -0.837 . . . . 0.0 111.009 179.905 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 98.9 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.569 ' O ' ' N ' ' B' ' 26' ' ' LEU . 10.2 m-20 -156.75 82.67 3.27 Favored Pre-proline 0 C--N 1.307 -1.257 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.463 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.71 76.26 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.742 0 C-N-CA 122.844 2.363 . . . . 0.0 112.341 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.569 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.7 mt -70.47 -47.01 62.65 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.026 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 58.0 t -59.32 -51.13 76.23 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 115.483 -0.78 . . . . 0.0 112.981 -178.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 21.9 t -72.28 -26.14 24.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.043 0.757 . . . . 0.0 113.043 -178.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.91 -52.79 17.94 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.972 -0.691 . . . . 0.0 111.41 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.36 -28.91 62.3 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.435 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 44.5 t -70.76 -46.94 62.02 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 112.188 0.44 . . . . 0.0 112.188 -179.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.5 tt -70.01 -25.31 27.6 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 N-CA-C 112.774 0.657 . . . . 0.0 112.774 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.7 mt -68.27 -35.91 72.97 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.691 -179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.85 -49.39 22.86 Favored Glycine 0 C--N 1.305 -1.177 0 C-N-CA 120.754 -0.736 . . . . 0.0 113.494 -177.141 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.456 ' H ' HG22 ' B' ' 35' ' ' ILE . 0.8 OUTLIER -49.31 -29.62 3.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 118.027 0.913 . . . . 0.0 109.825 -179.63 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.9 tp -61.59 -50.46 72.51 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.741 0.782 . . . . 0.0 109.225 178.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.593 ' ND1' ' N ' ' B' ' 38' ' ' PHE . 0.1 OUTLIER -56.12 -29.12 60.22 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.95 -179.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.593 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 28.2 t80 -64.0 -42.82 97.04 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 113.415 0.894 . . . . 0.0 113.415 -178.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 9.2 pt -69.71 -39.88 78.59 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 C-N-CA 120.215 -0.594 . . . . 0.0 112.19 -178.001 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.432 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.76 -28.51 64.74 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.246 0.546 . . . . 0.0 110.453 179.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.41 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 3.6 t-105 -52.16 -52.07 54.1 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.213 -178.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -48.93 -32.81 9.65 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.924 -177.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.432 HG22 ' O ' ' B' ' 40' ' ' ALA . 5.7 tt -49.4 -40.36 14.27 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.602 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.869 -178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.81 -47.91 52.11 Favored Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.486 ' ND1' ' O ' ' B' ' 45' ' ' HIS . 47.4 t-80 -41.98 -22.25 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 113.601 0.963 . . . . 0.0 113.601 -176.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.555 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.2 pp -47.53 -50.21 24.21 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 118.72 -1.192 . . . . 0.0 108.152 179.084 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.555 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 67.3 m-80 -48.72 -44.54 38.34 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.231 -179.709 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.498 ' NE2' ' O ' ' A' ' 43' ' ' ILE . 44.0 mm-40 -43.18 -98.5 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.081 0 CA-C-O 120.741 0.305 . . . . 0.0 111.725 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.77 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.0 tt -32.51 -63.06 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.717 -0.674 . . . . 0.0 112.044 -178.43 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.77 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -41.38 -46.43 3.34 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 120.816 0.341 . . . . 0.0 110.801 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.5 mtt-85 -91.2 39.03 0.98 Allowed 'General case' 0 C--N 1.308 -1.203 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' B' ' 49' ' ' ILE . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 37.0 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.412 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.0 p-10 41.32 54.54 7.83 Favored Pre-proline 0 C--N 1.309 -1.172 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.894 179.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.412 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 36.6 Cg_endo -65.67 -22.01 58.23 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 C-N-CA 121.96 1.773 . . . . 0.0 109.935 179.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.489 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -62.19 -40.13 95.03 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.279 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 95.4 t -69.9 -49.91 53.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 N-CA-C 112.643 0.608 . . . . 0.0 112.643 -178.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 p -72.79 -29.63 30.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -178.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.532 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -70.43 -52.05 25.05 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -177.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.41 -29.24 65.81 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.931 -0.708 . . . . 0.0 110.444 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 39.4 t -49.85 -50.93 43.69 Favored 'General case' 0 C--N 1.301 -1.531 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.199 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.532 HG22 ' O ' ' C' ' 29' ' ' ALA . 4.7 tp -48.79 -31.2 3.69 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 63.6 mt -61.59 -42.43 94.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 CA-C-O 121.358 0.599 . . . . 0.0 110.15 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -46.71 -50.75 13.98 Favored Glycine 0 C--N 1.3 -1.439 0 CA-C-N 115.45 -0.796 . . . . 0.0 112.13 -177.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 40.7 pt -71.17 -29.13 35.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 CA-C-N 117.752 0.776 . . . . 0.0 111.216 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 18.3 tp -60.09 -35.14 74.54 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.204 0.446 . . . . 0.0 112.204 -178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.9 OUTLIER -70.8 -33.23 70.5 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.645 -178.916 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 39.5 t80 -63.93 -47.78 79.17 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.41 -179.306 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -65.34 -32.23 57.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.221 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.703 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.1 -33.48 67.89 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-O 121.171 0.51 . . . . 0.0 110.313 179.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 8.9 t-105 -50.54 -51.32 48.97 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.663 -0.698 . . . . 0.0 112.539 -178.017 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.72 -26.21 8.93 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.317 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.755 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.5 tt -69.25 -41.44 81.15 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.985 0 O-C-N 122.19 -0.318 . . . . 0.0 111.422 -179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.16 -28.69 69.75 Favored Glycine 0 N--CA 1.47 0.95 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 52.2 t-80 -53.3 -28.57 28.82 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 112.594 0.591 . . . . 0.0 112.594 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.831 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.87 -33.81 4.85 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -177.415 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.831 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.6 m-20 -67.37 -52.64 37.58 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.058 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.524 ' OE1' ' N ' ' C' ' 48' ' ' GLN . 1.8 mm100 -43.62 -49.72 7.58 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 111.926 0.343 . . . . 0.0 111.926 -179.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.0 tt -65.25 -28.55 44.81 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 C-N-CA 120.788 -0.365 . . . . 0.0 111.262 -179.09 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.579 ' NZ ' ' CZ ' ' D' ' 51' ' ' ARG . 40.8 tptt -62.06 -42.18 98.93 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.213 179.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -49.55 134.95 19.03 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.708 -179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.098 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.97 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 17.6 t . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 8.7 t70 -88.27 141.93 31.22 Favored Pre-proline 0 C--N 1.308 -1.215 0 CA-C-N 116.125 -0.488 . . . . 0.0 109.789 -179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_exo -42.84 74.23 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 2.014 0 C-N-CA 122.402 2.068 . . . . 0.0 114.231 179.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.3 mp -70.64 -41.9 71.56 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 178.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 50.4 t -57.75 -49.28 81.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.944 -178.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -70.48 -25.3 26.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 122.317 -0.239 . . . . 0.0 111.37 -179.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.37 -47.23 84.48 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.849 -179.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.22 -53.98 10.99 Favored 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.511 179.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 29.2 t -51.66 -27.89 12.9 Favored 'General case' 0 C--N 1.306 -1.296 0 CA-C-N 115.476 -0.784 . . . . 0.0 113.023 -179.646 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.562 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -54.59 -46.51 72.33 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.227 -178.922 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.443 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.7 mt -67.26 -38.19 80.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.829 -0.348 . . . . 0.0 111.368 -179.735 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.81 -44.73 13.11 Favored Glycine 0 C--N 1.304 -1.222 0 CA-C-O 119.48 -0.622 . . . . 0.0 113.912 -176.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 25.0 pt -64.01 -29.55 47.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 CA-C-N 118.809 1.305 . . . . 0.0 110.645 -179.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.3 tp -65.88 -50.95 62.69 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.098 0.475 . . . . 0.0 110.362 179.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.567 ' ND1' ' C ' ' D' ' 37' ' ' HIS . 0.0 OUTLIER -63.09 -31.88 73.13 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.886 -179.15 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.559 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 77.9 t80 -65.25 -47.35 77.06 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.508 -0.315 . . . . 0.0 111.821 -179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 72.1 mt -69.95 -40.09 78.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 112.02 0.378 . . . . 0.0 112.02 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -67.5 -28.84 68.18 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-O 121.111 0.481 . . . . 0.0 110.4 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 7.2 t-105 -49.71 -39.36 36.83 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.014 -179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 26.0 p -47.97 -43.48 29.58 Favored 'General case' 0 C--N 1.297 -1.699 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -177.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.47 ' O ' HD22 ' D' ' 46' ' ' LEU . 3.1 pt -49.51 -28.78 3.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 120.357 -0.537 . . . . 0.0 111.874 -178.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.32 -52.9 50.47 Favored Glycine 0 C--N 1.307 -1.081 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.249 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 44.6 t-80 -44.82 -26.66 0.42 Allowed 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 111.852 0.316 . . . . 0.0 111.852 -177.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.533 HD23 ' N ' ' D' ' 47' ' ' ASN . 0.2 OUTLIER -47.47 -25.01 0.95 Allowed 'General case' 0 C--N 1.292 -1.899 0 O-C-N 121.593 -0.692 . . . . 0.0 111.817 -178.979 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.533 ' N ' HD23 ' D' ' 46' ' ' LEU . 50.6 m-80 -71.86 -28.9 63.85 Favored 'General case' 0 CA--C 1.548 0.866 0 N-CA-C 114.07 1.137 . . . . 0.0 114.07 179.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.697 ' N ' HE21 ' D' ' 48' ' ' GLN . 1.4 mm-40 -57.36 -53.59 56.4 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 179.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.7 mt -44.69 -84.85 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 115.231 -0.895 . . . . 0.0 110.333 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.2 tptt -44.86 -50.95 10.07 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.88 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.579 ' CZ ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.34 -71.48 0.05 OUTLIER 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.275 179.998 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.306 -1.13 0 N-CA-C 111.011 -0.835 . . . . 0.0 111.011 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 31.8 t . . . . . 0 N--CA 1.49 1.527 0 N-CA-C 109.454 -0.573 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.5 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 14.1 m-20 58.17 48.5 2.67 Favored Pre-proline 0 C--N 1.306 -1.322 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.191 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 69.5 Cg_endo -71.67 -16.49 30.08 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.591 2.194 . . . . 0.0 111.697 179.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.577 ' H ' HD12 ' A' ' 26' ' ' LEU . 1.3 mp -73.33 -50.58 21.29 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.811 179.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.0 t -65.0 -39.67 86.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.49 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -70.82 -36.47 64.62 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 N-CA-C 112.576 0.584 . . . . 0.0 112.576 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.93 -53.71 54.65 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.72 0.637 . . . . 0.0 112.72 -177.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -59.92 -50.34 74.14 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.471 -0.892 . . . . 0.0 109.45 -179.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.4 t -50.01 -51.37 42.49 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.145 179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.1 mt -49.03 -49.83 15.37 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.217 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.063 -178.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 87.2 mt -62.89 -43.35 98.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 C-N-CA 119.978 -0.689 . . . . 0.0 109.253 179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.13 28.55 Favored Glycine 0 C--N 1.303 -1.259 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.993 -178.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 69.6 mt -69.35 -32.8 54.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 CA-C-N 117.03 0.415 . . . . 0.0 110.985 -179.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 8.8 tp -61.01 -31.44 71.06 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.439 -179.214 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.504 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -71.99 -30.31 65.12 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 112.592 0.59 . . . . 0.0 112.592 -178.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 82.4 t80 -57.91 -51.02 71.35 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.579 -0.448 . . . . 0.0 112.035 -177.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.741 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.0 mp -53.71 -30.9 19.3 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.347 0 C-N-CA 120.682 -0.407 . . . . 0.0 110.641 -179.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.45 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.4 -29.0 62.32 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-O 121.071 0.462 . . . . 0.0 110.91 178.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -59.45 -51.38 70.13 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 113.026 0.751 . . . . 0.0 113.026 -177.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -49.47 -46.27 47.83 Favored 'General case' 0 C--N 1.296 -1.73 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -177.738 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 19.0 pt -64.57 -42.82 96.23 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.209 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.617 -178.551 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.86 -34.19 86.4 Favored Glycine 0 C--N 1.306 -1.099 0 N-CA-C 111.728 -0.549 . . . . 0.0 111.728 -179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -49.82 -27.99 5.8 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 120.576 0.226 . . . . 0.0 111.319 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.7 OUTLIER -44.57 -29.0 0.66 Allowed 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.605 -0.27 . . . . 0.0 111.274 -177.434 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 42.7 m-20 -60.28 -51.4 69.69 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.03 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.516 ' O ' ' NE2' ' A' ' 48' ' ' GLN . 1.0 OUTLIER -52.77 -57.65 9.47 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.143 -179.597 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 29.5 mm -48.45 -51.26 10.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 C-N-CA 120.799 -0.36 . . . . 0.0 110.299 -179.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.2 tmtp? -64.69 -72.25 0.16 Allowed 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.268 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.511 HH22 ' C ' ' D' ' 51' ' ' ARG . 67.8 ttt180 -80.36 110.83 16.18 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.512 -179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.117 0 N-CA-C 110.937 -0.865 . . . . 0.0 110.937 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 53.2 p . . . . . 0 N--CA 1.49 1.548 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' B' ' 26' ' ' LEU . 67.5 m-20 -152.39 75.75 7.11 Favored Pre-proline 0 C--N 1.307 -1.24 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.116 179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -48.0 79.6 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.723 2.282 . . . . 0.0 111.993 -179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.566 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.5 OUTLIER -70.52 -50.62 35.87 Favored 'General case' 0 C--N 1.302 -1.463 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.322 -179.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 55.9 t -56.54 -45.81 82.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.503 -179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.557 ' CG2' HD23 ' A' ' 26' ' ' LEU . 59.2 t -70.22 -24.96 26.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.843 0.354 . . . . 0.0 111.233 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.52 -37.16 84.97 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.549 -179.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -48.46 37.15 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.487 179.305 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.2 t -45.59 -50.81 12.84 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 112.857 0.688 . . . . 0.0 112.857 -176.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 8.6 tt -54.49 -29.09 19.8 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.465 -178.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 21.6 mt -73.32 -24.83 20.74 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 CA-C-O 121.402 0.62 . . . . 0.0 110.838 178.162 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -54.36 -52.08 46.94 Favored Glycine 0 C--N 1.305 -1.184 0 CA-C-N 115.258 -0.883 . . . . 0.0 112.263 -178.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.444 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.6 tt -71.22 -36.81 63.68 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 122.688 -0.301 . . . . 0.0 111.135 -179.895 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.4 tp -51.94 -50.17 61.71 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.389 0.614 . . . . 0.0 110.288 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.4 OUTLIER -67.98 -29.05 67.98 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.9 -179.532 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.517 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 32.6 t80 -68.27 -42.39 79.62 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 112.603 0.594 . . . . 0.0 112.603 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.417 ' O ' ' CG2' ' B' ' 42' ' ' THR . 20.0 pt -67.86 -39.66 82.2 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.232 0 C-N-CA 120.42 -0.512 . . . . 0.0 112.026 -178.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.482 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -70.98 -28.67 64.61 Favored 'General case' 0 C--N 1.3 -1.549 0 CA-C-O 121.17 0.51 . . . . 0.0 110.305 179.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.45 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 4.9 t-105 -51.29 -52.03 48.8 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.683 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.417 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -50.45 -35.79 30.44 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 120.642 -0.423 . . . . 0.0 111.523 -178.155 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.482 HG22 ' O ' ' B' ' 40' ' ' ALA . 6.0 tt -48.31 -36.58 6.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 111.788 0.292 . . . . 0.0 111.788 -177.752 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.85 -46.78 93.51 Favored Glycine 0 C--N 1.305 -1.143 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.414 ' O ' ' C ' ' B' ' 46' ' ' LEU . 57.9 t-80 -41.26 -23.22 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -175.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.58 HD12 ' N ' ' B' ' 47' ' ' ASN . 3.0 pp -49.0 -50.53 35.47 Favored 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 107.629 -1.248 . . . . 0.0 107.629 178.208 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.58 ' N ' HD12 ' B' ' 46' ' ' LEU . 58.8 m-80 -48.88 -46.98 43.39 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.261 -1.336 . . . . 0.0 111.27 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.458 ' OE1' HD23 ' A' ' 46' ' ' LEU . 10.9 mm100 -42.43 -100.0 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.098 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.73 HG23 ' H ' ' B' ' 50' ' ' LYS . 16.3 tt -34.4 -61.69 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 116.173 -0.467 . . . . 0.0 112.176 -178.195 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.73 ' H ' HG23 ' B' ' 49' ' ' ILE . 3.0 mmmp? -40.44 -49.73 2.86 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 120.804 0.335 . . . . 0.0 110.814 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.3 mtt-85 -70.63 -39.18 73.84 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.436 179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.145 0 N-CA-C 110.947 -0.861 . . . . 0.0 110.947 -179.981 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 34.7 t . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.421 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 4.4 p30 41.64 54.65 8.38 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.869 179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.421 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 32.2 Cg_endo -64.55 -18.67 63.6 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 C-N-CA 122.038 1.825 . . . . 0.0 110.463 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.554 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -63.08 -43.39 98.67 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.479 -179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.9 t -65.12 -45.53 93.9 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . 0.451 HG13 ' N ' ' C' ' 29' ' ' ALA . 7.3 p -72.42 -42.29 64.64 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 112.49 0.552 . . . . 0.0 112.49 -178.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.451 ' N ' HG13 ' C' ' 28' ' ' VAL . . . -70.74 -27.74 64.18 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.74 -43.37 65.95 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.886 -0.726 . . . . 0.0 111.349 -178.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 29.0 t -70.62 -29.03 65.3 Favored 'General case' 0 C--N 1.311 -1.085 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.585 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mm -48.37 -44.16 13.02 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 C-N-CA 121.019 -0.272 . . . . 0.0 110.288 -178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.3 mt -63.62 -48.32 87.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.501 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.85 -50.14 21.21 Favored Glycine 0 C--N 1.302 -1.329 0 CA-C-N 115.426 -0.806 . . . . 0.0 113.272 -177.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 14.3 pt -59.46 -29.31 41.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 117.727 0.763 . . . . 0.0 111.439 -179.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . 0.883 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -65.71 -28.59 69.17 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.684 -0.234 . . . . 0.0 111.365 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.613 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -70.91 -29.55 65.63 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 120.555 -0.458 . . . . 0.0 112.199 -178.861 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.613 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 52.0 t80 -60.7 -50.12 74.77 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.765 -0.374 . . . . 0.0 111.844 -178.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.6 tp -62.52 -28.97 45.77 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.596 -179.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.443 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -71.96 -35.04 69.45 Favored 'General case' 0 C--N 1.3 -1.565 0 CA-C-O 121.156 0.503 . . . . 0.0 110.393 179.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 5.5 t-105 -49.0 -51.87 28.17 Favored 'General case' 0 C--N 1.308 -1.211 0 CA-C-N 115.391 -0.822 . . . . 0.0 112.664 -177.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.25 -27.05 5.38 Favored 'General case' 0 C--N 1.297 -1.699 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.745 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.768 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.7 tt -69.69 -37.0 72.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 121.097 -0.241 . . . . 0.0 111.491 -179.037 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.76 -28.84 70.17 Favored Glycine 0 CA--C 1.529 0.92 0 N-CA-C 111.321 -0.711 . . . . 0.0 111.321 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 14.1 t-80 -51.18 -29.63 14.52 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 115.2 -0.5 . . . . 0.0 112.147 -179.379 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.859 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -48.18 -38.13 17.43 Favored 'General case' 0 C--N 1.309 -1.185 0 N-CA-C 113.508 0.929 . . . . 0.0 113.508 -177.648 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.859 ' H ' HD13 ' C' ' 46' ' ' LEU . 77.5 m-20 -67.63 -53.71 25.69 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 119.551 1.069 . . . . 0.0 111.314 -179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.515 ' H ' ' CD ' ' C' ' 48' ' ' GLN . 24.1 mp0 -51.67 -54.01 32.69 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 112.098 0.407 . . . . 0.0 112.098 -179.216 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 12.3 tt -62.04 -37.57 78.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.255 0 C-N-CA 120.455 -0.498 . . . . 0.0 110.845 -178.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.488 ' NZ ' ' NH2' ' D' ' 51' ' ' ARG . 39.0 tptt -72.04 102.49 2.99 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.862 0.363 . . . . 0.0 110.212 179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -170.5 119.31 0.56 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.483 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.107 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 179.989 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.6 t . . . . . 0 N--CA 1.491 1.62 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.676 ' O ' ' N ' ' D' ' 26' ' ' LEU . 12.0 t70 -76.21 119.17 76.08 Favored Pre-proline 0 C--N 1.305 -1.326 0 CA-C-O 118.773 -0.632 . . . . 0.0 109.859 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_exo -43.69 69.53 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.095 0 C-N-CA 122.814 2.343 . . . . 0.0 113.691 179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.676 ' N ' ' O ' ' D' ' 24' ' ' ASP . 11.8 tp -66.18 -38.99 89.39 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.158 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 94.5 t -60.32 -50.87 78.58 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-N 116.041 -0.527 . . . . 0.0 112.376 -178.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.7 p -72.45 -26.49 24.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 CA-C-O 120.891 0.377 . . . . 0.0 111.762 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.409 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -59.09 -38.08 78.65 Favored 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.321 -179.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.24 -52.81 12.68 Favored 'General case' 0 C--N 1.304 -1.399 0 C-N-CA 119.953 -0.699 . . . . 0.0 110.385 178.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 30.8 t -50.9 -27.74 8.16 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.061 -0.972 . . . . 0.0 112.64 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.55 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.0 -45.84 87.96 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.745 -178.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.415 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 72.3 mt -69.06 -33.73 60.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 C-N-CA 120.497 -0.481 . . . . 0.0 111.029 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.17 -44.89 15.12 Favored Glycine 0 C--N 1.305 -1.157 0 CA-C-O 119.469 -0.628 . . . . 0.0 114.098 -176.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 18.0 pt -59.58 -29.42 42.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 118.868 1.334 . . . . 0.0 110.694 -179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.61 -50.33 73.0 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-O 121.107 0.479 . . . . 0.0 110.819 179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.1 OUTLIER -65.08 -29.93 70.85 Favored 'General case' 0 C--N 1.303 -1.434 0 CA-C-N 115.581 -0.736 . . . . 0.0 111.073 -179.06 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 90.9 t80 -65.34 -50.1 66.87 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 116.558 -0.292 . . . . 0.0 111.75 -179.348 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 78.8 mt -66.3 -40.22 86.24 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 CA-C-O 120.691 0.281 . . . . 0.0 111.71 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.827 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -68.78 -27.9 66.3 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.593 -179.66 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.443 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 5.4 t-105 -61.46 -42.11 98.26 Favored 'General case' 0 C--N 1.294 -1.82 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.817 -178.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 25.9 p -49.25 -44.31 43.55 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 113.705 1.002 . . . . 0.0 113.705 -177.018 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.953 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -53.87 -28.25 16.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.902 -178.027 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.953 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -48.08 -51.4 19.75 Favored Glycine 0 C--N 1.308 -0.979 0 C-N-CA 120.203 -0.999 . . . . 0.0 110.773 -179.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 51.0 t-80 -43.36 -24.83 0.11 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 122.88 -0.188 . . . . 0.0 111.409 -177.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.424 HD12 ' C ' ' D' ' 46' ' ' LEU . 1.2 pp -46.28 -26.84 0.87 Allowed 'General case' 0 C--N 1.298 -1.656 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.834 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.493 ' CB ' HD21 ' C' ' 47' ' ' ASN . 67.1 m-80 -71.92 -28.99 63.84 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 113.731 1.012 . . . . 0.0 113.731 179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.685 ' N ' HE21 ' D' ' 48' ' ' GLN . 2.8 mm-40 -60.23 -54.05 50.44 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-O 120.979 0.418 . . . . 0.0 110.225 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.1 mt -43.66 -83.95 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.276 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.483 ' O ' ' N ' ' D' ' 52' ' ' GLY . 38.6 tptt -52.21 -44.98 65.04 Favored 'General case' 0 C--N 1.305 -1.346 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.894 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.511 ' C ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 64.22 -70.75 0.07 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 120.719 0.295 . . . . 0.0 110.415 179.959 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.206 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.407 ' O ' ' CB ' ' A' ' 24' ' ' ASP . 29.1 t . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.42 -0.585 . . . . 0.0 109.42 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.407 ' CB ' ' O ' ' A' ' 23' ' ' SER . 2.1 m-20 79.23 65.7 0.18 Allowed Pre-proline 0 C--N 1.309 -1.167 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.021 -179.513 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.532 ' O ' HG12 ' A' ' 28' ' ' VAL . 69.3 Cg_endo -85.46 14.5 2.45 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 122.887 2.391 . . . . 0.0 111.666 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.645 ' N ' HD23 ' A' ' 26' ' ' LEU . 1.8 pt? -62.55 -32.62 73.61 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.581 -179.58 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.462 HG22 HG11 ' B' ' 27' ' ' VAL . 2.1 t -59.88 -37.46 72.06 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.021 -179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.532 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.84 -30.19 31.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.524 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.83 -53.39 56.47 Favored 'General case' 0 C--N 1.314 -0.953 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.61 -50.69 72.3 Favored 'General case' 0 C--N 1.311 -1.102 0 C-N-CA 119.477 -0.889 . . . . 0.0 109.237 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 34.4 t -51.23 -50.78 58.49 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 114.179 -1.373 . . . . 0.0 110.705 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 19.8 mt -49.76 -48.0 21.69 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.409 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.403 HG22 ' HE2' ' B' ' 37' ' ' HIS . 94.8 mt -59.04 -48.36 86.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 C-N-CA 119.819 -0.752 . . . . 0.0 109.428 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.72 -49.19 28.41 Favored Glycine 0 C--N 1.303 -1.296 0 CA-C-N 115.708 -0.678 . . . . 0.0 111.75 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 38.7 mt -66.93 -42.82 89.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.413 0 CA-C-O 121.041 0.448 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.7 tp -52.12 -30.61 27.22 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.71 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.539 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -72.16 -30.38 64.95 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 112.403 0.519 . . . . 0.0 112.403 -179.212 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 68.0 t80 -53.59 -50.66 65.14 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -177.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.659 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -55.52 -32.36 30.11 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.327 0 C-N-CA 120.55 -0.46 . . . . 0.0 110.616 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.53 -29.28 62.35 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 121.081 0.467 . . . . 0.0 110.973 179.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -61.88 -51.57 67.65 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -177.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.456 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.76 -44.15 48.53 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -177.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.2 pt -63.35 -41.58 93.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.995 -178.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -61.65 -35.42 91.15 Favored Glycine 0 C--N 1.305 -1.141 0 N-CA-C 111.275 -0.73 . . . . 0.0 111.275 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 17.0 t-80 -49.19 -27.71 3.85 Favored 'General case' 0 C--N 1.302 -1.486 0 CA-C-N 115.755 -0.223 . . . . 0.0 111.582 -179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.619 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.61 -30.19 1.44 Allowed 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 111.684 0.253 . . . . 0.0 111.684 -177.485 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 85.0 m-20 -61.56 -51.99 66.28 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.049 -0.66 . . . . 0.0 110.214 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . 0.414 ' O ' ' O ' ' A' ' 51' ' ' ARG . 4.8 tm0? -46.21 -50.74 15.44 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.595 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 23.6 mm -50.55 -49.66 24.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.463 -179.591 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -75.0 -70.08 0.43 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.291 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.414 ' O ' ' O ' ' A' ' 48' ' ' GLN . 76.4 ttt180 -71.57 131.8 43.76 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.564 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.118 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -180.0 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 40.2 m . . . . . 0 N--CA 1.489 1.484 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.551 ' O ' ' N ' ' B' ' 26' ' ' LEU . 93.2 m-20 -105.74 116.24 60.22 Favored Pre-proline 0 C--N 1.311 -1.081 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.108 -179.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_exo -40.53 84.85 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.127 1.885 . . . . 0.0 112.793 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.551 ' N ' ' O ' ' B' ' 24' ' ' ASP . 12.5 mt -61.65 -40.52 95.21 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.822 178.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . 0.462 HG11 HG22 ' A' ' 27' ' ' VAL . 21.7 t -58.26 -47.75 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.399 -178.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.0 -25.31 23.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 CA-C-O 121.177 0.513 . . . . 0.0 110.759 179.537 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.493 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -65.15 -29.91 70.79 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.643 -178.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.12 -52.86 12.65 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 118.81 -1.156 . . . . 0.0 111.549 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 15.6 t -47.55 -26.81 1.55 Allowed 'General case' 0 C--N 1.307 -1.277 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -178.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.493 HG22 ' O ' ' B' ' 29' ' ' ALA . 4.8 tt -66.5 -41.39 88.47 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 120.163 -0.615 . . . . 0.0 110.4 -179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 71.5 mt -74.7 -25.64 19.13 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-O 121.31 0.576 . . . . 0.0 110.546 177.401 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -52.84 -50.64 49.37 Favored Glycine 0 C--N 1.303 -1.281 0 CA-C-N 115.058 -0.974 . . . . 0.0 112.187 -178.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.461 HG22 ' H ' ' B' ' 35' ' ' ILE . 1.7 tt -70.66 -30.18 41.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 122.851 -0.206 . . . . 0.0 111.527 -179.174 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -60.39 -50.68 72.64 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 121.182 0.515 . . . . 0.0 110.011 -179.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.525 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.1 OUTLIER -62.61 -29.66 70.77 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.84 -179.107 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.497 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 31.9 t80 -67.6 -44.41 78.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 -179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.418 ' O ' ' CG2' ' B' ' 42' ' ' THR . 19.2 pt -67.6 -39.14 81.74 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 C-N-CA 120.38 -0.528 . . . . 0.0 112.02 -178.377 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -71.14 -28.82 64.56 Favored 'General case' 0 C--N 1.3 -1.571 0 CA-C-O 121.133 0.492 . . . . 0.0 110.253 179.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.0 t-105 -50.0 -51.62 40.34 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 115.39 -0.823 . . . . 0.0 112.744 -178.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.418 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.0 OUTLIER -49.74 -34.48 19.2 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.476 -177.729 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 5.3 tt -48.81 -43.21 14.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 121.036 -0.266 . . . . 0.0 111.223 -178.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -51.09 -47.41 49.21 Favored Glycine 0 C--N 1.307 -1.034 0 N-CA-C 110.599 -1.0 . . . . 0.0 110.599 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.406 ' O ' ' C ' ' B' ' 46' ' ' LEU . 60.8 t-80 -41.37 -21.88 0.02 OUTLIER 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 114.012 1.116 . . . . 0.0 114.012 -175.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.506 ' HG ' ' H ' ' B' ' 47' ' ' ASN . 3.3 pp -49.5 -50.16 42.73 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.381 -1.328 . . . . 0.0 107.756 177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.506 ' H ' ' HG ' ' B' ' 46' ' ' LEU . 78.6 m-20 -51.09 -50.55 58.53 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.685 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.434 ' O ' ' O ' ' B' ' 47' ' ' ASN . 12.2 mm100 -37.51 -101.33 0.0 OUTLIER 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 -178.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.638 HG23 ' N ' ' B' ' 50' ' ' LYS . 19.8 tt -33.07 -54.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 116.126 -0.488 . . . . 0.0 112.083 -178.091 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.638 ' N ' HG23 ' B' ' 49' ' ' ILE . 0.1 OUTLIER -44.61 -53.01 7.59 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 120.94 -0.304 . . . . 0.0 110.706 179.975 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 91.0 mtt-85 -82.83 -17.2 44.82 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.61 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.175 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.991 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 46.2 m . . . . . 0 N--CA 1.489 1.521 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' C' ' 24' ' ' ASP . 22.3 p-10 -165.31 58.16 0.54 Allowed Pre-proline 0 C--N 1.306 -1.326 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.462 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -73.6 -2.7 12.55 Favored 'Trans proline' 0 N--CA 1.495 1.56 0 C-N-CA 122.847 2.364 . . . . 0.0 111.979 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.573 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.6 mp -63.52 -38.83 92.61 Favored 'General case' 0 C--N 1.304 -1.412 0 CA-C-O 121.086 0.469 . . . . 0.0 110.713 -179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 85.2 t -62.19 -48.59 87.71 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.483 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -178.575 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 1.7 p -73.13 -40.12 57.74 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 112.169 0.433 . . . . 0.0 112.169 -178.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.61 -28.06 64.56 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -178.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.92 -44.11 61.61 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.84 -0.744 . . . . 0.0 111.642 -178.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 30.9 t -71.33 -31.06 66.95 Favored 'General case' 0 C--N 1.311 -1.078 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -48.54 -36.27 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 121.155 -0.218 . . . . 0.0 110.464 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 83.0 mt -65.63 -48.21 83.4 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 C-N-CA 120.452 -0.499 . . . . 0.0 110.43 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.507 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.21 -50.32 22.99 Favored Glycine 0 C--N 1.302 -1.35 0 CA-C-N 115.429 -0.805 . . . . 0.0 113.887 -176.661 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 8.2 pt -53.28 -29.71 16.41 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 CA-C-N 117.877 0.838 . . . . 0.0 111.412 -178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . 0.794 ' O ' HD12 ' C' ' 36' ' ' LEU . 0.2 OUTLIER -68.83 -26.8 65.35 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.485 -0.325 . . . . 0.0 111.749 -179.328 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -29.49 66.27 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 -178.731 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 64.6 t80 -61.33 -47.29 86.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 112.099 0.407 . . . . 0.0 112.099 -178.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.408 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.7 tp -64.77 -29.54 47.67 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 C-N-CA 120.723 -0.391 . . . . 0.0 111.172 -178.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.526 ' HB3' ' CZ2' ' D' ' 41' ' ' TRP . . . -72.44 -36.22 68.49 Favored 'General case' 0 C--N 1.303 -1.422 0 CA-C-O 121.181 0.515 . . . . 0.0 110.548 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -49.95 -51.22 42.95 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.415 -0.811 . . . . 0.0 112.693 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.1 OUTLIER -53.67 -27.16 26.01 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 112.65 0.611 . . . . 0.0 112.65 -178.179 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.452 ' CG2' ' N ' ' C' ' 44' ' ' GLY . 4.1 tt -62.23 -48.01 90.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 C-N-CA 120.696 -0.402 . . . . 0.0 111.447 -178.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.452 ' N ' ' CG2' ' C' ' 43' ' ' ILE . . . -60.12 -28.55 66.71 Favored Glycine 0 C--N 1.307 -1.081 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 53.0 t-80 -48.31 -27.77 2.72 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.694 -0.253 . . . . 0.0 111.325 -178.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.6 ' CD1' HD22 ' C' ' 47' ' ' ASN . 1.9 pp -44.75 -34.68 2.36 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 120.459 -0.497 . . . . 0.0 111.283 -177.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.6 HD22 ' CD1' ' C' ' 46' ' ' LEU . 0.9 OUTLIER -64.66 -52.35 57.75 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.588 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.595 ' N ' ' NE2' ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.87 -58.4 3.96 Favored 'General case' 0 C--N 1.31 -1.13 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.605 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 15.2 tt -61.84 -32.42 53.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.252 0 CA-C-N 116.502 -0.317 . . . . 0.0 111.374 -178.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 34.7 tptt -63.81 -43.14 97.16 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.424 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 8.1 tmm_? -57.94 126.72 28.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.481 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.219 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 179.9 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 10.6 t . . . . . 0 N--CA 1.49 1.558 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.66 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.3 t70 -80.74 116.09 59.87 Favored Pre-proline 0 C--N 1.307 -1.245 0 CA-C-O 118.926 -0.559 . . . . 0.0 109.948 -179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -43.12 69.45 0.0 OUTLIER 'Trans proline' 0 N--CA 1.505 2.175 0 C-N-CA 122.995 2.464 . . . . 0.0 114.093 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.66 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.3 mp -62.67 -43.34 99.07 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 120.875 0.369 . . . . 0.0 110.049 179.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 78.5 t -57.34 -51.07 74.16 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 N-CA-C 112.865 0.691 . . . . 0.0 112.865 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.4 p -73.09 -27.34 24.23 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 CA-C-N 118.379 0.536 . . . . 0.0 112.284 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . 0.425 ' O ' HG22 ' D' ' 32' ' ' ILE . . . -63.64 -41.01 98.28 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.504 -178.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.36 -52.6 15.37 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.429 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 32.1 t -50.01 -36.5 28.89 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.517 -0.765 . . . . 0.0 112.721 -178.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.607 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -51.96 -36.77 20.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 120.758 -0.377 . . . . 0.0 110.512 -178.744 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 74.7 mt -70.73 -34.01 54.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 120.414 -0.514 . . . . 0.0 110.656 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.16 -47.68 15.44 Favored Glycine 0 C--N 1.306 -1.094 0 CA-C-O 119.631 -0.538 . . . . 0.0 114.143 -176.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -59.15 -29.43 41.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-N 118.449 1.125 . . . . 0.0 111.117 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 9.2 tp -61.49 -51.07 70.17 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 120.932 0.396 . . . . 0.0 110.816 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -65.26 -29.93 70.75 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.997 -179.168 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 68.9 t80 -67.35 -47.16 71.25 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.965 -179.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.7 mt -64.05 -42.93 97.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.452 ' O ' HG22 ' D' ' 43' ' ' ILE . . . -70.57 -29.34 65.75 Favored 'General case' 0 C--N 1.303 -1.42 0 CA-C-O 120.92 0.391 . . . . 0.0 110.538 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.526 ' CZ2' ' HB3' ' C' ' 40' ' ' ALA . 6.2 t-105 -53.47 -49.04 68.29 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.942 -179.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 23.2 p -49.03 -40.89 32.88 Favored 'General case' 0 C--N 1.3 -1.568 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.905 -178.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.456 ' O ' HD23 ' D' ' 46' ' ' LEU . 3.4 tt -49.52 -33.61 7.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 C-N-CA 120.875 -0.33 . . . . 0.0 111.087 -178.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -51.72 -49.01 48.87 Favored Glycine 0 C--N 1.307 -1.03 0 N-CA-C 110.555 -1.018 . . . . 0.0 110.555 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -43.23 -24.03 0.07 Allowed 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.516 0.198 . . . . 0.0 111.184 -177.8 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.456 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.1 pp -46.38 -27.18 0.99 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 120.287 -0.565 . . . . 0.0 111.973 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 36.5 m-20 -72.84 -28.33 62.48 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 119.433 1.015 . . . . 0.0 113.697 179.423 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.578 HE22 ' CD2' ' C' ' 46' ' ' LEU . 44.5 mm-40 -63.68 -53.73 46.7 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 120.911 0.386 . . . . 0.0 110.514 -179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 83.2 mt -44.57 -85.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.66 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.478 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.4 tptt -48.67 -48.71 39.73 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.436 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 64.46 -69.67 0.09 Allowed 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.332 179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.304 -1.194 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 3.5 t . . . . . 0 N--CA 1.49 1.525 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.8 m-20 75.81 56.03 0.23 Allowed Pre-proline 0 C--N 1.308 -1.219 0 CA-C-N 116.099 -0.501 . . . . 0.0 109.999 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 53.9 Cg_endo -69.36 12.11 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 C-N-CA 122.603 2.202 . . . . 0.0 111.912 -179.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.855 HD13 ' CG2' ' B' ' 28' ' ' VAL . 36.2 mt -57.95 -31.5 66.9 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.993 -179.733 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 32.4 t -64.83 -37.52 80.39 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-N 116.609 -0.269 . . . . 0.0 111.542 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -73.04 -32.61 39.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.343 0.498 . . . . 0.0 112.343 -179.335 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.85 -53.33 55.87 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 113.039 0.755 . . . . 0.0 113.039 -177.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.8 -49.94 75.8 Favored 'General case' 0 C--N 1.311 -1.103 0 C-N-CA 119.211 -0.996 . . . . 0.0 109.292 -179.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 44.9 t -49.19 -49.68 41.6 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.064 179.126 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.3 mt -51.6 -50.37 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.123 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 97.4 mt -58.6 -48.33 85.97 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.237 0 C-N-CA 119.995 -0.682 . . . . 0.0 109.41 179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.521 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.78 -46.61 24.96 Favored Glycine 0 C--N 1.302 -1.351 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.825 -178.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 mt -70.62 -30.62 43.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 117.275 0.537 . . . . 0.0 111.029 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 15.6 tp -61.3 -31.87 71.71 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 116.011 -0.54 . . . . 0.0 111.571 -179.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.533 ' C ' ' ND1' ' A' ' 37' ' ' HIS . 0.0 OUTLIER -72.21 -30.0 64.51 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 -179.372 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 77.1 t80 -49.82 -50.39 45.34 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 112.44 0.533 . . . . 0.0 112.44 -177.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD12 ' A' ' 39' ' ' ILE . 4.1 mp -60.13 -33.98 55.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 120.686 -0.406 . . . . 0.0 110.981 -179.23 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.431 ' HB1' ' CZ2' ' B' ' 41' ' ' TRP . . . -72.77 -29.63 63.46 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.874 179.514 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -64.26 -51.23 64.59 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -177.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.419 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.3 -40.76 49.54 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 113.104 0.779 . . . . 0.0 113.104 -177.694 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . 0.444 ' C ' HE22 ' B' ' 48' ' ' GLN . 13.0 pt -64.74 -44.19 96.5 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.188 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.196 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.47 -34.88 90.75 Favored Glycine 0 C--N 1.307 -1.068 0 N-CA-C 111.313 -0.715 . . . . 0.0 111.313 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . 0.456 ' CE1' HD11 ' A' ' 49' ' ' ILE . 9.8 t-160 -48.85 -26.2 2.29 Favored 'General case' 0 C--N 1.303 -1.456 0 CA-C-O 120.663 0.268 . . . . 0.0 111.129 -179.436 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.625 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.9 OUTLIER -45.39 -30.25 1.29 Allowed 'General case' 0 C--N 1.304 -1.386 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.072 -177.832 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 19.6 t-20 -63.42 -52.51 61.24 Favored 'General case' 0 C--N 1.305 -1.368 0 C-N-CA 120.2 -0.6 . . . . 0.0 110.701 179.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 14.6 tm0? -49.82 -49.29 49.4 Favored 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.583 -0.28 . . . . 0.0 110.772 -179.321 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 0.456 HD11 ' CE1' ' A' ' 45' ' ' HIS . 22.5 mm -50.96 -50.49 23.93 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 CA-C-O 120.759 0.314 . . . . 0.0 110.678 -179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 2.1 tmtp? -80.23 -70.83 0.49 Allowed 'General case' 0 C--N 1.307 -1.261 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.565 -179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.81 132.3 43.39 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.535 -179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . 0.44 ' C ' HD13 ' D' ' 46' ' ' LEU . . . . . . . . 0 C--N 1.305 -1.156 0 N-CA-C 111.093 -0.803 . . . . 0.0 111.093 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 23.3 p . . . . . 0 N--CA 1.491 1.579 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.55 ' O ' ' N ' ' B' ' 26' ' ' LEU . 17.2 m-20 -159.59 84.03 2.27 Favored Pre-proline 0 C--N 1.308 -1.23 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.724 -179.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -54.32 68.31 0.03 OUTLIER 'Trans proline' 0 N--CA 1.503 2.045 0 C-N-CA 123.035 2.49 . . . . 0.0 113.044 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.55 ' N ' ' O ' ' B' ' 24' ' ' ASP . 11.6 mt -67.18 -42.86 83.54 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.342 179.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 22.0 t -57.29 -49.42 80.01 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.776 -0.647 . . . . 0.0 112.348 -178.327 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.855 ' CG2' HD13 ' A' ' 26' ' ' LEU . 40.3 t -70.44 -24.31 25.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 CA-C-O 121.114 0.483 . . . . 0.0 110.663 179.577 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -60.98 -38.68 86.83 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.155 -179.302 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.57 -54.04 10.26 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 118.921 -1.111 . . . . 0.0 111.536 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 26.5 t -53.66 -39.36 65.0 Favored 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.427 HD13 HG21 ' B' ' 32' ' ' ILE . 4.7 tt -66.68 -40.69 86.74 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.936 -0.706 . . . . 0.0 110.272 -179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 54.3 mt -71.25 -44.3 73.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.328 179.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.27 -50.88 22.12 Favored Glycine 0 C--N 1.31 -0.915 0 C-N-CA 121.043 -0.599 . . . . 0.0 113.638 -176.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.411 ' H ' HG22 ' B' ' 35' ' ' ILE . 1.6 tt -51.85 -29.46 10.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 CA-C-N 117.904 0.852 . . . . 0.0 109.948 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 6.5 tp -64.81 -52.23 57.93 Favored 'General case' 0 C--N 1.307 -1.273 0 CA-C-O 121.377 0.608 . . . . 0.0 109.549 179.107 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.579 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -60.05 -29.94 68.86 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.948 -178.903 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.534 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 45.7 t80 -67.44 -45.97 74.47 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.609 ' O ' HG22 ' B' ' 42' ' ' THR . 25.5 pt -70.54 -35.55 62.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 N-CA-C 112.209 0.448 . . . . 0.0 112.209 -178.6 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.58 -26.97 65.66 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-O 121.429 0.633 . . . . 0.0 110.419 179.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.431 ' CZ2' ' HB1' ' A' ' 40' ' ' ALA . 7.2 t-105 -49.08 -43.2 40.9 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 115.122 -0.944 . . . . 0.0 112.673 -178.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.609 HG22 ' O ' ' B' ' 39' ' ' ILE . 7.8 t -47.48 -37.9 12.72 Favored 'General case' 0 C--N 1.299 -1.626 0 N-CA-C 111.888 0.329 . . . . 0.0 111.888 -177.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 50.9 mt -49.96 -45.67 22.72 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 C-N-CA 119.76 -0.776 . . . . 0.0 110.686 -179.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -52.75 -51.89 41.92 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -179.628 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . 0.436 ' NE2' ' CD1' ' A' ' 43' ' ' ILE . 0.8 OUTLIER -43.02 -22.6 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 112.786 0.662 . . . . 0.0 112.786 -176.8 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.61 HD12 ' N ' ' B' ' 47' ' ' ASN . 1.8 pp -49.8 -51.5 39.1 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 118.783 -1.167 . . . . 0.0 108.06 177.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.61 ' N ' HD12 ' B' ' 46' ' ' LEU . 61.5 m-80 -51.3 -50.05 60.11 Favored 'General case' 0 C--N 1.305 -1.328 0 CA-C-N 115.078 -0.965 . . . . 0.0 111.628 -179.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.444 HE22 ' C ' ' A' ' 43' ' ' ILE . 14.3 mm100 -41.23 -94.15 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.188 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.683 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -37.05 -60.4 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.135 0 CA-C-N 116.515 -0.311 . . . . 0.0 111.736 -178.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.683 ' H ' HG23 ' B' ' 49' ' ' ILE . 0.3 OUTLIER -42.41 -51.01 5.09 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 120.786 0.327 . . . . 0.0 110.962 -179.755 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.3 mtt-85 -84.61 46.65 1.26 Allowed 'General case' 0 C--N 1.307 -1.265 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.599 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.21 0 N-CA-C 110.936 -0.866 . . . . 0.0 110.936 -179.997 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 19.1 t . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.417 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 2.1 p30 40.54 54.24 6.6 Favored Pre-proline 0 C--N 1.311 -1.096 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.788 179.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.417 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 34.6 Cg_endo -63.93 -19.19 66.31 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 122.206 1.938 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.553 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.4 mp -62.23 -40.78 97.28 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-N 115.45 -0.795 . . . . 0.0 111.522 -179.242 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 99.6 t -70.12 -45.65 75.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.443 0 N-CA-C 112.952 0.723 . . . . 0.0 112.952 -178.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.4 p -71.98 -29.62 33.81 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 112.128 0.418 . . . . 0.0 112.128 -178.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . 0.51 ' O ' HG22 ' C' ' 32' ' ' ILE . . . -68.81 -51.75 37.5 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 -177.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.62 -29.02 64.2 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.506 -178.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 42.4 t -51.8 -50.98 59.71 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.381 -0.827 . . . . 0.0 111.152 -179.734 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.51 HG22 ' O ' ' C' ' 29' ' ' ALA . 6.2 tp -47.29 -29.01 1.38 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 71.7 mt -64.56 -42.59 95.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 CA-C-O 120.99 0.424 . . . . 0.0 110.544 179.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.89 -50.78 20.09 Favored Glycine 0 C--N 1.304 -1.205 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.023 -177.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 38.9 pt -70.39 -29.52 39.3 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-N 118.055 0.928 . . . . 0.0 111.14 -179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 5.9 tp -59.76 -31.4 69.62 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.953 -179.072 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.616 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.3 OUTLIER -71.42 -34.93 70.77 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 120.633 -0.427 . . . . 0.0 111.904 -179.464 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.616 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 47.8 t80 -62.0 -50.38 72.28 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 120.766 -0.374 . . . . 0.0 111.905 -178.631 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -64.07 -30.44 50.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.276 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.321 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.461 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.59 -36.11 68.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.964 0.411 . . . . 0.0 110.059 178.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.5 t-105 -49.15 -51.12 34.23 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.711 -0.677 . . . . 0.0 112.55 -177.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.437 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.82 -26.94 10.89 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 111.901 0.334 . . . . 0.0 111.901 -179.45 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.848 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -68.24 -38.06 78.98 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 C-N-CA 120.741 -0.384 . . . . 0.0 111.322 -179.03 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.92 -28.91 69.82 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -57.98 -28.47 64.41 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.868 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.91 -32.13 2.52 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 112.1 0.408 . . . . 0.0 112.1 -177.72 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.868 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.1 m-20 -67.2 -51.98 46.83 Favored 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.584 178.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 12.4 tm0? -41.3 -48.73 3.67 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 112.147 0.425 . . . . 0.0 112.147 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . 0.411 HG22 ' O ' ' C' ' 46' ' ' LEU . 11.5 tt -67.02 -23.86 31.44 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 C-N-CA 120.744 -0.382 . . . . 0.0 111.698 -178.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . . . . . . . . . 45.6 tptt -63.2 -47.88 80.69 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.536 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.2 tmm_? -67.17 139.43 57.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.475 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.208 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -179.966 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 31.2 t . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.669 ' O ' ' N ' ' D' ' 26' ' ' LEU . 20.2 t70 -84.16 117.86 69.79 Favored Pre-proline 0 C--N 1.306 -1.284 0 CA-C-O 118.854 -0.593 . . . . 0.0 109.899 -179.798 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -44.22 71.86 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.1 0 C-N-CA 122.723 2.282 . . . . 0.0 113.164 179.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.669 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.17 -41.68 89.99 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.24 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 55.2 t -59.0 -50.62 79.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 115.629 -0.714 . . . . 0.0 112.571 -178.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 4.9 p -73.52 -25.85 21.45 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.75 -46.98 70.54 Favored 'General case' 0 C--N 1.301 -1.534 0 CA-C-N 116.147 -0.479 . . . . 0.0 112.008 -178.581 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.3 -51.13 32.62 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.25 -179.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . 0.422 ' O ' ' N ' ' D' ' 34' ' ' GLY . 28.6 t -48.45 -37.87 18.4 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 112.995 0.739 . . . . 0.0 112.995 -178.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.573 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -49.85 -29.08 4.67 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.195 0 CA-C-N 118.398 0.545 . . . . 0.0 111.818 -178.653 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 92.9 mt -73.55 -24.72 20.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.524 0.678 . . . . 0.0 110.251 177.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . 0.429 ' O ' ' CD2' ' D' ' 37' ' ' HIS . . . -49.28 -50.41 29.02 Favored Glycine 0 C--N 1.302 -1.339 0 CA-C-N 114.76 -1.109 . . . . 0.0 112.519 -178.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 45.7 pt -65.86 -29.48 47.04 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 CA-C-N 117.137 0.469 . . . . 0.0 111.819 -178.958 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.7 tp -56.81 -50.6 71.86 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-O 121.059 0.457 . . . . 0.0 110.449 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 1.1 p80 -67.05 -30.13 70.11 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.296 -179.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 72.3 t80 -68.08 -49.32 62.01 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 111.757 0.28 . . . . 0.0 111.757 -179.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 84.2 mt -64.61 -39.36 85.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 CA-C-O 120.796 0.332 . . . . 0.0 111.311 -179.14 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.437 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -69.46 -26.61 64.67 Favored 'General case' 0 C--N 1.301 -1.51 0 CA-C-O 121.208 0.527 . . . . 0.0 110.336 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -60.92 -49.25 78.2 Favored 'General case' 0 C--N 1.293 -1.889 0 CA-C-N 116.206 -0.452 . . . . 0.0 112.084 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 66.5 p -47.63 -40.7 20.24 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 114.067 1.136 . . . . 0.0 114.067 -176.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.465 ' O ' HD23 ' D' ' 46' ' ' LEU . 4.4 pt -58.29 -27.94 33.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.613 -179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.501 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -47.71 -50.4 19.84 Favored Glycine 0 N--CA 1.471 1.002 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 -179.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -41.13 -21.35 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.427 0 O-C-N 122.645 -0.326 . . . . 0.0 111.568 -177.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.501 ' N ' ' O ' ' D' ' 44' ' ' GLY . 1.9 pp -45.95 -27.65 0.95 Allowed 'General case' 0 C--N 1.299 -1.616 0 C-N-CA 120.647 -0.421 . . . . 0.0 110.375 179.691 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 74.1 m-20 -65.2 -35.41 80.99 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 112.694 0.627 . . . . 0.0 112.694 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.643 HE22 HD11 ' C' ' 46' ' ' LEU . 50.4 mm-40 -64.97 -59.21 4.41 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 120.676 0.274 . . . . 0.0 111.203 179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 97.0 mt -38.64 -82.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.097 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.955 -179.573 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.515 ' O ' ' N ' ' D' ' 52' ' ' GLY . 40.4 tptt -51.93 -37.51 52.91 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 120.778 -0.369 . . . . 0.0 110.11 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 62.91 -70.55 0.06 Allowed 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.417 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.192 0 N-CA-C 110.939 -0.865 . . . . 0.0 110.939 -180.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . 0.421 ' O ' ' OD2' ' A' ' 24' ' ' ASP . 4.4 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.473 ' C ' ' H ' ' A' ' 26' ' ' LEU . 1.4 m-20 78.19 56.14 0.18 Allowed Pre-proline 0 C--N 1.31 -1.147 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.612 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.444 ' O ' HG12 ' A' ' 28' ' ' VAL . 19.7 Cg_endo -58.82 3.39 0.16 Allowed 'Trans proline' 0 C--N 1.309 -1.51 0 C-N-CA 122.279 1.986 . . . . 0.0 112.203 -179.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.619 HD22 HG23 ' B' ' 28' ' ' VAL . 99.3 mt -61.95 -29.81 70.49 Favored 'General case' 0 C--N 1.302 -1.488 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.854 179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 40.1 t -62.68 -40.2 87.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 CA-C-O 120.762 0.315 . . . . 0.0 111.033 -179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 25' ' ' PRO . 0.3 OUTLIER -72.32 -33.99 47.74 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -179.015 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -59.71 -53.29 59.68 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 112.94 0.718 . . . . 0.0 112.94 -177.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.65 -50.79 71.99 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.627 -0.829 . . . . 0.0 109.436 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 42.0 t -51.33 -49.49 61.28 Favored 'General case' 0 C--N 1.298 -1.668 0 CA-C-N 114.439 -1.255 . . . . 0.0 110.243 179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 17.1 mt -49.63 -50.27 17.86 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.082 -179.006 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 95.5 mt -59.0 -45.76 92.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 179.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -48.43 -49.64 25.78 Favored Glycine 0 C--N 1.302 -1.343 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.859 -178.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 44.5 mt -70.1 -29.95 41.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.341 0 CA-C-N 117.056 0.428 . . . . 0.0 111.069 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 6.7 tp -61.31 -33.42 73.57 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.881 -0.599 . . . . 0.0 111.989 -179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 34' ' ' GLY . 0.1 OUTLIER -71.79 -29.99 65.06 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 112.42 0.526 . . . . 0.0 112.42 -179.11 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 78.4 t80 -54.73 -51.47 65.51 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 120.6 -0.44 . . . . 0.0 111.834 -177.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.622 ' H ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -55.56 -32.8 31.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 C-N-CA 120.454 -0.499 . . . . 0.0 110.04 -179.678 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.15 -29.7 63.06 Favored 'General case' 0 C--N 1.3 -1.55 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.872 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.3 t-105 -58.92 -51.21 71.0 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 112.738 0.644 . . . . 0.0 112.738 -177.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.47 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -49.63 -44.09 47.18 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -177.772 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 16.7 pt -66.24 -44.11 91.45 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.181 0 C-N-CA 119.872 -0.731 . . . . 0.0 111.849 -178.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.54 -29.26 73.01 Favored Glycine 0 C--N 1.307 -1.057 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -48.83 -26.52 2.45 Favored 'General case' 0 C--N 1.299 -1.623 0 CA-C-N 115.523 -0.338 . . . . 0.0 110.615 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 1.4 pp -44.04 -31.68 0.98 Allowed 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.116 -0.493 . . . . 0.0 112.025 -176.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 44.3 m-20 -57.41 -51.83 67.85 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.302 -0.959 . . . . 0.0 109.716 179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 3.1 tm0? -51.46 -59.11 4.61 Favored 'General case' 0 C--N 1.306 -1.304 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.369 -179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.7 mm -47.89 -50.74 9.56 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.651 -179.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.8 tmtp? -70.5 -71.55 0.24 Allowed 'General case' 0 C--N 1.305 -1.356 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.39 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.404 HH22 ' C ' ' D' ' 51' ' ' ARG . 71.5 ttt180 -77.13 124.77 28.29 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.524 -179.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.186 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 -179.981 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 64.2 m . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.582 ' O ' ' N ' ' B' ' 26' ' ' LEU . 22.5 m-20 -98.23 108.09 45.16 Favored Pre-proline 0 C--N 1.31 -1.122 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.167 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_exo -43.33 80.57 0.01 OUTLIER 'Trans proline' 0 N--CA 1.495 1.614 0 C-N-CA 122.263 1.975 . . . . 0.0 113.078 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.582 ' N ' ' O ' ' B' ' 24' ' ' ASP . 10.5 mt -52.84 -39.05 62.2 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 178.569 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 38.3 t -56.36 -49.67 75.72 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.17 -0.923 . . . . 0.0 111.63 -179.11 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.619 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.66 -26.03 25.42 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 CA-C-O 121.123 0.487 . . . . 0.0 110.895 -179.974 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.534 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -63.94 -33.5 75.86 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.191 0.812 . . . . 0.0 113.191 -177.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.41 -51.49 17.1 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 118.913 -1.115 . . . . 0.0 111.261 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 30.5 t -47.11 -26.53 1.12 Allowed 'General case' 0 C--N 1.305 -1.327 0 CA-C-N 115.962 -0.563 . . . . 0.0 112.164 -179.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.534 HG22 ' O ' ' B' ' 29' ' ' ALA . 5.3 tt -68.36 -36.83 76.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 C-N-CA 120.231 -0.587 . . . . 0.0 110.494 -179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 51.2 mt -70.88 -45.35 73.66 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.822 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.86 -46.87 14.14 Favored Glycine 0 C--N 1.306 -1.134 0 C-N-CA 120.902 -0.666 . . . . 0.0 113.282 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 1.1 tt -62.0 -38.07 79.87 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 CA-C-N 118.191 0.996 . . . . 0.0 109.53 179.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -63.97 -45.89 87.07 Favored 'General case' 0 C--N 1.309 -1.154 0 CA-C-O 121.548 0.69 . . . . 0.0 109.197 178.528 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.37 -33.62 75.93 Favored 'General case' 0 C--N 1.301 -1.5 0 CA-C-N 114.752 -1.113 . . . . 0.0 110.546 -179.54 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -70.68 -41.62 71.78 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.628 ' O ' HG22 ' B' ' 42' ' ' THR . 28.2 pt -69.7 -37.39 73.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.791 0.664 . . . . 0.0 112.791 -177.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.429 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -68.95 -28.26 66.47 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 121.195 0.521 . . . . 0.0 110.314 -179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.469 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.5 t-105 -51.06 -50.41 58.71 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.427 -0.806 . . . . 0.0 112.267 -178.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.628 HG22 ' O ' ' B' ' 39' ' ' ILE . 13.4 t -47.77 -39.04 16.88 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 120.811 -0.355 . . . . 0.0 110.831 -177.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.451 ' N ' HG23 ' B' ' 42' ' ' THR . 4.8 tt -48.29 -35.85 6.08 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.479 -0.328 . . . . 0.0 111.599 -178.029 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -62.36 -49.89 69.92 Favored Glycine 0 C--N 1.308 -0.98 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -42.91 -24.86 0.08 Allowed 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.469 -0.365 . . . . 0.0 111.381 -177.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.819 HD21 HE21 ' C' ' 48' ' ' GLN . 0.6 OUTLIER -46.04 -28.96 1.31 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 120.3 -0.56 . . . . 0.0 111.454 -178.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.763 HD21 HE22 ' C' ' 48' ' ' GLN . 37.8 m-80 -74.02 -29.25 61.84 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 113.361 0.875 . . . . 0.0 113.361 178.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.443 ' O ' ' C ' ' B' ' 49' ' ' ILE . 0.1 OUTLIER -45.66 -90.91 0.0 OUTLIER 'General case' 0 C--N 1.317 -0.809 0 O-C-N 122.32 -0.237 . . . . 0.0 111.241 -178.569 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.859 HG23 ' H ' ' B' ' 50' ' ' LYS . 14.4 tt -32.93 -65.99 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.951 0 O-C-N 123.404 0.44 . . . . 0.0 111.423 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.859 ' H ' HG23 ' B' ' 49' ' ' ILE . 2.0 mmmp? -37.57 -53.03 1.21 Allowed 'General case' 0 C--N 1.312 -1.054 0 CA-C-O 120.878 0.371 . . . . 0.0 111.164 179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 88.2 mtt-85 -71.43 -39.65 70.93 Favored 'General case' 0 C--N 1.306 -1.322 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.554 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.183 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 -179.948 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.416 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 6.2 p-10 41.15 54.32 7.42 Favored Pre-proline 0 C--N 1.309 -1.153 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.897 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.416 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 31.5 Cg_endo -64.43 -19.95 65.77 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 C-N-CA 121.901 1.734 . . . . 0.0 110.213 179.775 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.516 HD12 ' N ' ' C' ' 26' ' ' LEU . 9.7 mp -65.42 -41.88 93.1 Favored 'General case' 0 C--N 1.304 -1.389 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.699 -179.372 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 86.0 t -65.02 -47.07 89.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 N-CA-C 112.66 0.615 . . . . 0.0 112.66 -178.629 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.51 -39.98 71.32 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 N-CA-C 112.005 0.372 . . . . 0.0 112.005 -178.633 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.43 -28.18 64.84 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -178.587 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.88 -39.06 66.72 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 112.659 0.614 . . . . 0.0 112.659 -178.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 35.1 t -64.21 -28.13 69.53 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-O 121.043 0.449 . . . . 0.0 111.427 -179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.416 HG12 ' H ' ' C' ' 32' ' ' ILE . 32.7 mm -46.61 -44.82 6.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.471 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.81 -42.88 96.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-O 121.255 0.55 . . . . 0.0 109.807 178.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.559 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.56 -50.57 24.51 Favored Glycine 0 C--N 1.303 -1.286 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.39 -178.332 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 25.5 pt -70.6 -29.44 38.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 CA-C-N 117.453 0.626 . . . . 0.0 111.379 -179.55 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 25.7 tp -60.25 -32.45 71.16 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 116.407 -0.361 . . . . 0.0 111.686 -179.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.76 -30.54 65.69 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 112.424 0.527 . . . . 0.0 112.424 -179.198 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.625 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 36.9 t80 -62.38 -50.94 69.55 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.262 -0.575 . . . . 0.0 111.704 -178.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.431 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.5 tp -63.17 -30.2 49.11 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.273 0 C-N-CA 120.424 -0.51 . . . . 0.0 110.493 -179.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.27 -31.77 66.06 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 120.518 -0.473 . . . . 0.0 110.032 179.004 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -49.01 -51.61 29.82 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.366 -177.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.447 ' H ' HG22 ' C' ' 42' ' ' THR . 0.0 OUTLIER -52.43 -27.47 16.05 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.75 -179.565 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.741 ' O ' HD12 ' C' ' 46' ' ' LEU . 2.0 tt -70.01 -44.22 78.62 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.966 0 O-C-N 122.038 -0.414 . . . . 0.0 110.946 -179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -71.9 -28.95 67.84 Favored Glycine 0 C--N 1.31 -0.909 0 N-CA-C 111.61 -0.596 . . . . 0.0 111.61 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -54.73 -28.71 50.21 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 112.24 0.459 . . . . 0.0 112.24 -179.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.764 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -45.75 -30.49 1.64 Allowed 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.871 0.693 . . . . 0.0 112.871 -176.914 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.764 ' H ' HD13 ' C' ' 46' ' ' LEU . 72.8 m-80 -66.18 -52.37 48.75 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.505 -0.878 . . . . 0.0 111.432 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.819 HE21 HD21 ' B' ' 46' ' ' LEU . 2.9 mm100 -47.66 -53.19 15.61 Favored 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 8.6 tt -59.54 -32.89 50.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 C-N-CA 120.813 -0.355 . . . . 0.0 111.017 -179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.541 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 42.0 tptt -60.74 -39.49 88.89 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 120.834 -0.347 . . . . 0.0 110.366 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 5.9 tmm_? -50.01 134.32 21.77 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.338 -179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.142 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.952 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 8.0 t . . . . . 0 N--CA 1.491 1.608 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.666 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.1 t70 -81.92 119.69 75.8 Favored Pre-proline 0 C--N 1.307 -1.282 0 CA-C-O 118.829 -0.605 . . . . 0.0 110.039 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -41.91 72.84 0.0 OUTLIER 'Trans proline' 0 N--CA 1.502 1.978 0 C-N-CA 122.789 2.326 . . . . 0.0 113.461 179.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.666 ' N ' ' O ' ' D' ' 24' ' ' ASP . 1.9 tp -66.4 -41.83 88.73 Favored 'General case' 0 C--N 1.302 -1.478 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.105 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 72.0 t -58.16 -50.84 76.91 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 CA-C-N 115.796 -0.638 . . . . 0.0 112.514 -178.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.9 p -72.51 -26.23 23.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.184 0 N-CA-C 112.194 0.442 . . . . 0.0 112.194 -179.594 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -61.64 -39.21 90.52 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.792 -178.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.11 -52.79 15.09 Favored 'General case' 0 C--N 1.303 -1.44 0 C-N-CA 119.919 -0.712 . . . . 0.0 110.681 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 26.1 t -49.77 -28.55 6.39 Favored 'General case' 0 C--N 1.304 -1.373 0 CA-C-N 115.478 -0.783 . . . . 0.0 112.989 -178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.597 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -58.66 -36.47 60.3 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 120.373 -0.531 . . . . 0.0 109.934 -179.278 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 8.3 mt -69.67 -31.66 49.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 116.436 -0.347 . . . . 0.0 111.151 179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.14 -45.95 15.32 Favored Glycine 0 C--N 1.306 -1.087 0 CA-C-O 119.715 -0.492 . . . . 0.0 113.817 -176.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 36.9 pt -64.24 -29.52 47.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 CA-C-N 118.257 1.029 . . . . 0.0 111.054 -179.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 7.8 tp -60.85 -49.85 75.83 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.1 0.476 . . . . 0.0 110.815 179.832 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.609 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -69.15 -31.28 69.83 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.033 -179.469 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.609 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 35.6 t80 -67.44 -46.85 71.88 Favored 'General case' 0 C--N 1.306 -1.301 0 CA-C-N 116.538 -0.301 . . . . 0.0 111.751 -179.441 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 96.4 mt -65.32 -42.53 93.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 CA-C-O 120.662 0.268 . . . . 0.0 111.624 -178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . . . . . . . . . . . -68.25 -27.28 66.2 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-O 121.25 0.548 . . . . 0.0 110.587 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.43 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 4.0 t-105 -61.1 -47.46 86.21 Favored 'General case' 0 C--N 1.295 -1.761 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.505 -179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 48.0 p -48.41 -46.78 37.76 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 113.512 0.93 . . . . 0.0 113.512 -176.623 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.438 ' O ' HD23 ' D' ' 46' ' ' LEU . 8.3 pt -57.37 -28.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.396 -178.773 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -48.18 -50.64 22.11 Favored Glycine 0 C--N 1.307 -1.057 0 C-N-CA 120.303 -0.951 . . . . 0.0 110.767 -179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 56.0 t-80 -42.39 -23.2 0.03 OUTLIER 'General case' 0 C--N 1.302 -1.492 0 O-C-N 122.801 -0.234 . . . . 0.0 111.44 -177.745 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.438 HD23 ' O ' ' D' ' 43' ' ' ILE . 1.4 pp -45.81 -25.78 0.56 Allowed 'General case' 0 C--N 1.298 -1.654 0 CA-C-O 119.208 -0.425 . . . . 0.0 111.773 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . . . . . . . . . 66.5 m-80 -70.93 -28.95 64.88 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 119.474 1.034 . . . . 0.0 113.417 179.709 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.544 ' N ' ' OE1' ' D' ' 48' ' ' GLN . 1.5 mp0 -70.81 -44.54 66.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-O 120.832 0.349 . . . . 0.0 110.547 -179.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 71.3 mt -44.68 -87.68 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.277 -179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.495 ' O ' ' N ' ' D' ' 52' ' ' GLY . 33.8 tptt -46.2 -43.06 14.97 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-O 120.788 0.328 . . . . 0.0 110.647 179.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.541 ' NE ' ' NZ ' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.89 -70.57 0.07 Allowed 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.356 179.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.495 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.162 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 25.1 t . . . . . 0 N--CA 1.491 1.618 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.503 ' C ' ' H ' ' A' ' 26' ' ' LEU . 7.3 m-20 43.05 52.43 8.09 Favored Pre-proline 0 C--N 1.309 -1.165 0 CA-C-N 116.376 -0.375 . . . . 0.0 110.104 179.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.46 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 9.5 Cg_endo -50.09 -7.13 0.09 OUTLIER 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 122.37 2.047 . . . . 0.0 111.513 -179.171 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.603 HD22 HG23 ' B' ' 28' ' ' VAL . 95.4 mt -65.3 -29.14 69.87 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 120.671 -0.411 . . . . 0.0 111.727 -179.43 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.23 -41.65 93.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-O 120.681 0.277 . . . . 0.0 111.487 -179.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -72.36 -34.05 47.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.501 0 N-CA-C 112.427 0.529 . . . . 0.0 112.427 -179.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -58.94 -53.49 57.86 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 112.951 0.723 . . . . 0.0 112.951 -177.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -57.73 -50.97 71.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.701 0.762 . . . . 0.0 109.72 -179.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 36.2 t -51.68 -50.19 60.93 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.646 179.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 22.7 mt -49.23 -48.25 18.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.383 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 60.7 mt -61.35 -43.13 96.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.076 -0.65 . . . . 0.0 109.291 179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.541 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.62 -49.16 22.05 Favored Glycine 0 C--N 1.3 -1.432 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.479 -178.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.406 HG21 HD13 ' A' ' 35' ' ' ILE . 31.1 mt -70.38 -30.35 42.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 CA-C-N 117.341 0.571 . . . . 0.0 110.82 179.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 12.9 tp -59.56 -34.11 72.28 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 115.944 -0.571 . . . . 0.0 111.411 -179.262 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.2 OUTLIER -72.66 -30.26 64.13 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 -179.443 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 45.9 t80 -51.56 -51.43 55.41 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.589 0.588 . . . . 0.0 112.589 -177.594 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.615 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -58.94 -32.19 46.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 C-N-CA 120.527 -0.469 . . . . 0.0 110.726 -179.174 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -72.98 -28.43 62.39 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.735 179.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -65.5 -51.98 56.05 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -176.967 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -52.15 -39.31 59.8 Favored 'General case' 0 C--N 1.299 -1.605 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -177.596 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 13.7 pt -63.81 -43.24 97.83 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.195 -178.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -66.95 -29.33 74.48 Favored Glycine 0 C--N 1.307 -1.069 0 N-CA-C 111.608 -0.597 . . . . 0.0 111.608 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 30.1 t-80 -48.99 -26.63 2.64 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-O 120.605 0.24 . . . . 0.0 111.021 -179.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.413 HD12 ' C ' ' A' ' 46' ' ' LEU . 1.3 pp -44.44 -29.42 0.69 Allowed 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 121.038 -0.265 . . . . 0.0 111.088 -177.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 75.9 m-20 -61.79 -52.26 64.92 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 120.166 -0.613 . . . . 0.0 110.573 -179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 7.1 tm0? -49.77 -52.07 34.52 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.589 -179.6 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 18.5 mm -44.93 -58.21 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.306 0 CA-C-O 120.781 0.324 . . . . 0.0 110.781 -179.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -77.92 -73.08 0.33 Allowed 'General case' 0 C--N 1.306 -1.291 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.487 -179.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.596 HH21 ' N ' ' D' ' 51' ' ' ARG . 70.9 ttt180 -69.66 129.53 39.87 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-O 120.828 0.347 . . . . 0.0 110.543 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.155 0 N-CA-C 110.963 -0.855 . . . . 0.0 110.963 -179.796 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 83.1 p . . . . . 0 N--CA 1.489 1.522 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.596 ' O ' ' N ' ' B' ' 26' ' ' LEU . 37.0 m-20 -90.68 115.38 64.07 Favored Pre-proline 0 C--N 1.308 -1.22 0 CA-C-O 119.209 -0.424 . . . . 0.0 110.288 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_exo -42.41 77.89 0.01 OUTLIER 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 122.49 2.126 . . . . 0.0 113.313 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.596 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.2 mt -61.28 -41.24 96.61 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 178.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 39.2 t -55.68 -48.69 77.47 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.78 -178.931 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . 0.603 HG23 HD22 ' A' ' 26' ' ' LEU . 0.3 OUTLIER -71.69 -24.82 23.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-O 120.867 0.365 . . . . 0.0 111.225 -179.501 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -34.7 77.07 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 112.611 0.597 . . . . 0.0 112.611 -178.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.47 -55.14 8.46 Favored 'General case' 0 C--N 1.31 -1.125 0 C-N-CA 118.56 -1.256 . . . . 0.0 111.363 -179.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 46.8 t -53.79 -28.95 38.08 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.511 -179.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.403 ' O ' ' CG1' ' B' ' 35' ' ' ILE . 31.1 mt -67.48 -44.89 86.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.905 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 81.6 mt -69.46 -39.66 78.89 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.675 0 CA-C-N 116.331 -0.395 . . . . 0.0 111.274 -179.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.69 -44.15 16.79 Favored Glycine 0 C--N 1.308 -1.021 0 C-N-CA 121.164 -0.541 . . . . 0.0 113.411 -177.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.403 ' CG1' ' O ' ' B' ' 32' ' ' ILE . 2.5 pt -53.59 -38.58 34.49 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 CA-C-N 118.677 1.239 . . . . 0.0 109.368 179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -67.23 -37.07 82.95 Favored 'General case' 0 C--N 1.307 -1.243 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -64.11 -42.21 96.97 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.098 -0.956 . . . . 0.0 111.632 -179.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -69.93 -44.5 69.47 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -178.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.585 ' O ' HG22 ' B' ' 42' ' ' THR . 27.7 pt -70.46 -36.55 66.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 C-N-CA 120.353 -0.539 . . . . 0.0 112.429 -178.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.23 -28.84 65.58 Favored 'General case' 0 C--N 1.305 -1.343 0 CA-C-O 121.137 0.494 . . . . 0.0 110.398 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.474 ' CD1' ' C ' ' B' ' 41' ' ' TRP . 5.9 t-105 -54.23 -42.63 70.05 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 115.557 -0.747 . . . . 0.0 112.173 -179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.585 HG22 ' O ' ' B' ' 39' ' ' ILE . 14.6 t -48.2 -37.11 15.05 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 120.802 -0.359 . . . . 0.0 111.954 -177.234 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . . . . . . . . . 70.5 mt -49.54 -49.22 19.26 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.859 -0.736 . . . . 0.0 111.304 -178.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -49.01 -50.82 26.58 Favored Glycine 0 C--N 1.307 -1.038 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -179.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -41.04 -23.3 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 112.977 0.732 . . . . 0.0 112.977 -176.314 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.624 HD12 ' N ' ' B' ' 47' ' ' ASN . 2.9 pp -50.44 -50.73 51.39 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.024 -1.07 . . . . 0.0 108.276 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.624 ' N ' HD12 ' B' ' 46' ' ' LEU . 64.8 m-80 -48.32 -46.61 36.64 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 114.674 -1.148 . . . . 0.0 111.39 -178.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.401 ' O ' ' C ' ' B' ' 49' ' ' ILE . 13.8 mm100 -43.22 -96.45 0.0 OUTLIER 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.715 HG23 ' H ' ' B' ' 50' ' ' LYS . 11.6 tt -35.72 -61.52 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.098 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -178.499 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.715 ' H ' HG23 ' B' ' 49' ' ' ILE . 25.0 mmtp -39.33 -62.72 0.63 Allowed 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 120.764 0.316 . . . . 0.0 111.272 -179.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 87.2 mtt-85 -67.72 -27.81 67.12 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.552 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.222 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.875 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 27.8 t . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.424 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 7.0 p-10 40.7 54.09 6.69 Favored Pre-proline 0 C--N 1.311 -1.072 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.766 179.462 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.424 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 33.9 Cg_endo -64.16 -19.08 65.63 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.203 1.935 . . . . 0.0 110.832 -179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.549 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.5 mp -61.94 -44.97 95.67 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.807 -0.633 . . . . 0.0 111.43 -179.088 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.88 -45.77 96.08 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -178.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 p -71.71 -41.07 70.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -178.361 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.8 -28.03 64.34 Favored 'General case' 0 C--N 1.304 -1.395 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -178.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.13 -36.11 64.14 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.191 -0.603 . . . . 0.0 112.589 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 31.8 t -70.21 -29.13 65.89 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 112.41 0.522 . . . . 0.0 112.41 -178.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.449 HG12 ' H ' ' C' ' 32' ' ' ILE . 16.8 mm -45.66 -38.35 2.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.445 -177.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 96.7 mt -67.43 -42.4 87.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.371 0.605 . . . . 0.0 109.946 178.633 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.554 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -49.1 -50.3 28.26 Favored Glycine 0 C--N 1.3 -1.425 0 CA-C-N 115.271 -0.877 . . . . 0.0 113.268 -177.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.5 pt -68.6 -29.53 44.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 CA-C-N 117.792 0.796 . . . . 0.0 111.529 -178.82 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 20.6 tp -62.84 -28.69 70.19 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.384 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.624 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.1 OUTLIER -71.29 -36.53 71.69 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -178.815 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.624 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 34.0 t80 -58.45 -50.61 73.08 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.145 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.433 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -63.34 -30.33 49.51 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 C-N-CA 120.334 -0.546 . . . . 0.0 110.28 -179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.507 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.35 -35.0 68.41 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-O 121.14 0.495 . . . . 0.0 110.081 178.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -49.03 -51.48 30.73 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 115.573 -0.74 . . . . 0.0 112.413 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.433 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -51.92 -27.61 13.61 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.411 -0.359 . . . . 0.0 111.844 -178.983 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.865 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.5 tt -66.05 -34.03 67.54 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.102 0 C-N-CA 120.698 -0.401 . . . . 0.0 111.35 -178.827 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.51 -32.18 62.3 Favored Glycine 0 C--N 1.309 -0.945 0 N-CA-C 111.187 -0.765 . . . . 0.0 111.187 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -53.8 -28.9 37.93 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 112.389 0.515 . . . . 0.0 112.389 -178.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.865 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -45.0 -31.04 1.15 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 120.106 -0.637 . . . . 0.0 111.086 -177.398 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.729 ' H ' HD13 ' C' ' 46' ' ' LEU . 32.1 m120 -65.06 -51.88 58.93 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.021 178.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.714 HE22 HH21 ' C' ' 51' ' ' ARG . 49.0 tp60 -43.0 -53.98 4.51 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.623 0.601 . . . . 0.0 112.623 -178.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tt -59.1 -28.46 38.98 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 120.657 -0.417 . . . . 0.0 111.211 -178.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.628 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 41.0 tptt -68.21 -42.66 79.52 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 120.667 -0.413 . . . . 0.0 110.242 179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . 0.714 HH21 HE22 ' C' ' 48' ' ' GLN . 6.1 tmm_? -59.13 132.26 53.5 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.526 -179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.304 -1.196 0 N-CA-C 110.958 -0.857 . . . . 0.0 110.958 179.955 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 23.1 t . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.665 ' O ' ' N ' ' D' ' 26' ' ' LEU . 9.7 t0 -83.23 118.62 72.18 Favored Pre-proline 0 C--N 1.306 -1.315 0 CA-C-O 118.84 -0.6 . . . . 0.0 110.154 -179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_exo -43.66 72.3 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.142 0 C-N-CA 122.699 2.266 . . . . 0.0 113.187 179.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.665 ' N ' ' O ' ' D' ' 24' ' ' ASP . 12.2 tp -65.6 -42.31 91.77 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.37 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 53.5 t -58.72 -49.42 82.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 CA-C-N 115.645 -0.707 . . . . 0.0 112.777 -178.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 p -72.54 -25.93 23.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 N-CA-C 112.335 0.495 . . . . 0.0 112.335 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -67.44 -39.09 85.38 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.802 -178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.71 -53.51 13.28 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.558 -0.857 . . . . 0.0 110.545 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 5.0 m -50.62 -29.66 11.5 Favored 'General case' 0 N--CA 1.43 -1.447 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -179.185 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.58 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.3 OUTLIER -52.87 -33.09 18.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.065 -179.126 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.4 HG21 HD13 ' D' ' 33' ' ' ILE . 12.3 mt -69.97 -36.86 70.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.938 179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -48.34 11.65 Favored Glycine 0 C--N 1.307 -1.055 0 CA-C-O 119.326 -0.708 . . . . 0.0 113.903 -176.411 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 10.2 pt -52.81 -33.85 19.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 119.064 1.432 . . . . 0.0 110.32 -179.583 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 11.2 tp -68.65 -30.37 69.06 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . . . . . . . . . 14.5 t-80 -65.97 -49.45 67.81 Favored 'General case' 0 C--N 1.305 -1.351 0 CA-C-N 115.566 -0.743 . . . . 0.0 111.321 -179.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . . . . . . . . . 48.2 t80 -68.2 -43.4 78.13 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.936 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.4 mt -61.43 -43.97 97.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 C-N-CA 120.91 -0.316 . . . . 0.0 111.74 -178.643 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.402 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -70.54 -28.41 64.9 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 121.097 0.475 . . . . 0.0 110.729 -179.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . 0.42 ' CD1' ' C ' ' D' ' 41' ' ' TRP . 5.2 t-105 -60.06 -45.19 93.67 Favored 'General case' 0 C--N 1.292 -1.922 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.858 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 38.0 p -48.69 -44.98 38.48 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -176.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.447 ' O ' HD23 ' D' ' 46' ' ' LEU . 6.3 pt -59.22 -29.03 40.8 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 C-N-CA 119.552 -0.859 . . . . 0.0 110.817 -179.203 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.47 ' O ' ' N ' ' D' ' 46' ' ' LEU . . . -49.01 -51.17 25.73 Favored Glycine 0 C--N 1.309 -0.962 0 N-CA-C 110.904 -0.878 . . . . 0.0 110.904 -179.562 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . 0.523 ' CD2' ' NE2' ' D' ' 48' ' ' GLN . 47.3 t-80 -40.48 -21.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 112.513 0.56 . . . . 0.0 112.513 -176.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.491 ' HA ' HD12 ' D' ' 49' ' ' ILE . 1.8 pp -48.43 -38.43 19.7 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 177.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.461 ' N ' ' HG ' ' D' ' 46' ' ' LEU . 61.2 m-20 -45.99 -38.0 7.22 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 113.793 -1.548 . . . . 0.0 112.482 -176.122 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.523 ' NE2' ' CD2' ' D' ' 45' ' ' HIS . 8.9 pm0 -93.33 -24.99 17.93 Favored 'General case' 0 C--N 1.313 -0.991 0 CA-C-N 118.194 0.452 . . . . 0.0 111.995 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' D' ' 46' ' ' LEU . 53.6 mt -50.73 -87.69 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.319 -0.552 . . . . 0.0 110.564 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.519 ' O ' ' N ' ' D' ' 52' ' ' GLY . 35.8 tptt -44.12 -38.55 3.72 Favored 'General case' 0 C--N 1.307 -1.267 0 CA-C-O 120.783 0.325 . . . . 0.0 110.694 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.628 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 63.15 -70.9 0.06 Allowed 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.421 179.645 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.15 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 33.5 t . . . . . 0 N--CA 1.49 1.532 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.451 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 15.7 m-20 52.63 53.15 11.88 Favored Pre-proline 0 C--N 1.305 -1.329 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.055 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.451 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 11.9 Cg_endo -54.09 -11.96 3.19 Favored 'Trans proline' 0 C--N 1.307 -1.616 0 C-N-CA 122.396 2.064 . . . . 0.0 111.243 -179.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 26' ' ' LEU . 8.9 mp -61.2 -41.57 97.06 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.668 -178.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 18.4 t -68.2 -38.22 79.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -178.888 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -72.7 -29.75 31.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.502 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -62.27 -53.65 52.14 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.802 0.667 . . . . 0.0 112.802 -177.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -58.11 -50.33 73.86 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.287 -0.965 . . . . 0.0 108.908 179.877 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 38.7 t -48.25 -51.12 27.0 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 114.218 -1.356 . . . . 0.0 109.887 179.291 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 21.6 mt -50.32 -47.26 26.01 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.175 -179.581 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 89.1 mt -63.25 -43.55 98.78 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.234 0 C-N-CA 120.111 -0.635 . . . . 0.0 109.511 179.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.486 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -47.1 -50.33 16.38 Favored Glycine 0 C--N 1.302 -1.331 0 CA-C-N 115.366 -0.834 . . . . 0.0 112.139 -177.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 28.9 pt -70.66 -29.66 39.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.405 0 CA-C-N 117.301 0.55 . . . . 0.0 111.322 -179.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.7 tp -62.81 -35.37 79.68 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.698 -179.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.638 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.3 OUTLIER -72.9 -29.41 63.12 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 112.54 0.571 . . . . 0.0 112.54 -179.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.638 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 44.4 t80 -52.9 -47.84 67.63 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.726 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.641 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.5 mp -61.07 -30.04 46.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.319 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.78 -179.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -73.94 -29.46 62.03 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-O 121.08 0.467 . . . . 0.0 111.156 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 8.2 t-105 -59.98 -47.64 84.98 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 112.959 0.726 . . . . 0.0 112.959 -177.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.439 ' CG2' ' O ' ' A' ' 39' ' ' ILE . 0.0 OUTLIER -48.39 -39.19 21.54 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 113.287 0.847 . . . . 0.0 113.287 -177.124 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 6.3 pt -66.02 -44.28 92.2 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 C-N-CA 118.6 -1.24 . . . . 0.0 110.934 -179.194 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -59.45 -41.39 97.07 Favored Glycine 0 C--N 1.303 -1.289 0 C-N-CA 120.857 -0.687 . . . . 0.0 111.592 -179.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -49.8 -27.38 4.93 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 111.786 0.291 . . . . 0.0 111.786 -179.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.542 HD12 ' C ' ' A' ' 46' ' ' LEU . 0.6 OUTLIER -45.75 -29.46 1.31 Allowed 'General case' 0 C--N 1.308 -1.227 0 C-N-CA 121.015 -0.274 . . . . 0.0 111.439 -177.838 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . 0.511 ' O ' ' N ' ' A' ' 51' ' ' ARG . 82.9 m-20 -61.47 -52.16 65.68 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 120.085 -0.646 . . . . 0.0 110.476 -179.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 9.1 tm0? -53.09 -52.73 57.65 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.861 -179.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 30.8 mm -55.32 -48.95 76.13 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 120.97 -0.292 . . . . 0.0 110.814 -179.422 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.1 tmtp? -81.27 -72.25 0.43 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.487 -179.675 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.537 HH22 ' C ' ' D' ' 51' ' ' ARG . 72.5 ttt180 -77.7 135.41 38.05 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.562 -179.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.154 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.95 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 17.4 m . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.552 ' O ' ' N ' ' B' ' 26' ' ' LEU . 0.6 OUTLIER -110.24 86.28 5.08 Favored Pre-proline 0 C--N 1.311 -1.098 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.237 -178.947 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 63.0 Cg_exo -38.9 87.58 0.01 OUTLIER 'Trans proline' 0 C--N 1.314 -1.241 0 C-N-CA 122.02 1.814 . . . . 0.0 111.968 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.552 ' N ' ' O ' ' B' ' 24' ' ' ASP . 8.4 mt -58.27 -37.85 75.79 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.664 -0.698 . . . . 0.0 109.273 178.798 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 13.1 t -58.95 -45.01 92.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.641 -179.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -71.19 -23.39 23.21 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-O 121.092 0.472 . . . . 0.0 110.378 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.435 ' HB3' ' O ' ' B' ' 26' ' ' LEU . . . -63.4 -44.73 93.84 Favored 'General case' 0 C--N 1.303 -1.431 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.999 -179.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.61 -51.04 25.34 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.651 -179.746 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 28.5 t -47.06 -48.03 22.52 Favored 'General case' 0 C--N 1.304 -1.413 0 N-CA-C 112.692 0.627 . . . . 0.0 112.692 -177.479 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 19.5 tt -70.1 -27.17 31.46 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 118.589 0.631 . . . . 0.0 111.987 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 41.2 mt -70.86 -49.59 49.37 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.576 -0.45 . . . . 0.0 111.214 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -48.7 -49.59 27.46 Favored Glycine 0 C--N 1.307 -1.075 0 C-N-CA 121.182 -0.533 . . . . 0.0 113.543 -176.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . 0.412 ' H ' HG22 ' B' ' 35' ' ' ILE . 2.3 tt -49.73 -29.85 5.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 CA-C-N 117.346 0.573 . . . . 0.0 110.458 -179.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.1 tp -64.31 -51.28 64.21 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-O 121.368 0.604 . . . . 0.0 109.376 178.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.576 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -55.01 -29.67 57.84 Favored 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.863 -179.089 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . 0.425 ' N ' ' ND1' ' B' ' 37' ' ' HIS . 30.5 t80 -65.5 -45.02 85.19 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 113.26 0.837 . . . . 0.0 113.26 -178.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.4 ' O ' ' CG2' ' B' ' 42' ' ' THR . 10.9 pt -67.81 -39.29 81.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.328 0 C-N-CA 120.338 -0.545 . . . . 0.0 111.929 -178.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -70.91 -28.7 64.72 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.063 0.459 . . . . 0.0 110.144 179.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . . . . . . . . . 5.2 t-105 -49.8 -51.22 41.19 Favored 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 -178.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.4 ' CG2' ' O ' ' B' ' 39' ' ' ILE . 0.1 OUTLIER -48.91 -33.95 11.8 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 120.273 -0.571 . . . . 0.0 111.224 -177.797 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.402 HD13 HG21 ' B' ' 43' ' ' ILE . 5.6 tt -50.52 -41.77 20.65 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 C-N-CA 121.024 -0.27 . . . . 0.0 111.344 -179.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -53.65 -48.81 60.06 Favored Glycine 0 C--N 1.309 -0.934 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 6.9 t-160 -42.0 -23.03 0.02 OUTLIER 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 123.406 0.682 . . . . 0.0 112.006 -177.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . 0.535 ' C ' HD12 ' B' ' 46' ' ' LEU . 1.3 pp -57.67 -49.23 77.19 Favored 'General case' 0 C--N 1.301 -1.513 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 176.891 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . 0.489 ' N ' HD12 ' B' ' 46' ' ' LEU . 51.3 m-80 -57.68 -48.64 78.97 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.375 -0.83 . . . . 0.0 112.702 -177.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.501 HE22 ' ND2' ' A' ' 47' ' ' ASN . 2.6 mm100 -66.93 -70.29 0.26 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 112.763 0.653 . . . . 0.0 112.763 -178.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.611 HG23 ' N ' ' B' ' 50' ' ' LYS . 15.1 tt -33.64 -53.7 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 O-C-N 123.16 0.288 . . . . 0.0 111.768 -178.119 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.611 ' N ' HG23 ' B' ' 49' ' ' ILE . 28.5 mmtp -49.13 -50.49 37.19 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.376 179.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 94.6 mtt-85 -67.97 -43.5 78.87 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.555 179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.168 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 -179.961 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . 0.429 ' N ' ' CD ' ' C' ' 25' ' ' PRO . 1.7 p30 40.28 53.16 5.58 Favored Pre-proline 0 C--N 1.309 -1.161 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.689 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . 0.429 ' CD ' ' N ' ' C' ' 24' ' ' ASP . 18.7 Cg_endo -57.53 -9.78 5.83 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 C-N-CA 122.343 2.029 . . . . 0.0 110.909 -179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.507 HD12 ' N ' ' C' ' 26' ' ' LEU . 10.6 mp -62.34 -43.38 98.96 Favored 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.454 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 57.0 t -69.21 -43.38 81.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -178.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.2 p -72.61 -41.5 63.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 C-N-CA 120.877 -0.329 . . . . 0.0 111.78 -179.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.82 -27.86 64.18 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 113.018 0.747 . . . . 0.0 113.018 -178.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.05 -36.05 64.34 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 112.813 0.672 . . . . 0.0 112.813 -178.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 32.9 t -69.79 -27.85 65.26 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -179.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.405 HG12 ' H ' ' C' ' 32' ' ' ILE . 24.6 mm -46.05 -35.09 2.1 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.665 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.603 -178.133 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 67.9 mt -70.53 -43.01 78.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.245 0.545 . . . . 0.0 110.044 178.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.547 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -48.32 -50.22 23.83 Favored Glycine 0 C--N 1.304 -1.213 0 CA-C-N 115.496 -0.775 . . . . 0.0 112.726 -177.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 31.9 pt -68.05 -29.42 44.62 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 117.615 0.707 . . . . 0.0 111.197 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 24.4 tp -63.21 -29.58 70.89 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.836 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.633 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -72.37 -31.17 65.37 Favored 'General case' 0 C--N 1.309 -1.176 0 C-N-CA 120.583 -0.447 . . . . 0.0 112.159 -179.749 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.633 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 48.5 t80 -62.82 -50.26 71.68 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 120.844 -0.342 . . . . 0.0 111.908 -178.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' C' ' 42' ' ' THR . 5.4 tp -64.53 -29.35 47.13 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-O 121.021 0.439 . . . . 0.0 110.486 -179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.424 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -71.84 -36.75 70.26 Favored 'General case' 0 C--N 1.3 -1.57 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.085 179.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 9.1 t-105 -50.77 -51.46 50.13 Favored 'General case' 0 C--N 1.306 -1.289 0 N-CA-C 113.277 0.843 . . . . 0.0 113.277 -177.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.441 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -49.63 -27.19 4.32 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-N 116.555 -0.293 . . . . 0.0 111.724 -178.83 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.84 ' O ' HD12 ' C' ' 46' ' ' LEU . 4.4 tt -64.9 -37.4 80.11 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.192 0 C-N-CA 120.951 -0.3 . . . . 0.0 111.658 -178.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . . . . . . . . . . . -70.63 -29.49 69.61 Favored Glycine 0 CA--C 1.53 1.009 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -179.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -54.95 -28.64 52.81 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -179.466 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.857 HD13 ' H ' ' C' ' 47' ' ' ASN . 0.0 OUTLIER -46.94 -33.11 4.33 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.218 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.857 ' H ' HD13 ' C' ' 46' ' ' LEU . 27.0 m120 -64.33 -52.41 58.58 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 110.588 179.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . 0.48 ' OE1' ' CD2' ' B' ' 46' ' ' LEU . 41.9 tp60 -38.85 -44.72 1.08 Allowed 'General case' 0 C--N 1.309 -1.195 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.807 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 76.6 mt -60.14 -28.36 41.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 120.935 -0.306 . . . . 0.0 111.211 -179.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.556 ' HZ2' ' NH2' ' D' ' 51' ' ' ARG . 38.7 tptt -61.49 -45.93 92.16 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.989 -179.577 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 4.1 tmm_? -57.92 130.39 46.31 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-O 120.877 0.37 . . . . 0.0 110.563 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.129 0 N-CA-C 110.933 -0.867 . . . . 0.0 110.933 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 35.0 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.617 ' O ' ' N ' ' D' ' 26' ' ' LEU . 10.5 t0 -93.65 130.67 34.32 Favored Pre-proline 0 C--N 1.309 -1.173 0 CA-C-O 118.947 -0.549 . . . . 0.0 109.857 179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_exo -44.81 74.47 0.01 OUTLIER 'Trans proline' 0 N--CA 1.504 2.102 0 C-N-CA 122.366 2.044 . . . . 0.0 113.507 179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' D' ' 24' ' ' ASP . 4.2 mp -70.4 -42.32 71.85 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 120.991 0.424 . . . . 0.0 110.019 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 79.6 t -58.77 -50.22 80.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.462 -178.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 2.5 p -73.07 -25.24 21.56 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.219 0 N-CA-C 112.567 0.581 . . . . 0.0 112.567 -179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -70.34 -51.86 26.91 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 111.882 0.327 . . . . 0.0 111.882 -178.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.96 -26.78 62.41 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.101 0.477 . . . . 0.0 110.795 -179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 31.0 t -66.74 -44.28 81.94 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.796 179.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.569 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.4 OUTLIER -54.42 -25.51 14.22 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 113.149 0.796 . . . . 0.0 113.149 -178.597 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . . . . . . . . . 58.6 mt -70.05 -29.78 41.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 C-N-CA 119.748 -0.781 . . . . 0.0 111.041 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -47.36 -44.62 21.4 Favored Glycine 0 C--N 1.306 -1.109 0 CA-C-O 119.803 -0.443 . . . . 0.0 113.798 -176.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 33.7 pt -64.86 -29.65 48.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 CA-C-N 118.174 0.987 . . . . 0.0 111.111 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 10.8 tp -60.71 -50.93 71.52 Favored 'General case' 0 C--N 1.305 -1.356 0 CA-C-O 121.007 0.432 . . . . 0.0 110.433 -179.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.626 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -67.52 -31.57 71.77 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 115.767 -0.651 . . . . 0.0 111.117 -179.282 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.626 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 61.4 t80 -67.09 -49.78 63.85 Favored 'General case' 0 C--N 1.306 -1.311 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.742 -179.349 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 86.1 mt -63.79 -39.47 85.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 CA-C-O 120.841 0.353 . . . . 0.0 111.24 -179.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.84 ' O ' HD12 ' D' ' 43' ' ' ILE . . . -70.44 -27.6 64.38 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.639 179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 4.4 t-105 -58.6 -45.79 88.38 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 112.244 0.461 . . . . 0.0 112.244 -178.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 76.0 p -47.72 -37.19 12.68 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 114.388 1.255 . . . . 0.0 114.388 -176.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.94 HD13 ' N ' ' D' ' 44' ' ' GLY . 0.0 OUTLIER -59.08 -27.42 36.05 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.339 -0.944 . . . . 0.0 111.211 -178.995 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . 0.94 ' N ' HD13 ' D' ' 43' ' ' ILE . . . -47.59 -47.47 23.46 Favored Glycine 0 C--N 1.309 -0.926 0 N-CA-C 110.996 -0.841 . . . . 0.0 110.996 -179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 38.2 m80 -40.81 -22.21 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.538 0 N-CA-C 113.334 0.864 . . . . 0.0 113.334 -176.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.495 HD12 ' N ' ' D' ' 47' ' ' ASN . 3.4 pp -54.36 -47.23 72.84 Favored 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.01 -1.076 . . . . 0.0 108.6 177.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.495 ' N ' HD12 ' D' ' 46' ' ' LEU . 69.3 m-80 -47.27 -43.75 22.42 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-N 114.89 -1.05 . . . . 0.0 112.606 -177.293 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.579 ' OE1' HD11 ' C' ' 46' ' ' LEU . 0.0 OUTLIER -79.69 -51.96 8.57 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 122.289 -0.257 . . . . 0.0 110.447 -179.493 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . . . . . . . . . 96.9 mt -42.62 -78.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.721 -179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.509 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.8 tptt -50.09 -41.7 48.72 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-O 120.826 0.346 . . . . 0.0 110.082 -179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.556 ' NH2' ' HZ2' ' C' ' 50' ' ' LYS . 0.0 OUTLIER 62.75 -71.05 0.05 Allowed 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.479 179.778 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.176 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' SER . . . . . . . . . . . . . 28.5 t . . . . . 0 N--CA 1.489 1.511 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' PRO . 2.2 m-20 48.89 51.54 11.11 Favored Pre-proline 0 C--N 1.308 -1.221 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.59 179.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.467 ' CD ' ' N ' ' A' ' 24' ' ' ASP . 55.4 Cg_endo -68.73 -26.46 32.8 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 C-N-CA 122.237 1.958 . . . . 0.0 110.673 179.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -66.13 -44.38 84.38 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.362 -178.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 24.3 t -63.42 -44.81 99.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -178.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.431 HG13 ' N ' ' A' ' 29' ' ' ALA . 4.5 p -71.64 -43.7 70.54 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.22 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -178.83 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.431 ' N ' HG13 ' A' ' 28' ' ' VAL . . . -70.25 -26.15 63.7 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 113.079 0.77 . . . . 0.0 113.079 -178.58 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.24 -39.93 74.75 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.254 -178.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 32.4 t -66.78 -28.18 68.18 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 120.54 0.209 . . . . 0.0 111.114 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.404 HD12 ' HA ' ' A' ' 29' ' ' ALA . 41.0 mt -47.52 -50.17 8.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.204 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.069 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . . . . . . . . . 69.8 mt -59.66 -46.38 93.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.245 0 C-N-CA 119.897 -0.721 . . . . 0.0 109.184 178.599 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.539 ' O ' ' CD2' ' A' ' 37' ' ' HIS . . . -49.0 -51.23 25.47 Favored Glycine 0 C--N 1.303 -1.287 0 CA-C-N 115.4 -0.818 . . . . 0.0 111.916 -178.426 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 76.1 mt -71.02 -31.16 44.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.404 0 CA-C-N 117.292 0.546 . . . . 0.0 110.679 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 10.6 tp -59.06 -33.24 70.56 Favored 'General case' 0 C--N 1.302 -1.495 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.441 -179.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.549 ' ND1' ' N ' ' A' ' 38' ' ' PHE . 0.1 OUTLIER -71.73 -30.63 65.83 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.805 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . 0.549 ' N ' ' ND1' ' A' ' 37' ' ' HIS . 89.8 t80 -55.94 -50.77 69.84 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 112.319 0.488 . . . . 0.0 112.319 -177.723 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.676 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.3 mp -56.86 -31.1 34.93 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 120.539 -0.464 . . . . 0.0 110.689 -179.067 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.495 ' HB3' ' CZ2' ' B' ' 41' ' ' TRP . . . -73.21 -29.32 62.72 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 121.146 0.498 . . . . 0.0 110.851 179.44 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' TRP . . . . . . . . . . . . . 5.8 t-105 -58.66 -51.35 70.31 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 112.787 0.662 . . . . 0.0 112.787 -177.132 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' THR . . . . . 0.42 ' H ' HG22 ' A' ' 42' ' ' THR . 0.0 OUTLIER -50.41 -42.88 54.4 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -177.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ILE . . . . . . . . . . . . . 15.2 pt -66.7 -46.01 86.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 C-N-CA 119.72 -0.792 . . . . 0.0 111.605 -178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -64.26 -29.87 76.21 Favored Glycine 0 C--N 1.305 -1.181 0 N-CA-C 111.468 -0.653 . . . . 0.0 111.468 -179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' HIS . . . . . . . . . . . . . 10.4 t-160 -49.12 -26.73 2.93 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 120.778 0.323 . . . . 0.0 110.717 -179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.601 ' CD2' HE22 ' B' ' 48' ' ' GLN . 1.1 pp -44.42 -29.96 0.78 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.924 -176.692 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -58.27 -52.89 63.69 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.221 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLN . . . . . . . . . . . . . 2.3 tm0? -52.77 -56.32 16.47 Favored 'General case' 0 C--N 1.307 -1.246 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.416 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 27.6 mm -48.55 -53.67 6.19 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 116.471 -0.331 . . . . 0.0 110.713 -179.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 1.3 tmtp? -71.37 -72.82 0.2 Allowed 'General case' 0 C--N 1.304 -1.404 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.599 -179.469 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.582 HH22 ' CA ' ' D' ' 51' ' ' ARG . 76.0 ttt180 -75.4 115.32 14.93 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.634 -179.725 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.092 0 N-CA-C 110.813 -0.915 . . . . 0.0 110.813 179.886 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 99.8 p . . . . . 0 N--CA 1.491 1.582 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' ASP . . . . . 0.564 ' O ' ' N ' ' B' ' 26' ' ' LEU . 41.4 m-20 -157.7 75.82 3.93 Favored Pre-proline 0 C--N 1.308 -1.214 0 CA-C-N 116.422 -0.354 . . . . 0.0 110.726 -179.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' PRO . . . . . . . . . . . . . 92.2 Cg_exo -44.99 79.11 0.01 OUTLIER 'Trans proline' 0 N--CA 1.498 1.769 0 C-N-CA 123.307 2.671 . . . . 0.0 112.502 179.718 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.564 ' N ' ' O ' ' B' ' 24' ' ' ASP . 0.7 OUTLIER -67.07 -44.69 79.47 Favored 'General case' 0 C--N 1.303 -1.441 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.105 179.98 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' VAL . . . . . . . . . . . . . 33.3 t -56.19 -49.98 73.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 CA-C-N 115.723 -0.671 . . . . 0.0 111.919 -178.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 1.3 p -71.87 -26.35 25.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 118.002 0.365 . . . . 0.0 111.81 -179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' ALA . . . . . 0.572 ' O ' HG22 ' B' ' 32' ' ' ILE . . . -61.35 -41.45 97.09 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 116.163 -0.472 . . . . 0.0 112.243 -178.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.31 -52.07 15.23 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.249 179.359 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' SER . . . . . . . . . . . . . 22.2 t -48.74 -26.94 2.6 Favored 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.849 -179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.572 HG22 ' O ' ' B' ' 29' ' ' ALA . 9.7 tt -59.63 -39.11 78.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.301 -179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' ILE . . . . . . . . . . . . . 61.4 mt -67.35 -40.81 85.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.916 -179.36 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . -45.44 -45.21 11.53 Favored Glycine 0 C--N 1.305 -1.178 0 C-N-CA 120.881 -0.676 . . . . 0.0 113.644 -175.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -66.95 -34.77 72.11 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 CA-C-N 118.622 1.211 . . . . 0.0 109.611 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 10.0 tp -64.05 -43.13 96.45 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 178.489 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . 0.537 ' ND1' ' C ' ' B' ' 37' ' ' HIS . 0.0 OUTLIER -63.3 -34.1 76.95 Favored 'General case' 0 C--N 1.301 -1.539 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.164 -179.703 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' PHE . . . . . . . . . . . . . 61.7 t80 -65.23 -49.72 68.6 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 112.81 0.67 . . . . 0.0 112.81 -178.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' ILE . . . . . 0.41 ' O ' ' CG2' ' B' ' 42' ' ' THR . 37.1 pt -66.28 -38.0 80.92 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 112.546 0.573 . . . . 0.0 112.546 -178.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.472 ' O ' HG22 ' B' ' 43' ' ' ILE . . . -71.26 -29.28 64.89 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 120.422 -0.511 . . . . 0.0 110.386 179.776 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' TRP . . . . . 0.495 ' CZ2' ' HB3' ' A' ' 40' ' ' ALA . 6.8 t-105 -57.46 -50.66 72.32 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' THR . . . . . 0.428 ' H ' HG22 ' B' ' 42' ' ' THR . 0.0 OUTLIER -49.04 -38.71 24.64 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.908 -177.88 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' ILE . . . . . 0.472 HG22 ' O ' ' B' ' 40' ' ' ALA . 4.5 tt -47.74 -39.76 7.51 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.648 0 C-N-CA 120.831 -0.348 . . . . 0.0 111.845 -177.587 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' GLY . . . . . . . . . . . . . . . -55.53 -46.8 80.04 Favored Glycine 0 C--N 1.308 -1.015 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' HIS . . . . . . . . . . . . . 57.7 t-80 -42.51 -25.27 0.08 Allowed 'General case' 0 C--N 1.303 -1.439 0 CA-C-N 115.543 -0.329 . . . . 0.0 111.192 -177.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -45.67 -27.18 0.74 Allowed 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.45 -0.5 . . . . 0.0 111.306 -179.166 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' ASN . . . . . . . . . . . . . 82.2 m-20 -72.9 -29.44 63.14 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 179.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' GLN . . . . . 0.601 HE22 ' CD2' ' A' ' 46' ' ' LEU . 20.4 mm100 -52.98 -80.71 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 117.906 0.321 . . . . 0.0 111.316 -178.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' ILE . . . . . 0.412 ' C ' ' O ' ' B' ' 48' ' ' GLN . 18.4 mm -35.31 -75.18 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.384 -179.212 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' B' ' 49' ' ' ILE . 28.4 mmtp -36.43 -74.7 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.237 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.569 -179.77 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' ARG . . . . . . . . . . . . . 92.7 mtt-85 -57.69 -82.11 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.354 0 CA-C-O 120.936 0.398 . . . . 0.0 110.491 179.988 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.305 -1.171 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -179.939 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 23' ' ' SER . . . . . . . . . . . . . 9.1 t . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 24' ' ' ASP . . . . . . . . . . . . . 1.8 p30 40.3 55.48 7.0 Favored Pre-proline 0 C--N 1.309 -1.179 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.161 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 25' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -66.72 -17.74 52.7 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 121.984 1.789 . . . . 0.0 110.267 179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . 0.531 HD12 ' N ' ' C' ' 26' ' ' LEU . 8.7 mp -60.72 -38.78 86.24 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-N 115.383 -0.826 . . . . 0.0 111.608 -179.107 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 27' ' ' VAL . . . . . . . . . . . . . 25.5 t -67.15 -45.75 85.84 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -178.461 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 28' ' ' VAL . . . . . . . . . . . . . 2.8 p -71.45 -34.79 54.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 N-CA-C 113.239 0.829 . . . . 0.0 113.239 -177.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.12 -52.72 64.15 Favored 'General case' 0 C--N 1.31 -1.122 0 N-CA-C 113.003 0.742 . . . . 0.0 113.003 -177.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -62.31 -50.47 71.5 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.032 -178.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 31' ' ' SER . . . . . . . . . . . . . 37.3 t -49.88 -50.16 46.9 Favored 'General case' 0 C--N 1.301 -1.514 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.153 178.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.3 mm -47.69 -46.76 11.47 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.271 0 CA-C-N 115.817 -0.629 . . . . 0.0 111.198 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 33' ' ' ILE . . . . . . . . . . . . . 94.6 mt -62.23 -37.72 79.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.496 0.665 . . . . 0.0 109.593 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 34' ' ' GLY . . . . . 0.535 ' O ' ' CD2' ' C' ' 37' ' ' HIS . . . -47.46 -49.69 19.92 Favored Glycine 0 C--N 1.301 -1.408 0 CA-C-N 115.076 -0.966 . . . . 0.0 112.636 -177.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 35' ' ' ILE . . . . . . . . . . . . . 26.5 pt -70.25 -29.4 39.25 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-N 117.742 0.771 . . . . 0.0 111.8 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 36' ' ' LEU . . . . . . . . . . . . . 23.9 tp -59.96 -36.05 76.28 Favored 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 116.631 -0.259 . . . . 0.0 111.373 -179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 37' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' C' ' 38' ' ' PHE . 0.2 OUTLIER -71.96 -30.01 64.85 Favored 'General case' 0 C--N 1.306 -1.294 0 N-CA-C 112.69 0.626 . . . . 0.0 112.69 -178.962 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 38' ' ' PHE . . . . . 0.631 ' N ' ' ND1' ' C' ' 37' ' ' HIS . 35.6 t80 -61.02 -51.42 69.31 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 120.261 -0.576 . . . . 0.0 111.66 -178.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 39' ' ' ILE . . . . . 0.443 ' O ' ' CG2' ' C' ' 42' ' ' THR . 4.3 tp -60.32 -30.48 46.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 C-N-CA 120.228 -0.589 . . . . 0.0 110.531 -179.178 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 40' ' ' ALA . . . . . 0.516 ' O ' HG22 ' C' ' 43' ' ' ILE . . . -72.11 -33.48 67.87 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.065 178.799 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 41' ' ' TRP . . . . . . . . . . . . . 4.9 t-105 -49.65 -52.31 31.75 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.829 -0.623 . . . . 0.0 112.609 -177.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 42' ' ' THR . . . . . 0.443 ' CG2' ' O ' ' C' ' 39' ' ' ILE . 0.0 OUTLIER -50.15 -28.57 7.59 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-N 116.672 -0.24 . . . . 0.0 111.6 -179.021 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 43' ' ' ILE . . . . . 0.821 ' O ' HD12 ' C' ' 46' ' ' LEU . 3.2 tt -67.4 -35.28 73.1 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 C-N-CA 121.006 -0.278 . . . . 0.0 111.362 -178.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 44' ' ' GLY . . . . . 0.411 ' O ' HD13 ' C' ' 46' ' ' LEU . . . -72.89 -29.29 65.3 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 112.089 -0.405 . . . . 0.0 112.089 179.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 45' ' ' HIS . . . . . . . . . . . . . 41.6 t-80 -50.78 -33.24 22.58 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -178.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 46' ' ' LEU . . . . . 0.821 HD12 ' O ' ' C' ' 43' ' ' ILE . 0.0 OUTLIER -44.24 -32.18 1.2 Allowed 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 120.152 -0.619 . . . . 0.0 111.87 -176.712 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' C' C ' 47' ' ' ASN . . . . . 0.715 ' H ' HD13 ' C' ' 46' ' ' LEU . 56.3 m-80 -62.85 -50.55 70.49 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.306 -0.957 . . . . 0.0 110.289 178.233 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 48' ' ' GLN . . . . . . . . . . . . . 16.7 mp0 -46.33 -60.24 2.44 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 112.166 0.432 . . . . 0.0 112.166 -179.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 49' ' ' ILE . . . . . . . . . . . . . 10.6 tt -57.35 -29.28 32.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -178.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 50' ' ' LYS . . . . . 0.58 ' NZ ' ' NE ' ' D' ' 51' ' ' ARG . 40.7 tptt -61.5 -45.78 92.77 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 120.514 -0.474 . . . . 0.0 110.189 -179.837 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 51' ' ' ARG . . . . . . . . . . . . . 7.1 tmm_? -53.62 132.4 40.54 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-O 120.874 0.369 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 52' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.306 -1.119 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.966 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 23' ' ' SER . . . . . . . . . . . . . 28.1 t . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' D' D ' 24' ' ' ASP . . . . . 0.634 ' O ' ' N ' ' D' ' 26' ' ' LEU . 25.9 t0 -77.06 123.97 87.3 Favored Pre-proline 0 C--N 1.307 -1.27 0 CA-C-O 118.996 -0.526 . . . . 0.0 109.964 -179.471 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 25' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -46.56 72.64 0.01 OUTLIER 'Trans proline' 0 N--CA 1.501 1.961 0 C-N-CA 122.262 1.974 . . . . 0.0 113.476 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 26' ' ' LEU . . . . . 0.634 ' N ' ' O ' ' D' ' 24' ' ' ASP . 5.6 mp -68.67 -42.2 78.21 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.862 0.363 . . . . 0.0 110.387 179.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 27' ' ' VAL . . . . . . . . . . . . . 25.1 t -56.31 -50.97 69.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-N 116.388 -0.369 . . . . 0.0 111.826 -178.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 p -72.09 -24.64 22.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-O 120.956 0.408 . . . . 0.0 111.324 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 29' ' ' ALA . . . . . . . . . . . . . . . -60.83 -31.64 71.05 Favored 'General case' 0 C--N 1.304 -1.399 0 CA-C-N 115.775 -0.648 . . . . 0.0 112.019 -178.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.86 -52.77 13.47 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 118.953 -1.099 . . . . 0.0 110.305 179.388 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 31' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -49.08 -26.88 2.94 Favored 'General case' 0 N--CA 1.429 -1.503 0 C-N-CA 124.158 0.983 . . . . 0.0 112.899 -179.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.56 HD13 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -58.66 -48.88 84.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 C-N-CA 120.409 -0.516 . . . . 0.0 110.639 -179.424 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' D' D ' 33' ' ' ILE . . . . . 0.46 ' N ' ' CG2' ' D' ' 32' ' ' ILE . 85.2 mt -70.54 -29.87 40.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 120.345 -0.542 . . . . 0.0 110.543 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 34' ' ' GLY . . . . . . . . . . . . . . . -46.24 -44.1 14.64 Favored Glycine 0 C--N 1.307 -1.077 0 CA-C-O 119.698 -0.501 . . . . 0.0 113.54 -176.651 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 35' ' ' ILE . . . . . . . . . . . . . 23.3 pt -65.05 -29.2 46.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-N 118.462 1.131 . . . . 0.0 110.624 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 36' ' ' LEU . . . . . . . . . . . . . 8.3 tp -60.66 -46.13 91.48 Favored 'General case' 0 C--N 1.305 -1.336 0 CA-C-O 121.042 0.449 . . . . 0.0 110.722 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 37' ' ' HIS . . . . . 0.628 ' ND1' ' N ' ' D' ' 38' ' ' PHE . 0.2 OUTLIER -70.27 -30.51 67.55 Favored 'General case' 0 C--N 1.304 -1.38 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.162 -179.5 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' D' D ' 38' ' ' PHE . . . . . 0.628 ' N ' ' ND1' ' D' ' 37' ' ' HIS . 59.5 t80 -66.91 -50.06 63.59 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 120.961 -0.296 . . . . 0.0 111.507 -179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 39' ' ' ILE . . . . . . . . . . . . . 77.7 mt -66.5 -38.79 82.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 N-CA-C 111.807 0.299 . . . . 0.0 111.807 -179.015 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 40' ' ' ALA . . . . . 0.404 ' O ' ' CG1' ' D' ' 43' ' ' ILE . . . -67.46 -27.76 67.3 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-O 121.367 0.604 . . . . 0.0 110.286 -179.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 41' ' ' TRP . . . . . . . . . . . . . 5.4 t-105 -56.23 -48.84 75.69 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.748 -178.736 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 42' ' ' THR . . . . . . . . . . . . . 62.8 p -49.04 -50.04 38.31 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -176.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 43' ' ' ILE . . . . . 0.685 ' O ' HD22 ' D' ' 46' ' ' LEU . 7.6 pt -53.35 -29.52 16.47 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.052 -178.449 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 44' ' ' GLY . . . . . . . . . . . . . . . -57.82 -51.84 55.68 Favored Glycine 0 CA--C 1.53 1.027 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 -179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 45' ' ' HIS . . . . . . . . . . . . . 55.3 t-80 -44.36 -23.36 0.11 Allowed 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 112.783 0.66 . . . . 0.0 112.783 -176.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' D' D ' 46' ' ' LEU . . . . . 0.872 HD23 ' H ' ' D' ' 47' ' ' ASN . 0.3 OUTLIER -54.91 -47.18 74.7 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 119.249 -0.98 . . . . 0.0 108.366 178.476 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' D' D ' 47' ' ' ASN . . . . . 0.872 ' H ' HD23 ' D' ' 46' ' ' LEU . 60.6 m-80 -45.32 -35.63 3.62 Favored 'General case' 0 C--N 1.301 -1.512 0 CA-C-N 114.773 -1.103 . . . . 0.0 112.074 -176.891 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 48' ' ' GLN . . . . . 0.692 HE22 HD21 ' C' ' 47' ' ' ASN . 3.0 mm-40 -77.3 -50.55 12.59 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 122.267 -0.271 . . . . 0.0 110.827 179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 49' ' ' ILE . . . . . 0.403 ' C ' ' O ' ' D' ' 48' ' ' GLN . 44.9 mt -35.85 -77.07 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.908 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.351 -179.164 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 50' ' ' LYS . . . . . 0.516 ' O ' ' N ' ' D' ' 52' ' ' GLY . 39.7 tptt -43.95 -38.15 3.29 Favored 'General case' 0 C--N 1.308 -1.221 0 CA-C-O 120.884 0.373 . . . . 0.0 110.236 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' D' D ' 51' ' ' ARG . . . . . 0.582 ' CA ' HH22 ' A' ' 51' ' ' ARG . 0.0 OUTLIER 61.57 -71.83 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.573 179.599 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' D' D ' 52' ' ' GLY . . . . . 0.516 ' N ' ' O ' ' D' ' 50' ' ' LYS . . . . . . . . 0 C--N 1.305 -1.149 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' RIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_